Portal de recerca
RED TEMATICA DE INVESTIGACION COOPERATIVA EN CANCER (RTICC)
Dades bàsiques
- Codi Financador:
- RD12/0036/0014
- Any inicial:
- 2013
- Any final:
- 2017
Objectius del projecte
FAVORABLE
Documents
- No hi ha documents
Participants
-
Eva Villamon Ribate
Licenciado
-
Irene Luna Del Valle
Licenciado
-
Miguel Ángel Sanz Alonso
Investigador Principal
-
Jose Ramon Vílchez Gutierrez
Licenciado
-
Esperanza Such Taboada
Licenciado
-
Alexander Neef
Licenciado
-
Aurora Rodríguez Ródenas
Licenciado
-
Antonio Rosal Vela
Licenciado
-
Claudia Sargas Simarro
Licenciado
Grups d'Investigació
-
Hematología y Hemoterapia
Investigador Principal
Javier De La Rubia Comos
Finançadors
Resultats del Projecte
Acute Myeloid Leukemia in Adults
Versluis, J; (...); Nagler, A
Article. 10.1007/978-3-030-02278-5_69. 2019
Aplicación de técnicas de identificación de poblaciones celulares por citometría de flujo
LOURDES CORDÓN GALLEGO, Sempere Talens, A., Cuñat Estellés, P.
Capítulo de un Libro. 2014
Epigenomic Biomarkers for the Advance of Personalized Medicine
JESUS MENDEZ, JUAN SANDOVAL DEL AMOR
Capítulo de un Libro. 2015
[Translated article] New challenges in advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2024.05.001. 2024
6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150)
Wei, AH; (...); DiNardo, CD
Article. 10.1038/s41408-021-00555-8. 2021
A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia
Sweet, Kendra; (...); Montesinos, Pau
Article. 10.1080/10428194.2021.1950706. 2021
A case of megaloblastic anemia simulating a cold autoimmune hemolytic anemia.
De La Puerta R; (...); Solves P
Article. 2020
A CD38/CD28xCD3 Trispecific T-Cell Engager (TCE) As a Potentially Active Agent for the Treatment of Older Patients with Acute Myeloid Leukemia (AML)
Zabaleta, Aintzane; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2023-184797. 2023
A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML
Perez Miguez, Carlos; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2024-201407. 2024
A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients.
Lozano ML; (...); Vicente V
Article. 10.1016/j.bcmd.2020.102505. 2021
A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study.
Rios-Tamayo, Rafael; (...); Mateos, Maria Victoria
Article. 10.1080/16078454.2023.2178997. 2023
A global study for acute myeloid leukemia with RARG rearrangement.
Zhu, Hong-Hu; (...); Chen, Su-Ning
Article. 10.1182/bloodadvances.2022008364. 2023
A High Percentage of DNAM-1+and Low Percentage of Tactile plus NK Cells at Diagnosis Correlate with Complete Response and Survival in AML: A Sub-Analysis of the Ven-a-Qui Pethema Trial
Bergua Burgues, Juan Miguel; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2023-189676. 2023
A Lot to Learn about Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia
Editorial Material. 10.1016/j.bbmt.2017.03.011. 2017
A multicentre ambispective observational study into the incidence and clinical management of aplastic anaemia in Spain (IMAS study)
Vallejo C; (...); Codesido ML
Article. 10.1007/s00277-023-05602-x. 2024
A NEW INTRONIC MUTATION CAUSES AN ABERRANT SPLICING IN THE ANK1 GENE
Liquori, A.; (...); Cervera, J., V
Meeting Abstract. 2018
A new precision medicine test to guide personalized treatments decision for acute myeloid leukemia patients.
Ballesteros, J; (...); Robles, A
Meeting Abstract. 2017
A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia
Onecha, E; (...); Ayala, R
Article. 10.3324/haematol.2018.194712. 2019
A novel DNA methylation-based approach for molecular subtyping and improved prognostication of colorectal cancer using formalin-fixed and paraffin-embedded tissue
Mattesen, TB; (...); Bramsen, JB
Meeting Abstract. 10.1158/1538-7445.AM2019-466. 2019
A Novel Epigenetic Signature for Early Diagnosis in Lung Cancer
Diaz-Lagares A; (...); Sandoval J
Article. 10.1158/1078-0432.CCR-15-2346. 2016
A NOVEL IN VITRO METHOD TO QUANTIFY THE PHARMACOLOGY ACTIVITY OF BISPECIFIC ANTIBODIES IN HEMATOLOGICAL SAMPLES
Primo, D; (...); Ballesteros, J
Meeting Abstract. 2017
A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial.
Ribera JM; (...); Orfao A
Article. 10.1002/cam4.2814. 2020
A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART (R) Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Wei, Andrew H.; (...); Davidson-Moncada, Jan K.
Meeting Abstract. 10.1182/blood-2019-125966. 2019
A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-108 (Lacutoclax) As Monotherapy and in Combination with Azacitidine in Subjects with Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
Burgues, Juan Miguel Bergua; (...); Curran, Emily K.
Meeting Abstract. 10.1182/blood-2024-208792. 2024
A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine for patients with newly diagnosed CD123-positive acute myeloid leukemia.
Daver, Naval Guastad; (...); Sallman, David Andrew
Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.TPS6585. 2024
A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine or magrolimab for patients with CD123-positive acute myeloid leukemia (AML)
Daver, Naval Guastad; (...); Sweet, Kendra Lynn
Meeting Abstract. 2023
A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia
Daver, Naval; (...); Sweet, Kendra
Meeting Abstract. 10.1182/blood-2021-146585. 2021
A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX.
Rodríguez-Arbolí E; (...); Montesinos P
Article. 10.1002/cncr.35618. 2024
A Phase 3 Randomized Study (PRIMULA) of the Epigenetic Combination of Pracinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, with Azacitidine (AZA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Intensive Chemotherapy (IC)
Garcia-Manero, Guillermo; (...); Ades, Lionel
Meeting Abstract. 10.1182/blood-2019-125924. 2019
A PHASE 3 STUDY OF ENASIDENIB (ENA) VERSUS CONVENTIONAL CARE REGIMENS (CCR) IN OLDER PATIENTS WITH LATE-STAGE MUTANT-IDH2 (MIDH2) RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML)
Papayannidis, C.; (...); de Botton, S.
Meeting Abstract. 2021
A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia.
Vives S; (...); PETHEMA Group
Article. 10.1002/cncr.33403. 2021
A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients
Sanchez, MPM; (...); Montesinos, P
Article. 10.1007/s00277-021-04542-8. 2021
A phase I/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies.
Daver, Naval Guastad; (...); Zweidler-McKay, Patrick A.
Meeting Abstract. 2020
A phase Ib/II study of the CD123-targeting antibody-drug conjugate IMGN632 as monotherapy or in combination with venetoclax and/or azacitidine for patients with CD123-positive acute myeloid leukemia.
Daver, Naval Guastad; (...); Zweidler-McKay, Patrick A.
Meeting Abstract. 2020
A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis
Cibeira, MT; (...); Blade, J
Article. 10.1111/bjh.13500. 2015
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia
Martínez-Cuadrón D; (...); CETLAM and PETHEMA groups
Article. 10.1007/s00277-018-3229-5. 2018
A phase III study of venetoclax plus low-dose cytarabine in previously untreated older patients with acute myeloid leukemia (VIALE-C): A six-month update.
Wei, AH; (...); Panayiotidis, P
Meeting Abstract. 2020
A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia.
Montesinos, Pau; (...); McMullin, Mary Frances
Article. 10.1007/s00280-023-04516-9. 2023
A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients
Martinez-Cuadron, D; (...); Spanish PETHEMA group
Article. 10.1016/j.leukres.2018.11.006. 2019
A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDS
Oster, HS; (...); Mittelman, M
Article. 10.1182/bloodadvances.2020004055. 2021
A prognostic model for survival after salvage treatment with FLAG-Ida plus /- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia
Bergua JM; (...); PETHEMA group
Article. 10.1111/bjh.14107. 2016
A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia.
Zeidner JF; (...); Douglas Smith B
Letter. 10.1038/s41408-021-00568-3. 2021
A randomized phase II study comparing consolidation with a single dose of Y-90 ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results
Lopez-Guillermo, Armando; (...); Tomas, Jose Francisco
Article. 10.1080/10428194.2021.1971216. 2021
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
Hajek, R; (...); Ludwig, H
Article. 10.1038/leu.2016.176. 2017
A randomized, open-label study of the efficacy and safety of galinpepimut-S (GPS) maintenance monotherapy compared to investigator's choice of best available therapy (BAT) in patients with acute myeloid leukemia (AML) who have achieved complete remission (CR) after second-line salvage therapy
Jamy, Omer Hassan; (...); Cicic, Dragan
Meeting Abstract. 2023
A Rare Case of Pure Erythroid Sarcoma in a Pediatric Patient: Case Report and Literature Review.
Manresa, P; (...); Martirena, F
Article. 10.3390/children4120113. 2017
A reproducible strategy for analysis of minimal residual disease measured by Standardized multiparametric flow cytometry in b acute lymphoblastic leukemia
Palao, HS; (...); Lopez, F
Letter. 10.1002/cyto.b.21720. 2019
A retrospective audit of platelet transfusion in a hematology service of a tertiary-care hospital: Effectiveness of training to improve compliance with standards
Letter. 10.1016/j.transci.2013.11.009. 2014
A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome
Huerta, A; (...); de Cordoba, SR
Article. 10.1016/j.kint.2017.06.022. 2018
A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries.
Berard, Emilie; (...); Recher, Christian
Article. 10.1038/s41408-022-00700-x. 2022
A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study
Maggioni, Giulia; (...); Della Porta, Matteo G.
Article. 10.1016/S2352-3026(22)00323-4. 2023
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
Encinas, Cristina; (...); Martinez-Lopez, Joaquin
Article. 10.1038/s41408-022-00652-2. 2022
A Single-Run Next-Generation Sequencing (NGS) Assay for the Simultaneous Detection of Both Gene Mutations and Large Chromosomal Abnormalities in Patients with Myelodysplastic Syndromes (MDS) and Related Myeloid Neoplasms
Liquori, A; (...); Cervera, J
Article. 10.3390/cancers13081947. 2021
A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)
Kuendgen, A.; (...); Sanz, G.
Meeting Abstract. 10.1016/j.leukres.2023.107226. 2023
A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Pemmaraju, Naveen; (...); Daver, Naval
Meeting Abstract. 10.1182/blood-2021-146681. 2021
A systematic review and meta-analysis of the impact of WT1 polymorphism rs16754 in the effectiveness of standard chemotherapy in patients with acute myeloid leukemia
Megías-Vericat JE; (...); Aliño SF
Article. 10.1038/tpj.2015.80. 2016
A systematic review of venetoclax for the treatment of unfit AML patients in real-world: is all that glitters gold?
Solana-Altabella A; (...); Montesinos P
Article. 10.1007/s00277-024-05891-w. 2024
A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients
Pineda, B; (...); Eroles, P
Article. 10.1186/s13148-019-0626-0. 2019
A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): Results of a randomised controlled clinical trial
Meeting Abstract. 2018
Aberrant Alternative Splicing in U2af1/Tet2 Double Mutant Mice Contributes to Major Hematological Phenotypes
Martínez-Valiente C; (...); Sanjuan-Pla A
Article. 10.3390/ijms22136963. 2021
Abnl Marro: An International Cooperative Trial for Patients with MDS/MPN Overlap Syndromes
Savona, Michael R.; (...); Solary, Eric
Meeting Abstract. 10.1182/blood-2019-130722. 2019
ABO incompatibility does not influence transfusion requirements in patients undergoing single-unit umbilical cord blood transplantation
Article. 10.1038/bmt.2016.264. 2017
ACCELERATED FAILURE TIME MODELS AS A CLINICALLY PLAUSIBLE WAY TO DESCRIBE SURVIVAL IN MDS - AN ANALYSIS OF THE IWG-PM DATABASE
Pfeilstoecker, M.; (...); Greenberg, P.
Meeting Abstract. 10.1016/j.leukres.2023.107230. 2023
Accuracy and prognostic impact of FDG PET/CT and biopsyin bone marrow assessment of follicular lymphomaat diagnosis: A Nation-Wide cohort study.
Rodenas-Quinonero, Isabel; (...); Ortuno, Francisco Jose
Article. 10.1002/cam4.5424. 2022
Activity, Tolerability, and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed/Refractory NPM1-Mutated AML
Erba, Harry; (...); Fathi, Amir
Meeting Abstract. 2023
Acute hemolytic reaction by anti-Wra: Case report and review of the hemovigilance database of a tertiary care hospital.
Solves, Pilar; (...); de la Rubia, Javier
Article. 10.1016/j.transci.2021.103342. 2022
Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry.
Hernandez-Boluda, Juan-Carlos; (...); PETHEMA group
Article. 10.1016/j.leukres.2022.106821. 2022
ACUTE MYELOID LEUKEMIA IN PATIENTS 70 AND ABOVE. AZACITIDINE VERSUS INTENSIVE CHEMOTHERAPY
De La Fuente, A.; (...); Ramos, F.
Meeting Abstract. 2014
Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols
Sitges, M; (...); Vives, S
Article. 10.1111/ejh.13417. 2020
Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): Clinical and biological features and comparison with other acute myeloid leukemias with cytogenetic aberrations involving long arm of chromosome 3
Raya JM; (...); Florensa L
Article. 10.1179/1607845415Y.0000000003. 2015
Acute Myeloid Leukemia: Experience of a Single Center in Colombia
Sossa, C; (...); Chalela, C
Meeting Abstract. 10.1016/j.clml.2018.07.067. 2018
Acute Promyelocytic Leukemia during Pregnancy: A Systematic Review of the Literature
Santolaria, A; (...); Sanz, MA
Review. 10.3390/cancers12040968. 2020
Acute Promyelocytic Leukemia: A Constellation of Molecular Events around a Single PML-RARA Fusion Gene
Review. 10.3390/cancers12030624. 2020
Acute Promyelocytic Leukemia: A Constellation of Molecular Events around a Single PML-RARA Fusion Gene (vol 12, 624, 2020)
Article. 10.3390/cancers13143440. 2021
ADAMTS13 RECOVERY IN ACUTE THROMBOTIC THROMBOCYTOPENIC PURPURA AFTER CAPLACIZUMAB THERAPY. THE SPANISH REGISTRY.
Mingot-Castellano, Maria Eva; (...); Pascual Izquierdo, Cristina
Article. 10.1182/blood.2023022725. 2024
Addition of chemotherapy to nivolumab after PD-1 inhibitor failure as bridge to allogeneic stem cell transplantation in classical Hodgkin's lymphoma: report on three cases and literature review
Review. 10.1177/20406207211038181. 2021
Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial
Dohner, H; (...); Ottmann, OG
Article. 10.1097/HS9.0000000000000617. 2021
Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice
Stadtmauer, Edward A.; (...); ZOE-SCT Study Grp Collaborators
Article. 10.1080/21645515.2021.1953346. 2021
Adoptive transfer of ex-vivo expanded SARS-CoV-2-specific Cytotoxic Lymphocytes: a viable strategy for COVID-19 immunosuppressed patients?
Guerreiro M; (...); Piñana JL
Article. 10.1111/tid.13602. 2021
Advances in haploidentical stem cell transplantation for hematologic malignancies
Review. 10.3109/10428194.2016.1167204. 2016
Advances in the management of coagulopathy in acute promyelocytic leukemia
Article. 10.1016/S0049-3848(20)30399-6. 2020
Adverse prognostic impact of complex karyotype (>= 3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL)
Genesca, E; (...); Ribera, JM
Article. 10.1016/j.leukres.2021.106612. 2021
Adverse prognostic value of MYBL2 overexpression and association with microRNA-30 family in acute myeloid leukemia patients.
Fuster O; (...); Barragán E
Article. 10.1016/j.leukres.2013.09.015. 2013
Age-related neuropathies and tubulin acetylation
Fernández-Barrera J, Correas I, Alonso MA
Editorial Material. 10.18632/aging/101432. 2018
AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib plus Azacitidine Versus Placebo plus Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation
Montesinos, Pau; (...); Doehner, Hartmut
Meeting Abstract. 10.1182/blood-2021-147805. 2021
AGILE: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adult Patients with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation
Montesinos Fernandez, Pau; (...); Paschka, Peter
Meeting Abstract. 10.1182/blood-2019-123045. 2019
Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B- Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study
Bar, Noffar; (...); Costa, Luciano
Meeting Abstract. 10.1182/blood-2023-180013. 2023
Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
Wong, Sandy W.; (...); Costa, Luciano J.
Meeting Abstract. 10.1182/blood-2022-159009. 2022
alpha-Thalassemia Does Not Seem to Influence Erythrocyte Deformability in Sickle Cell Trait Carriers
Vayá A; (...); Barragán E
Article. 10.3109/03630269.2014.888353. 2014
ALTERED PHENOTYPES OF MATURING NEUTROPHILS IN MDS
Meeting Abstract. 10.1016/S0145-2126(17)30114-5. 2017
Alternative Donor Transplantation for Severe Aplastic Anemia: A Comparative Study of the Saawp EBMT
Montoro, Juan; (...); De Latour, Regis Peffault
Meeting Abstract. 10.1182/blood-2023-174724. 2023
Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT.
Montoro J; (...); Peffault de Latour R
Article. 10.1182/blood.2024024173. 2024
Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience.
Chihara D; (...); Yakoub-Agha I
Letter. 10.3324/haematol.2022.281754. 2023
Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Maffini, Enrico; (...); Mohty, Mohamad
Article. 10.1038/s41409-023-02027-y. 2023
Allogeneic hematopoietic cell transplantation in an adult patient with Glanzmann thrombasthenia.
Article. 10.1002/ccr3.1206. 2017
Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Genetic Features: Relevance of the Genetic Underlying Category. A Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT.
Esteve, Jordi; (...); Ciceri, Fabio
Article. 10.1002/ajh.27647. 2025
Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia
Dholaria, B; (...); Mohty, M
Article. 10.1186/s13045-021-01086-2. 2021
Allogeneic hematopoietic stem cell transplant recipients in Spain: Human leukocyte antigen characteristics and diversity by high-resolution analysis.
Guerreiro, Manuel; (...); Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH)
Article. 10.1111/tan.14179. 2021
Allogeneic Hematopoietic Stem Cell Transplantation Achieves Long-Term Survival in Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
Berning, Philipp; (...); Glass, Bertram
Meeting Abstract. 10.1182/blood-2022-164637. 2022
Allogeneic hematopoietic stem cell transplantation achieves long-term survival in Natural killer/T-cell lymphoma in the era of Asparaginase-based Chemotherapy
Berning, P.; (...); Glass, B.
Meeting Abstract. 2023
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study
Stahl, M; (...); Zeidan, AM
Article. 10.1016/j.bbmt.2018.03.025. 2018
Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel
de Witte, T; (...); Kröger N
Review. 10.1182/blood-2016-06724500. 2017
Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis.
Berning, Philipp; (...); Glass, Bertram
Article. 10.1038/s41375-023-01924-x. 2023
Allogeneic Hematopoietic Stem Cell Transplantation for T Cell Lymphomas: Improved Results Overtime
Novelli, Silvana; (...); Caballero, Dolores
Meeting Abstract. 10.1182/blood-2019-126507. 2019
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS: EXPERIENCE OF 4 CENTERS
Benzaquen, A.; (...); Hernandez-Boluda, J. C.
Meeting Abstract. 2019
Allogeneic hematopoietic stem cell transplantation in patients with multiple myeloma. Impact of disease characteristics, disease status at transplant, and prior number of lines of therapy. Results of retrospective, multicentre Spanish study
De la Rubia, J; (...); Gonzalez, MS
Meeting Abstract. 2019
Allogeneic Hematopoietic Stem Cell Transplantation in Transformed Follicular Lymphoma (tFL): Results of a Retrospective Multicenter Study from GELTAMO/GETH-TC Spanish Groups
Rey-Bua, Beatriz; (...); Martin Garcia-Sancho, Alejandro
Article. 10.3390/cancers14225670. 2022
Allogeneic hsct in HIV-1 infected patients with hematological disorders: Multicenter experience from GETH (Spanish group of HSCT and cell therapy)
Kwon, M; (...); Diez-Martin, JL
Meeting Abstract. 2019
Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion
Garderet, L; (...); Kröger N
Article. 10.1016/j.bbmt.2017.11.017. 2018
Allogeneic Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia (AML) in Second Complete Remission (CR2) Transplanted from Unrelated Donors with Post Transplant Cyclophosphamide (PTCy). a Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Nagler, Arnon; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2021-144894. 2021
Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) in second complete remission (CR2) transplanted from unrelated donors with post-transplant cyclophosphamide (PTCy). A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler, Arnon; (...); Mohty, Mohamad
Article. 10.1038/s41409-023-01940-6. 2023
Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
Poire, X; (...); Nagler, A
Article. 10.1186/s13045-017-0393-3. 2017
Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in first complete remission: data from the EBMT.
Al Hamed R; (...); Mohty M
Article. 10.1038/s41409-024-02373-5. 2024
Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience.
Gutierrez, Antonio; (...); Geltamo
Article. 10.3390/cancers14112673. 2022
Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers.
Novelli, Silvana; (...); Caballero, Dolores
Article. 10.1016/j.jtct.2021.03.014. 2021
Allogeneic stem-cell transplantation in HIV-1-infected patients with high-risk hematological disorders
Kwon, M; (...); Grp Espanol Trasplante Hematopoyet
Article. 10.1097/QAD.0000000000002209. 2019
ALLOGENEIC TRANSPLANTATION FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA WITH MYELODYSPLASIA-RELATED FEATURES AS PER THE INTERNATIONAL CONSENSUS CLASSIFICATION (ICC) 2022: FROM THE ALWP OF THE EBMT
Nagler, Arnon; (...); Mohty, Mohamad
Meeting Abstract. 2024
ALLOGENEIC TRANSPLANTATION OF HEMATOPOIETIC PROGENITORS (T-ALO) IN PATIENTS WITH MULTIPLE MYELOMA (MM). IMPACT OF BIOLOGICAL CHARACTERISTICS TO DIAGNOSIS, TPH DISEASE SITUATION AND TREATMENT LINES. SPANISH MULTICENTRIC RETROSPECTIVE STUDY
Perez, A.; (...); Solano, C.
Meeting Abstract. 2019
All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies
Sanz MA; (...); IC-APL and PETHEMA and HOVON Groups
Article. 10.1007/s00277-015-2393-0. 2015
AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular.
Castano-Diez, Sandra; (...); Diaz-Beya, Marina
Article. 10.1182/bloodadvances.2024013648. 2025
An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS
Stahl, Maximilian; (...); Zeidan, Amer M.
Letter. 10.1182/bloodadvances.2022008747. 2023
An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens
Sobas, M; (...); GATLA Cooperative Grp
Article. 10.1080/10428194.2018.1516875. 2019
An Epigenetic Signature in Adipose Tissue Is Linked to Nicotinamide N-Methyltransferase Gene Expression.
Crujeiras, AB; (...); Fernandez-Real, JM
Article. 10.1002/mnfr.201700933. 2018
An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia
Shouval, Roni; (...); Nagler, Arnon
Article. 10.1158/1078-0432.CCR-17-0489. 2017
AN INTERIM ANALYSIS OF FOVOCIP: A MULTICENTER RANDOMIZED TRIAL OF FOSFOMYCIN VERSUS CIPROFLOXACIN FOR FEBRILE NEUTROPENIA PREVENTION IN HEMATOLOGIC PATIENTS
Fernandez Moreno, Ahinoa; (...); Bernal, Teresa
Meeting Abstract. 2024
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults
Savona MR; (...); MDS
Article. 10.1182/blood-2014-10-607341. 2015
An investigation of the potential association between gastrointestinal viral and bacterial infection and development of intestinal acute graft versus host disease following allogeneic hematopoietic stem cell transplantation.
Bueno F; (...); Navarro D
Article. 10.1002/jmv.26892. 2021
An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia.
Fiedler, Walter; (...); Blum, William
Article. 10.3324/haematol.2022.281128. 2022
Analysis of copy number alterations reveals the lncRNA ALAL-1 as a regulator of lung cancer immune evasion
Athie, A; (...); Huarte, M
Article. 10.1083/jcb.201908078. 2020
Analysis of minimal residual disease in bone marrow by NGF and in peripheral blood by mass spectrometry in newly diagnosed multiple myeloma patients enrolled in the GEM2012MENOS65 clinical trial.
Puig, Noemi; (...); Mateos, Maria-Victoria
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.8010. 2021
Analysis of Peripheral Blood and Bone Marrow Residual Disease Dynamics during Intensive Treatment and Maintenance in Patients with Multiple Myeloma Included in the GEM12MENOS65 and GEM14MAIN Clinical Trials
Puig, Noemi; (...); Victoria Mateos, Maria
Meeting Abstract. 10.1182/blood-2023-184837. 2023
Analysis of post Allo-HCT relapse in acute leukaemia patients, a comparative on second Allo-HCT and donor lymphocyte infusions
Orti, G; (...); Valcarcel, D
Meeting Abstract. 2017
ANALYSIS OF PROGRESSION-FREE SURVIVAL OF AND GLOBAL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA OLDER THAN 65 YEARS CANDIDATES FOR AUTOLOGOUS PERIPHERAL BLOOD TRANSPLANTATION NON-CANDIDATES
Cejalvo, MJ; (...); De la Rubia, J
Meeting Abstract. 2017
Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions
Orti, G; (...); Valcarcel, D
Article. 10.1016/j.exphem.2018.03.002. 2018
ANALYSIS OF RESIDUAL DISEASE IN PERIPHERAL BLOOD BY MEANS OF MASS SPECTROMETRY IN PATIENTS WITH MULTIPLE MYELOMA OF THE GEM 2012 MINUS65. COMPARISON WITH THE IMWG STANDARD RESPONSE AND RESIDUAL DISEASE CRITERIA
Puig, N.; (...); Mateos, M., V
Meeting Abstract. 2021
Analysis of SNP Array Abnormalities in Patients with DE NOVO Acute Myeloid Leukemia with Normal Karyotype
Ibanez, M; (...); Cervera, J
Article. 10.1038/s41598-020-61589-9. 2020
Analysis of the Possible Persistent Genotoxic Damage in Workers Linked to the Ardystil Syndrome
Montoro, Alegria; (...); Ignacio Villaescusa, Juan
Article. 10.1089/gtmb.2015.0177. 2016
ANALYSIS OF THE PREDICTIVE VALUE OF THE DIRECT ANTIGLOBULIN TEST (PAD) IN THE DIAGNOSIS OF THE NEWBORN HEMOLYTIC DISEASE (EHRN) FOR ABO INCOMPATIBILITY
Alberte, CF; (...); Alonso, MAS
Meeting Abstract. 2017
ANALYSIS OF THE PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN ELDERLY PATIENTS (65 YEARS OLD) WITH MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION.
Cejalvo, MJ; (...); De la Rubia J
Meeting Abstract. 2018
Analysis of three salvage treatment regimens after relapsed/refractory acute myeloi leukemia (AML) (FLAG-Ida, FLAGO-IDA and PLERIFLAG)
Bergua, J; (...); Montesinos, P
Meeting Abstract. 2018
Anti-CD19 CAR-T cell therapy in elderly patients: multicentric real-world experience from GETH-TC/GELTAMO.
Bailen, Rebeca; (...); Kwon, Mi
Article. 10.1016/j.jtct.2024.06.022. 2024
Anti-D Alloimmunization after RhD-Positive Platelet Transfusion in RhD-Negative Women under 55 Years Diagnosed with Acute Leukemia: Results of a Retrospective Study
Villalba, A; (...); Solves, P
Article. 10.1159/000488804. 2018
Antineoplastic agents exacerbating Charcot Marie Tooth disease: red flags to avoid permanent disability
Ibañez-Juliá MJ; (...); Psimaras, D
Article. 10.1080/0284186X.2017.1415462. 2018
ANTITHYMOCYTE GLOBULIN - OR ALEMTUZUMAB-BASED GVHD PROPHYLAXIS IN REDUCED- INTENSITY CONDITIONING ALLO-HCT FOR ACUTE LYMPHOBLASTIC LEUKEMIA IN CR1: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY
Bug, Gesine; (...); Mohty, Mohamad
Meeting Abstract. 2023
Apicobasal Polarity Controls Lymphocyte Adhesion to Hepatic Epithelial Cells
Reglero-Real N; (...); Millán J
Article. 10.1016/j.celrep.2014.08.007. 2014
Application of a Validated Composite Comorbidity Score Measuring Both Fitness and Cytogenetic Risk to Assess Outcomes in 1L AML Patients Who Received Venetoclax Plus Azacitidine in Viale-A
Venditti, Adriano; (...); Pullarkat, Vinod A.
Meeting Abstract. 10.1182/blood-2022-158500. 2022
Application of FISH 7q in MDS patients without monosomy 7 or 7q deletion by conventional G-banding cytogenetics: does -7/7q- detection by FISH have prognostic value?
Ademà V; (...); Solé F
Article. 10.1016/j.leukres.2012.12.010. 2013
APPLICATION OF THE MASS SEQUENCING FOR THE STUDY OF MUTATIONS, REORDERINGS AND CHANGES IN GENE EXPRESSION IN THE HEMATOLOGICAL MYELOID NEOPLASIAS
Simarro, CS; (...); Gonzalez, EB
Meeting Abstract. 2018
APPROACH TO THE STUDY OF THE ALTERATIONS OF METABOLISM IN THE LMA
Simarro, CS; (...); Gonzalez, EB
Meeting Abstract. 2018
Are any specific respiratory viruses more severe than others in recipients of allogeneic stem cell transplantation? A focus on lower respiratory tract disease.
Pérez A; (...); Piñana JL
Article. 10.1038/s41409-024-02304-4. 2024
Are next-generation sequencing results knocking on Heaven's door for transplantation planning in chronic myelomonocytic leukemia?
Sanz GF, Ibañez M, Mora E
Editorial Material. 10.3324/haematol.2019.240853. 2020
Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet
Lengfelder E; (...); European LeukemiaNet
Article. 10.1038/leu.2015.12. 2015
ASB1 differential methylation in ischaemic cardiomyopathy: relationship with left ventricular performance in end-stage heart failure patients
Ortega, A; (...); Rivera, M
Article. 10.1002/ehf2.12289. 2018
Asparaginase use for the treatment of acute lymphoblastic leukemia
Barba, Pere; (...); Rives, Susana
Article. 10.1016/j.medcli.2016.12.006. 2017
Assemblable 3D biomimetic microenvironment for hMSC osteogenic differentiation
Martins, Luis A.; (...); Gomez-Ribelles, Jose Luis
Article. 10.1088/1748-605X/ad7dc4. 2024
Assessment of immunodeficiency scoring index performance in enterovirus/rhinovirus respiratory infection after allogeneic hematopoietic stem cell transplantation
Perez, A; (...); Pinana, JL
Article. 10.1111/tid.13301. 2020
Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin
Rodriguez-Veiga, R; (...); spanish PETHEMA group
Article. 10.1007/s00277-017-3004-z. 2017
Assessment of the Immunodeficiency Scoring Index for predicting outcomes after Respiratory Syncytial Virus infection in Allogeneic Stem Cell Transplant recipients.: ISI performance for RVS infections after allo-HCT.
Mico-Cerda, Mireia; (...); Pinana, Jose Luis
Article. 10.1016/j.jtct.2025.02.012. 2025
Assessment of the potential value of plasma Torque Teno virus DNA load monitoring to predict cytomegalovirus DNAemia in patients with hematological malignancies treated with small molecule inhibitors: A proof-of-concept study.
de la Asunción CS; (...); Navarro D
Article. 10.1002/jmv.28933. 2023
Assessment of Treatment Response By Ife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS65 Clinical Trial
Puig, Noemi; (...); Mateis, Maria-Victoria
Meeting Abstract. 10.1182/blood-2021-151557. 2021
Association of Unbalanced Translocation der(1;7) with Germline GATA2 Mutations.
Kozyra, EJ; (...); Wlodarski, MW
Article. 10.1182/blood.2021012781. 2021
Atypical B-Cell Acute Lymphoblastic Leukemia with iAMP21 in the Context of Constitutional Ring Chromosome 21: A Case Report and Review of the Genetic Insights.
Gil, Jose Vicente; (...); Llop, Marta
Article. 10.3390/ijms26010357. 2025
Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy.
Wei, AH; (...); DiNardo, CD
Article. 10.1038/s41408-021-00565-6. 2021
Author Correction: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA.
Sánchez R; (...); Martínez-López J
Correction. 10.1038/s41598-024-57570-5. 2024
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.
Bernard E; (...); Papaemmanuil E
Correction. 10.1038/s41591-021-01253-5. 2021
Autoimmune cytopenias after umbilical cord blood transplantation in adults with hematological malignancies: a single-center experience
Article. 10.1038/bmt.2014.107. 2014
Autoimmune hemolytic anemia (AIHA) following allogeneic hematopoietic stem cell transplantation (HSCT): A retrospective analysis and a proposal of treatment on behalf of the Grupo Espanol De Trasplante de Medula Osea en Nimos (GETMON) and the Grupo Espanol de Trasplante Hematopoyetico (GETH)
Gonzalez-Vicent, M; (...); Sanz, MA
Review. 10.1016/j.tmrv.2018.02.005. 2018
Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis
Casanova, B; (...); Coret, F
Article. 10.1007/s10072-017-2933-6. 2017
Autologous or allogeneic hematopoietic stem cell transplantation as front-line treatment for adult secondary acute myeloid leukemia patients: the PETHEMA registry experience.
Serrano, Josefina; (...); Montesinos, Pau
Article. 10.1016/j.jtct.2025.02.011. 2025
Autologous stem cell ovarian transplant (ASCOT), allowed 5 pregnancies in poor responders (PR) women
De Castellvi, NP; (...); Pellicer, A
Meeting Abstract. 2018
Autologous stem cell ovarian transplantation to increase reproductive potential in patients who are poor responders
Herraiz, S; (...); Pellicer, A
Article. 10.1016/j.fertnstert.2018.04.025. 2018
Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial
Briones J; (...); Grupo Español de Linfomas y Trasplante Autologo de Médula Ósea (GELTAMO)
Letter. 10.3324/haematol.2014.108308. 2014
Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial
Briones J; (...); GELTAMO
Article. 10.3324/haematol.2013.093450. 2014
Autologous stem cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study.
García-Sancho AM; (...); Caballero D
Article. 10.3324/haematol.2021.279426. 2022
Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure
Jiménez-Ubieto A; (...); Lahuerta JJ
Article. 10.1016/j.bbmt.2017.05.021. 2017
Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment
Jimenez-Ubieto, A; (...); GELTAMO Grp Espanol Linfomas Tr
Article. 10.1002/hon.2553. 2018
Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure without the need for immunotherapy.
Jiménez-Ubieto A; (...); GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) Cooperative Stu
Article. 10.1016/j.hemonc.2019.06.001. 2019
Autologous Stem Cell Transplantation may potentially abrogate the negative prognostic effect of early relapse after chemo or inmunochemotherapy in Follicular Lymphoma
Ubieto, AJ; (...); Lahuerta, JJ
Meeting Abstract. 2018
Autologous Stem Cell Transplantation Remains a Curative Option As Second Line Treatment for Patients with Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geth-TC/Geltamo Study
Bento, Leyre; (...); Garcia-Sancho, Alejandro Martin
Meeting Abstract. 10.1182/blood-2023-186730. 2023
AUTONOMOUS TRANSPLANTATION CAN MITIGATE THE ADVERSE PROGNOSIS OF THE EARLY RELAPSE AFTER CHEMO OR IMMUNOCHEMOTHERAPY INDUCTION IN FOLLICULAR LYMPHOMA
Ubieto, AJ; (...); Lahuerta, J. J.
Meeting Abstract. 2017
Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI).
Pascual-Izquierdo C; (...); Mingot-Castellano ME
Article. 10.1002/ajh.27498. 2024
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma.
Kwon M; (...); Barba P
Article. 10.3324/haematol.2022.280805. 2023
Axicabtagene Ciloleucel Compared to Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma in the Real World Setting in Spain
Kwon, Mi; (...); Barba, Pere
Meeting Abstract. 10.1182/blood-2021-147369. 2021
Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries
Diez-Campelo, M; (...); Fenaux, P
Article. 10.1111/bjh.15190. 2018
Azacitidine in older patients with acute myeloid leukemia (AML). Results from the ALMA study according to the MRC risk index score.
Falantes, Jose F.; (...); Ramos, Fernando
Meeting Abstract. 2015
Azacitidine or Decitabine Monotherapy for the Treatment of AML: A Comparative Systematic Review and Meta-Analysis
Saiz-Rodriguez, M; (...); Montesinos, P
Meeting Abstract. 2021
AZACITIDINE VS. DECITABIN IN PATIENTS WITH ACUTE MYELOID LEUKEMIA RE-DIAGNOSED: RESULTS OF THE PETHEMA AML REGISTER
Jorge, Labrador; (...); Pau, Montesinos
Meeting Abstract. 2021
Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry
Labrador J; (...); Montesinos P
Article. 10.3390/cancers14092342. 2022
Baseline circulating myeloid-derived suppressor cells correlate with neutrophil-to-lymphocyte ratio and overall survival in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors
Garcia-Sanchez, J.; (...); Lahoz, A.
Meeting Abstract. 2021
Baseline circulating myeloid-derived suppressor cells subpopulations, neutrophils/lymphocytes ratio, and response to PD-1/PD-L1 inhibitor in non-small cell lung cancer patients.
SAnchez, JosE GarcIa; (...); Lahoz, Agustin
Meeting Abstract. 2020
Basic Science and Pathogenesis.
Comas-Alberti, Aina; (...); Antonell, Anna
Article. 10.1002/alz.088732. 2024
BEAM Vs Cyclophosphamide-Based Conditioning Regimen in Aggressive Multiple Sclerosis: A Retrospective Analysis of European Blood and Marrow Transplantation Society
Saccardi, Riccardo; (...); Snowden, John A.
Meeting Abstract. 10.1182/blood-2019-125233. 2019
Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial
Gonzalez-Calle, Veronica; (...); Mateos, Maria-Victoria
Meeting Abstract. 10.1182/blood-2022-162584. 2022
Belantamab Mafodotin in Combination with VRd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-VRd Trial
Gonzalez-Calle, Veronica; (...); Mateos, Maria-Victoria
Meeting Abstract. https://doi.org/10.1182/blood-2022-162584. 2024
Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Experience with a Spanish Cohort
De la Rubia, Javier; (...); Alegre, Adrian
Meeting Abstract. 10.1182/blood-2022-158538. 2022
Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain.
de la Rubia, Javier; (...); Alegre, Adrian
Article. 10.3390/cancers15112964. 2023
Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group
Redondo, AM; (...); GEL-TAMO
Article. 10.1111/bjh.15713. 2019
Bendamustine plus rituximab in untreated chronic lymphocytic leukemia patients. The MDA-CLL-2015-02 study
De La Fuente, A; (...); Baltasar, P
Meeting Abstract. 2017
Best practices and recommendations for drug regimens and plasma exchange for immune thrombotic thrombocytopenic purpura
Gomez-Segui, I, Izquierdo, CP, Comos, JD
Review. 10.1080/17474086.2021.1956898. 2021
Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups
Bastos-Oreiro, Mariana; (...); Garcia-Sancho, Alejandro Martin
Article. 10.3389/fimmu.2022.855730. 2022
Biallelic TET2 mutation sensitizes to 5'-azacitidine in acute myeloid leukemia.
Stölzel F; (...); Allan, James M.
Article. 10.1172/jci.insight.150368. 2022
Biomimetic 3D Environment Based on Microgels as a Model for the Generation of Drug Resistance in Multiple Myeloma.
Marin-Paya, Juan Carlos; (...); Gomez Ribelles, Jose Luis
Article. 10.3390/ma14237121. 2021
Biomimetic microspheres for 3D mesenchymal stem cell culture and characterization
Clara-Trujillo, S; (...); Ribelles, JLG
Article. 10.1016/j.colsurfb.2019.01.050. 2019
Bispecific T-Cell Engagers for B-Cell NON-Hodgkin Lymphoma Patients before Allogeneic Stem Cell Transplantation. a Study on Behalf Od Geth-TC
Pena, Marta; (...); Balari, Anna Maria Sureda
Meeting Abstract. 10.1182/blood-2023-181815. 2023
Bladder cancer patients have increased NETosis and impaired DNaseI-mediated NET degradation that can be therapeutically restored in vitro.
Article. 10.3389/fimmu.2023.1171065. 2023
Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Approved CD123-Targeted Therapy Tagraxofusp: The First European Real-World Evidence Prospective Registry of First-Line Adult Patients
Platzbecker, Uwe; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2022-160127. 2022
BLINATUMOMAB IMPROVED OVERALL SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY PHILADELPHIA NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY (TOWER)
Topp, M. S.; (...); Kantarjian, H.
Meeting Abstract. 2016
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H; (...); Topp, MS
Article. 10.1056/NEJMoa1609783. 2017
Bloodstream Infections in Adult Patients Undergoing Cord Blood Transplantation from Unrelated Donors after Myeloablative Conditioning Regimen
Article. 10.1016/j.bbmt.2014.12.038. 2015
BONE BIOPSY AGAINST PET/CT IN THE DETERMINATION OF MEDULAR INFILTRATION IN INITIAL STATISTICS IN FOLLICULAR LYMPHOMA: DIAGNOSTIC PRECISION AND PRONOSTIC IMPACT
Reguilon Gallego, L.; (...); Jerez Cayuela, A.
Meeting Abstract. 2019
BONE MARROW BIOPSY SUPERIORITY OVER PET/CT IN PREDICTING PROGRESSION FREE SURVIVAL IN A HOMOGENOUSLY-TREATED COHORT OF DIFFUSE LARGE B-CELL LYMPHOMA
Liang, THC; (...); Ortuno, FJ
Meeting Abstract. 2017
Bone marrow biopsy superiority over PET/CT in predicting progression-free survival in a homogeneously-treated cohort of diffuse large B-cell lymphoma
Chen-Liang, TH; (...); Jose Ortuno, Francisco
Article. 10.1002/cam4.1205. 2017
Bone marrow derived stem cells restore ovarian function and fertility in premature ovarian insufficiency women. Interim report of a randomized trial: mobilization versus ovarian injection
De Castellvi, NP; (...); Pellicer, A.
Meeting Abstract. 2020
Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis
Ramos, F; (...); Hernandez-Rivas, JM
Article. 10.18632/oncotarget.9026. 2016
Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial
Rosiñol L; (...); Bladé J
Article. 10.1038/leu.2017.35. 2017
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplantation in multiple myeloma.
Rosiñol L; (...); Bladé J
Article. 10.1182/blood.2019000241. 2019
Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma
Blanes M; (...); de la Rubia J
Article. 10.3109/10428194.2014.922182. 2015
BRAF V600E mutation in adult acute lymphoblastic leukemia.
Alonso CM; (...); Sanz Alonso MA
Letter. 10.3109/10428194.2012.733878. 2013
BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study
de Juan I; (...); Bolufer P
Article. 10.1007/s10689-015-9814-z. 2015
Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Daver, Naval; (...); Sweet, Kendra
Meeting Abstract. 10.1182/blood-2022-158030. 2022
Building a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in HematologY Added Value Framework for Hematologic Malignancies: A Comparative Analysis of Existing Tools.
Cerisoli, Francesco; (...); Hernandez Rivas, Jesus Maria
Article. 10.1016/j.jval.2022.04.1729. 2022
BUMEL vs MEL-200 prior autologous transplant for patients with newly diagnosed multiple myeloma previously treated with bortezomib, lenalidomide and dexamethasone: final results of a phase 3 trial
Lahuerta Palacios, Juan Jose; (...); Blade, Joan
Meeting Abstract. 2022
Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience
Gayoso, J; (...); Diez-Martin, JL
Article. 10.1038/bmt.2016.115. 2016
Cancer Epigenetic Biomarkers in Liquid Biopsy for High Incidence Malignancies
Palanca-Ballester, Cora; (...); Calvo, Alfonso
Article. 10.3390/cancers13123016. 2021
Caplacizumab Frontline Added to Therapeutic Plasma Exchange and Immunosuppression Prevents Unfavorable Outcomes in Immune-Mediated TTP: An International Real-World Study of the TTP-IWG (The Capla 500 Project)
Coppo, Paul; (...); Scully, Marie
Meeting Abstract. 10.1182/blood-2023-179316. 2023
Caplacizumab Treatment in Elderly Patients with iTTP: Updated Experience from the Spanish TTP Registry
Gomez Segui, Ines; (...); De La Rubia, Javier
Meeting Abstract. 10.1182/blood-2023-180970. 2023
CART-AI-Radiomics: Survival and Neurotoxicity Prediction in B-Cell Lymphoma Patients Treated with CAR-T Cells through an Imaging Features-Based Model
Ferrer Lores, Blanca; (...); Jose Terol, Maria
Meeting Abstract. 10.1182/blood-2023-185088. 2023
Case report of a trichohepatoenteric syndrome due to heterozygous compound of novel mutations in ttc37 gen
Polo, B.; (...); Cervera, J.
Meeting Abstract. 2019
CASE REPORT OF SHAAF-YANG SYNDROME WITH A DE NOVO MUTATION IN MAGEL2 GEN
Pi, G.; (...); Cervera, J.
Meeting Abstract. 2019
Case Report: Partial Uniparental Disomy Unmasks a Novel Recessive Mutation in the LYST Gene in a Patient With a Severe Phenotype of Chediak-Higashi Syndrome.
Boluda-Navarro, Mireia; (...); Cervera, Jose Vicente
Article. 10.3389/fimmu.2021.625591. 2021
Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry.
Madry, Krzysztof; (...); Smith, Alex
Article. 10.1111/bjh.18542. 2022
CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8(+) T Cell-Relevant Genes
Aznar, MA; (...); Melero, I
Article. 10.1158/2326-6066.CIR-17-0159. 2018
Central nervous system disorders after hematopoietic stem cell transplantation: a prospective study of the Infectious Diseases Working Party of EBMT.
Schmidt-Hieber M; (...); Styczynski J
Article. 10.1007/s00415-019-09578-5. 2020
Central Nervous System Involvement in Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation.
Balaguer-Rosello, Aitana; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2020.12.019. 2021
Central nervous system manifestations in acute and chronic graft-versus-host disease.
Lambert N; (...); Maquet P
Article. 10.1093/brain/awae340. 2024
CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia
Barragán E; (...); Odero MD
Letter. 10.3324/haematol.2014.118117. 2015
Circulating megakaryocyte in primary myelofibrosis. An uncommon finding in a myelofibrosis blood smear.
Cantó PA, Peris MLS, Castera EM
Editorial Material. 10.5045/br.2021.2020269. 2021
Circulating MicroRNAs as Novel Biomarkers of Stenosis Progression in Asymptomatic Carotid Stenosis
Dolz, S; (...); Lago, A
Article. 10.1161/STROKEAHA.116.013650. 2017
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma.
Garces, Juan-Jose; (...); Paiva, Bruno
Article. 10.1200/JCO.21.01365. 2022
Cis-Acting Splicing-Associated Variants Can Redefine the Molecular Signature of Genes Commonly Mutated in Acute Myeloid Leukemia
Morote-Faubel, Mireya; (...); Cervera, Jose
Meeting Abstract. 10.1182/blood-2023-177571. 2023
Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile
Martín-Martín L; (...); Almeida J
Article. 10.18632/oncotarget.4146. 2015
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes.
Bersanelli M; (...); Della Porta MG
Article. 10.1200/JCO.20.01659. 2021
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).
Stahl M; (...); Zeidan AM
Article. 10.1016/j.blre.2023.101128. 2023
Clinical and Biological Characterization of Low Risk MDS Patients According to Ring Sideroblasts (RS). Comparison between the 3 Subgroups in WHO2017 Classification. Study from the Spanish MDS Registry
Lopez Cadenas, Felix; (...); Diez-Campelo, Maria
Meeting Abstract. 10.1182/blood-2021-152678. 2021
Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group
Nomdedeu, M; (...); Spanish MDS Group
Article. 10.1016/j.leukres.2017.10.011. 2017
Clinical and biological significance of Y chromosome loss in a series of 2,423 male patients with Myelodysplastic syndromes and Chronic Myelomonocytic Leukemia
Costa, D.; (...); Campo, E.
Meeting Abstract. 2018
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes.
Tentori CA; (...); Della Porta MG
Article. 10.1200/JCO.23.02175. 2024
Clinical and molecular characterization by next generation sequencing of Spanish patients affected by congenital deficiencies of fibrinogen.
Moret, A; (...); Bonanad, S
Letter. 10.1016/j.thromres.2019.06.015. 2019
CLINICAL AND MOLECULAR CHARACTERIZATION OF PATIENTS WITH THERAPY RELATED MYELOID NEOPLASMS
Calvete, O.; (...); Sole, F.
Meeting Abstract. 10.1016/j.leukres.2023.107176. 2023
Clinical and Molecular Characterization of Patients with Therapy Related Myeloid Neoplasms ( TRMN)
Calvete, Oriol; (...); Kanagal-Shamanna, Rashmi
Meeting Abstract. 10.1182/blood-2023-188701. 2023
CLINICAL APPLICATION OF THE MASSIVE SEQUENCING ADDRESSED IN ACUTE MYELOBLASTIC LEUKEMIA
Garcia, ML; (...); Gonzalez, EB
Meeting Abstract. 2017
Clinical Benefit of Glasdegib Plus Low-Dose Cytarabine in Patients with De Novo and Secondary Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial
Heuser, M; (...); Cortes, JE
Meeting Abstract. 10.1016/j.clml.2019.07.116. 2019
Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial (vol 100, pg 1181, 2021)
Heuser, Michael; (...); Cortes, Jorge E.
Article. 10.1007/s00277-021-04545-5. 2021
Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
Heuser M; (...); Cortes JE
Article. 10.1007/s00277-021-04465-4. 2021
Clinical Characteristics and Cardioavscular Events in Patients with Esential Thrombocythemia with < 10% Vs. >= 10% JAK2 V617F Allele Burden
Xicoy, Blanca; (...); Zamora, Lurdes
Meeting Abstract. 10.1182/blood-2019-126980. 2019
Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country.
Muntañola A; (...); Bosch F
Letter. 10.1186/s40164-020-00195-x. 2020
Clinical Characteristics and Transfusion Management of Patients Diagnosed of Multiple Myeloma Receiving Daratumumab: Experience of a Single Centre
Arnao, M; (...); Sanz, G
Meeting Abstract. 10.1016/j.clml.2019.09.254. 2019
Clinical Characteristics of Chilean Adult Patients with Acute Myeloid Leukemia (AML): Analysis within the Framework of the Epidemiological Registry of AML of the Pethema Group
Romero, Alejandra; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2022-163869. 2022
Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid
Sanchez, R; (...); Martinez-Lopez, J
Article. 10.1007/s00277-017-3002-1. 2017
Clinical Characteristics, Treatment Approach and Long-Term Outcomes of 678 Patients with Symptomatic Waldenstrom's Macroglobulinemia: Comprehensive Insights from a Spanish Registry of IgM Gammapathies
Askari, Elham; (...); Garcia-Sanz, Ramon
Meeting Abstract. 10.1182/blood-2023-189581. 2023
Clinical Effectiveness of Influenza Vaccination After Allogeneic Hematopoietic Stem Cell Transplantation: A Cross-sectional, Prospective, Observational Study
Pinana, JL; (...); Navarro, D
Article. 10.1093/cid/ciy792. 2019
Clinical Features and Treatment in Patients Diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm: Interim Analysis from the Pethema Epidemiologic Registry (EPI-BLAS study)
Vicente, Navarro; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2023-190296. 2023
Clinical Impact of Next Generation Flow in Bone Marrow Vs Qip-Mass Spectrometry in Peripheral Blood to Assess Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients Receiving Maintenance As Part of the GEM2014MAIN Trial
Puig, Noemi; (...); Mateos, Maria-Victoria
Meeting Abstract. 10.1182/blood-2022-165441. 2022
Clinical Implications of p53 Dysfunction in Patients with Myelodysplastic Syndromes
Riva, Elena; (...); Della Porta, Matteo G.
Meeting Abstract. 10.1182/blood-2022-166050. 2022
Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry.
Bernal, Teresa; (...); Montesinos, Pau
Article. 10.1002/cam4.6120. 2023
Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib
Perl, AE; (...); Tiu, RV
Meeting Abstract. 2021
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.
Perl, Alexander E.; (...); Altman, Jessica K.
Article. 10.1038/s41408-022-00677-7. 2022
Clinical Outcomes of Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Hematopoietic Stem Cell Transplantation Who Fail Rituximab: A Multinational, Retrospective Chart Review Study
Sanz, Jaime; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2021-147296. 2021
Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Bazarbachi, A; (...); Mohty, M
Article. 10.3324/haematol.2019.243410. 2020
Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Daver, Naval G.; (...); Kantarjian, Hagop M.
Meeting Abstract. 10.1182/blood-2019-128648. 2019
CLINICAL RESULTS AND TRANSFUSIONAL MANAGEMENT IN PATIENTS WITH MULTIPLE MYELOMA IN TREATMENT WITH DARATUMUMAB: EXPERIENCE OF A SINGLE CENTER
Blanco, J. A.; (...); Sanz Santillana, G.
Meeting Abstract. 2019
Clinical Significance and Transcriptional Profiling of Persistent Minimal Residual Disease (MRD) in Multiple Myeloma (MM) Patients with Standard-Risk (SR) and High-Risk (HR) Cytogenetics
Goicoechea, I; (...); Paiva, B
Meeting Abstract. 10.1182/blood-2018-99-113312. 2018
Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy
Labrador, J; (...); GATLA Grp
Article. 10.1080/10428194.2018.1522438. 2019
Clinical significance of Pneumocystis jirovecii DNA detection by real-time PCR in hematological patient respiratory specimens.
Piñana JL; (...); Navarro D
Letter. 10.1016/j.jinf.2020.01.001. 2020
Clinical Significance of Sensitive Flow-MRD Monitoring in Elderly Multiple Myeloma Patients on the Pethema/GEM2010MAS65 Trial
Paiva, Bruno; (...); San Miguel, Jesus F.
Meeting Abstract. 2014
Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia Diagnostics
Alonso, CM; (...); Barragan, E
Article. 10.1016/j.jmoldx.2018.09.009. 2019
CLINICAL-BIOLOGICAL AND PROGNOSTIC CHARACTERISTICS OF LOW RISK SMD WITHOUT RING SIDEROBLASTS AND COMPARISON WITH ITS COUNTERPART WITH RING SIDEROBLASTS
Cadenas Felix, Lopez; (...); Ferreiras David, Valcarcel
Meeting Abstract. 2021
Clinician Concepts of Cure in Adult Relapsed and Refractory Philadelphia-Negative B Cell Precursor Acute Lymphoblastic Leukemia: A Delphi Study
Bassan, R; (...); Cong, Z
Article. 10.1007/s12325-019-00910-z. 2019
Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance
Schanz, J; (...); Haase, D
Article. 10.1002/gcc.22667. 2018
Clonal composition and its prognostic significance in patients with MDS
Schanz, J; (...); Int Working Grp Prognosis MDS
Meeting Abstract. 2018
Clonal Cytopenias and Oligoblastic Myelogenous Leukemia (myelodysplasia) Have Neoplastic, not Hyperplastic, Erythropoiesis Reply
Arenillas, L; (...); Florensa, L
Letter. 10.1200/JCO.2016.71.3941. 2017
Clonal Evolution Analysis Using Next Generation Sequencing (NGS) Panel in a Cohort of 3,025 Patients With Acute Myeloid Leukemia (AML)
Colmenares, Rafael; (...); Montesinos, Pau
Meeting Abstract. 2023
Clonal genetic evolution at relapse of favorable-risk acute myeloid leukemia with NPM1 mutation is associated with phenotypic changes and worse outcomes
Martinez-Losada, C; (...); Sanchez-Garcia, J
Letter. 10.3324/haematol.2018.188433. 2018
Clonal Hematopoiesis Landscape in Patients with De Novo Acute Myeloid Leukemia By Deep Sequencing
Ibanez, Mariam; (...); Cervera, Jose
Meeting Abstract. 10.1182/blood.V128.22.598.598. 2016
CMV REACTIVATIONS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FROM HLA-MATCHED AND HAPLOIDENTICAL DONORS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE.
Article. 10.1016/j.jtct.2024.01.082. 2024
CNS Prophylaxis in Adult ALL Patients after Stem Cell Transplantation: An EBMT Survey on General Practice
Chiusolo, Patrizia; (...); Ciceri, Fabio
Meeting Abstract. 10.1182/blood-2023-182831. 2023
Co-culture of multiple myeloma cell lines and bone marrow mesenchymal stem cells in a 3D microgel environment.
Garcia-Briega, M Inmaculada; (...); Ribelles, Jose Luis Gomez
Article. 10.1016/j.bioadv.2025.214243. 2025
Cohort-Controlled Comparison of Umbilical Cord Blood Transplantation Using Carlecortemcel-L, a Single Progenitor-Enriched Cord Blood, to Double Cord Blood Unit Transplantation
Stiff, PJ; (...); Sanz, G
Article. 10.1016/j.bbmt.2018.02.012. 2018
Combining gene mutation with gene expression analysis improves outcomes prediction in acute promyelocytic leukemia.
Lucena-Araujo, Antonio R.; (...); Rego, Eduardo M.
Article. 10.1182/blood.2019000239. 2019
Comment on "Outcomes of autologous transplantation for multiple myeloma according to different induction regimens".
Article. 10.5581/1516-8484.20140020. 2014
Common seasonal respiratory virus infections in allogeneic stem cell transplant recipients during the SARS-COV-2 pandemic.
De La Puerta R; (...); Piñana JL
Article. 10.1038/s41409-021-01319-5. 2021
Community acquired respiratory virus infections in adult patients undergoing umbilical cord blood transplantation.
Montoro J; (...); Piñana JL
Article. 10.1038/s41409-020-0943-0. 2020
Community-Acquired Respiratory Virus Infections: A Threat to Long-Term survivors after Allogeneic Stem Cell Transplant?
Pinana, Jose Luis; (...); Solano, Carlos
Article. 10.1093/cid/ciae602. 2024
Community-acquired respiratory virus lower respiratory tract disease in allogeneic stem cell transplantation recipient: Risk factors and mortality from pulmonary virus-bacterial mixed infections
Pinana, JL; (...); Navarro, D
Article. 10.1111/tid.12926. 2018
Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy
Iaccarino, L; (...); Lo-Coco, F
Letter. 10.1080/10428194.2017.1369067. 2018
COMPARATIVE STUDY OF HEREDITARY SPHEROCYTOSIS USING FLOW CYTOMETRY AND OSMOTIC GLOBULAR FRAGILITY
Cordon Gallego, L.; (...); Sanz Alonso, M. A.
Meeting Abstract. 2015
Comparative Study of Post-Transplant Lymphoproliferative Disorders after Solid Organ Transplantation Versus Hematopoietic Stem Cell Transplantation
Romero, Samuel, Sr.; (...); Sanz, Miguel Angel
Article. 2015
COMPARATIVE STUDY OF THE CLINICAL-BIOLOGICAL CHARACTERISTICS TO THE DIAGNOSIS AND RELAPSE IN PATIENTS WITH MULTIPLE MYELOMA
Valenzuela, AV; (...); Ramos, IJ
Meeting Abstract. 2018
COMPARATIVE STUDY OF THE CHARACTERISTICS OF THE DIAGNOSIS AND RESPONSE TO TREATMENT IN PATIENTS AGED=60 YEARS VS. <60 YEARS WITH ACQUIRED PURPLE THROMBOTIC THROMBOCYTOPENIC. RESULTS OF THE SPANISH REGISTRATION OF PTT (REPTT)
Aracil Eva, Frances; (...); Comos Javier, De la Rubia
Meeting Abstract. 2021
Comparative Study of Treosulfan Plus Fludarabine (FT14) with Busulfan Plus Fludarabine (FB4) for Acute Myeloid Leukemia in First or Second Complete Remission: An Analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)
Gavriilaki, Eleni; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2021-146303. 2021
Comparing Older Matched Related to Younger Matched Unrelated Donors in Acute Myeloid Leukemia in Remission Using Post-Transplant Cyclophosphamide
Piemontese, Simona; (...); Ciceri, Fabio
Meeting Abstract. 10.1182/blood-2023-182923. 2023
Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT
Kharfan-Dabaja, MA; (...); Mohty, M
Article. 10.1038/s41409-021-01317-7. 2021
Comparison Between First-Generation 4-Color Vs. Second-Generation 8-Color Multiparameter Flow Cytometry (MFC) to Monitor Minimal Residual Disease (MRD) in Multiple Myeloma (MM)
Arana, Paula; (...); San Miguel, Jesus
Meeting Abstract. 2015
COMPARISON BETWEEN INTERMITTENT AND CONTINUOUS HAEMATOPOIETIC PROGENITOR COLLECTION OF THE SPECTRA OPTIA APHERESIS SYSTEM IN A SINGLE CENTRE
De la Puerta Paula, R.; (...); Gomez Segui, I
Meeting Abstract. 2019
Comparison between Two Protocols for Platelet Transfusion in Patients Undergoing ABO Incompatible Hematopoietic Stem Cell Transplantation
Carpio, N; (...); Sanz, M
Meeting Abstract. 2018
COMPARISON OF AZACITIDINE AND DECITABINE FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: SYSTEMATIC REVIEW AND META-ANALYSIS
Saiz-Rodriguez, M.; (...); Labrador, J.
Meeting Abstract. 2020
Comparison of Clinical Characteristics and Prognosis of a Series of Patients from the Spanish Registry of MDS Diagnosed with Myelodysplastic/Myeloproliferative Neoplasms According to the 2016 Reviewed Classification of the World Health Organization
Xicoy, B; (...); Tzu, HCL
Meeting Abstract. 10.1182/blood-2018-99-111883. 2018
COMPARISON OF CLINICAL CHARACTERISTICS AND PROGNOSIS OF CHRONIC MYELOMONOCYTIC LEUKEMIA WITH AND WITHOUT AUTOINMUNE DISEASE
Moreno, AT; (...); Santillana, GS
Meeting Abstract. 2018
COMPARISON OF CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED MDS (T-MDS) AND 4738 PATIENTS FROM THE REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM DATABASE WITH PRIMARY-MDS (P-MDS)
Kuendgen, A.; (...); Sanz, G.
Meeting Abstract. 2021
Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Post-transplant Cyclophosphamide in Patients with Acute Leukemia.
Nagler A; (...); Mohty M
Article. 10.1158/1078-0432.CCR-20-2809. 2020
Comparison of Haploidentical Peripheral Blood Cell Transplantation Using Post-Transplant Cyclophosphamide With Double Cord Blood Transplantation in Adults With Acute Leukemia
Ruggeri, A; (...); Mohty, M
Meeting Abstract. 2021
Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55-65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia
Ribera, JM; (...); PETHEMA Grp
Article. 10.1016/j.leukres.2018.03.010. 2018
Comparison of Matched Sibling, Unrelated and Haploidentical Donor Transplants Using Post-Transplant Cyclophosphamide in Patients with Acute Myeloid Leukemia, a Study of the ALWP EBMT
Sanz, Jaime; (...); Mohty, Mohamad
Meeting Abstract. 2020
Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT
Ruggeri, A; (...); Eurocord & Acute Leukemia Working
Article. 10.1038/leu.2013.259. 2014
Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia
Ruggeri A; (...); ALWP-EBMT study
Article. 10.1038/leu.2015.98. 2015
Comparison of outcomes after unrelated double-unit cord blood and haploidentical peripheral blood stem cell transplantation in adults with acute myeloid leukemia, a study on behalf of Eurocord and ALWP-EBMT.
Ruggeri, Annalisa; (...); Mohty, Mohamad
Article. 10.1016/j.jtct.2022.07.006. 2022
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
Sargas, Claudia; (...); Montesinos, Pau
Article. 10.1038/s41408-023-00835-5. 2023
COMPARISON OF THREE PANELS OF NGS APPLICATION IN ONCOHEMATOLOGY TO DISCARD SOMATIC AND/OR GERMINAL VARIANTS
Guzman-Gimenez, C.; (...); Such, E.
Meeting Abstract. 2021
COMPARISON OF THREE STRATEGIES OF GVHD PROPHYLAXIS AFTER T-CELL REPLETE HAPLOIDENTICAL HEMATOPOIETIC TRANSPLANTATION: TACROLIMUS vs. CALCINEURIN INHIBITORS-MMF vs. SIROLIMUS-MMF.
Esquirol A; (...); Martino R
Article. 10.1016/j.jtct.2024.07.027. 2024
Comparison of transfusion requirements in adult patients undergoing Haploidentical or single-unit umbilical cord blood stem cell transplantation
Article. 10.1111/ejh.13270. 2019
Comparison of Unrelated Cord Blood and Peripheral Blood Stem Cell Transplantation in Adults with Myelodysplastic Syndrome after Reduced-Intensity Conditioning Regimen: A Collaborative Study from Eurocord (Cord blood Committee of Cellular Therapy & Immunobiology Working Party of EBMT) and Chronic Malignancies Working Party
Robin M; (...); Kroger N
Article. 10.1016/j.bbmt.2014.11.675. 2015
Complex Karyotype with >= 3 Cytogenetic Alterations is a New Marker of Worse Prognosis in Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL)
Genesca, Eulalia; (...); Maria Ribera, Josep
Meeting Abstract. 2020
Comprehensive detection of CRLF2 alterations in acute lymphoblastic leukemia: a rapid and accurate novel approach.
Gil, Jose Vicente; (...); Barragan, Eva
Article. 10.3389/fmolb.2024.1362081. 2024
COMPREHENSIVE LONG-TERM FOLLOW-UP OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A REPORT FROM A SINGLE CENTRE
Sempere, A.; (...); Jarque, I.
Meeting Abstract. 2016
CONCORDANCE STUDY ON THE CATEGORIZATION OF NON-CANONICAL VARIANTS OF JAK2 GENE
Guzman-Gimenez, C.; (...); Such, E.
Meeting Abstract. 2021
CONCURRENT MUTATIONS IN ZRSR2 AND TET2 CAUSE SMD-COMPATIBLE ANOMALIES IN A MOUSE MODEL
Cristian, Garcia-Ruiz; (...); Alejandra, Sanjuan-Pla
Meeting Abstract. 2021
Concurrent Zrsr2 mutation and Tet2 loss promote myelodysplastic neoplasm in mice
Garcia-Ruiz C; (...); Sanjuan-Pla A
Article. 10.1038/s41375-022-01674-2. 2022
CONDITIONING INTENSITY IN STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR ACUTE MYELOID LEUKEMIA: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT
Sanz, Jaime; (...); Ciceri, Fabio
Meeting Abstract. 2024
Consensus document for anaesthesiologist-assisted sedation in interventional cardiology procedures.
Martinez-Dolz, L; (...); Alvarez, J
Article. 10.1016/j.redare.2021.01.001. 2021
Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes.
Zeidan, Amer M.; (...); Fenaux, Pierre
Article. 10.1182/blood.2022018604. 2023
Considering Bone Marrow Blasts from Nonerythroid Cells Improves the Prognostic Evaluation of Myelodysplastic Syndromes with Ring Sideroblasts
Arenillas, Leonor; (...); Florensa, Lourdes
Meeting Abstract. 2016
Considering Bone Marrow Blasts from Nonerythroid Cellularity Improves the Prognostic Evaluation of MDS in the Context of IPSS-R and Permits a Better Risk Assessment of MDS Patients Classified into the Intermediate Risk Category
Calvo, Xavier; (...); Florensa, Lourdes
Meeting Abstract. 10.1182/blood.V128.22.3185.3185. 2016
Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes
Arenillas L; (...); Florensa L
Article. 10.1200/JCO.2016.66.9705. 2016
Contemporary Approach to The Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes- Recommendations from The International Consortium for MDS (icMDS).
Aakash, Fnu; (...); Loghavi, Sanam
Article. 10.1016/j.modpat.2024.100615. 2024
Continuous ambulatory peritoneal dialysis, ascitic and pleural body fluids evaluation with the Mindray BC-6800 hematology analyzer
Article. 10.1002/jcla.22240. 2018
Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials.
Gonzalez-Gil C; (...); Genesca E
Article. 10.3324/haematol.2024.285416. 2024
Conventional induction and post-remission therapy in APL: Have we arrived?
Sanz MA, Iacoboni G, Montesinos P
Article. 10.1016/j.beha.2014.04.004. 2014
Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group
Boluda, Blanca; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2022-160136. 2022
CO-OCCURRENCE PROFILES OF GERMLINE AND ACQUIRED VARIANTS IN MYELODYSPLASTIC SYNDROMES IN YOUNG ADULTS WITHOUT PRIOR ORGAN DYSFUNCTION
Hua, Chen-Liang Tzu; (...); Andres, Jerez
Meeting Abstract. 2021
Copper deficiency: a cause of misdiagnosis of myelodysplastic syndrome
Villalba, A; (...); Senent, L
Letter. 10.1007/s00277-018-3334-5. 2018
Cord blood transplantation for adult mature lymphoid neoplasms in Europe and Japan.
Watanabe, Mizuki; (...); Gluckman, Eliane
Article. 10.1182/bloodadvances.2023010598. 2024
CORD BLOOD TRANSPLANTATION FOR AML: COMPARABLE LFS IN PATIENTS WITH DE NOVO VERSUS SECONDARY AML
Baron, Frederic; (...); Ciceri, Fabio
Meeting Abstract. 2023
Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study.
Baron, Frederic; (...); Ciceri, Fabio
Article. 10.1111/bjh.19130. 2023
Cord blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukaemia in first remission
Baron, F; (...); Nagler, A
Article. 10.1111/joim.12870. 2019
Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
Martínez-Cuadrón D; (...); CETLAM and PETHEMA groups
Article. 10.1007/s00277-018-3277-x. 2018
Correction to: Spanish registry of hemoglobinopathies and rare anemias (REHem- AR): demographics, complications, and management of patients with ß-thalassemia.
Bardón-Cancho EJ; (...); Cela E
Correction. 10.1007/s00277-024-05838-1. 2024
Correction to: Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus.
Montesinos P; (...); Sanz MÁ
Correction. 10.1007/s00277-020-03933-7. 2020
Correction: Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients.
Spyridonidis A; (...); Mohty M
Correction. 10.1038/s41409-020-0835-3. 2020
Correction: Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era.
Mussetti, Alberto; (...); Sureda, Anna
Correction. 10.1038/s41409-023-01967-9. 2023
Correction: Vitamin C and folate status in hereditary fructose intolerance.
Cano A; (...); de Las Heras J
Correction. 10.1038/s41430-023-01334-3. 2023
Correlation of myelodysplastic syndromes with i(17)(q10) and TP53 and SETBP1 mutations
Adema V; (...); Solé F
Letter. 10.1111/bjh.13355. 2015
Corrigendum to "Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study" [Leuk. Res. 92 (March) (2020) 106352].
Rodríguez-Medina C; (...); Montesinos P
Correction. 10.1016/j.leukres.2020.106388. 2020
Corrigendum: Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia (vol 13, 1302993, 2023)
Orgueira, Adrian Mosquera; (...); Encinas, Manuel Mateo Perez
Correction. 10.3389/fonc.2023.1302993. 2023
Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain
Ostermann, H; (...); Charbonneau, C
Article. 10.1186/2050-6511-15-52. 2014
COST MINIMIZATION ANALYSIS OF RITUXIMAB BIOSIMILAR VERSUS REFERENCE RITUXIMAB IN THE TREATMENT OF FOLLICULAR LYMPHOMA
Gironella, M.; (...); Oyaguez, I
Meeting Abstract. 2019
Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain
Mareque, M; (...); Sierra, J
Article. 10.2147/CEOR.S302097. 2021
COST-EFFECTIVENESS OF GEMTUZUMAB OZOGAMICIN IN COMBINATION WITH STANDARD CHEMOTHERAPY IN FIRST-LINE TREATMENT IN PATIENTS WITH CD-33-POSITIVE ACUTE MYELOID LEUKEMIA IN SPAIN
Montesinos, P.; (...); Guinea, J. M.
Meeting Abstract. 2020
Cost-Effectiveness Of Midostaurin In The Treatment Of Acute Myeloid Leukemia With The FLT3 Mutation In Spain
Arenaza, A; (...); Vinent, JL
Article. 10.2147/CEOR.S222879. 2019
Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain
Camara, R; (...); Grau, S
Article. 10.1007/s12325-017-0600-1. 2017
Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
Grau, S; (...); Gozalbo, I
Article. 10.1007/s10198-017-0907-5. 2018
Cost-utility analysis of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukaemia
Casado, LF; (...); Castro, A
Article. 10.1111/ejh.13007. 2018
COST-UTILITY OF IDELALISIB IN COMBINATION WITH RITUXIMAB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Casado, LF; (...); Castro-Gomez, A
Meeting Abstract. 10.1016/j.jval.2017.08.898. 2017
Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study
Lancet, Jeffrey; (...); Carraway, Hetty E.
Meeting Abstract. 10.1182/blood-2023-173149. 2023
COVALENT-101: phase I study of BMF-219, a covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL (NCT05153330)
Rosenberg, Aaron; (...); Khouri, Jack
Meeting Abstract. 2023
CRISPR to fix bad blood: a new tool in basic and clinical hematology
Gonzalez-Romero, E; (...); Sanjuan-Pla, A
Review. 10.3324/haematol.2018.211359. 2019
Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality
Martínez-López J; (...); Lahuerta JJ
Article. 10.1182/blood-2015-04-638742. 2015
Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry
Puig N; (...); García-Sanz R
Article. 10.1038/leu.2013.217. 2014
CRITICAL REVIEW OF THE DOUBLE NEGATIVITY IN THE SERUM AND URINE IMMUNOFIXATION (IF) TO ESTABLISH THE CATEGORY OF COMPLETE REMISSION IN MULTIPLE MYELOMA (MM)
Anglada, LL; (...); Lahuerta, J. J.
Meeting Abstract. 2017
Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products
Eduardo Megias, Juan; (...); Iorio, Alfonso
Meeting Abstract. 10.1182/blood-2019-127946. 2019
Cryopreservation of Allogeneic Hematopoietic Progenitor Cells in The Current SARS-Cov-2 Pandemic: Experience of A Single Centre
Moreno, D; (...); Carpio, N
Meeting Abstract. 2021
Curative Strategy (GEM- CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd
Mateos, Maria-Victoria; (...); San-Miguel, Jesus F.
Meeting Abstract. 10.1182/blood-2021-148423. 2021
Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)
Mateos, Maria-Victoria; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2022-159606. 2022
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance.
Mateos, Maria-Victoria; (...); San-Miguel, Jesus F
Article. 10.1200/JCO.23.02771. 2024
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS).
Bewersdorf, Jan Philipp; (...); Zeidan, Amer M.
Article. 10.1016/j.blre.2023.101072. 2023
Current management of patients with chronic myelomonocytic leukemia
Review. 10.1097/CCO.0000000000000486. 2018
Current Results on Overall Survival with oral Azacitidine Therapy in Patients with acute Myeloid Leukemia in first Remission after intensive Chemotherapy in the Phase 3 QUAZAR Study
Pfeilstoecker, M.; (...); Roboz, G. J.
Meeting Abstract. 2022
CURRENT STATE OF ACUTE MYELOID LEUKEMIA IN SPAIN: RESULTS FROM A DELPHI STUDY ON EPIDEMIOLOGY, DISEASE MANAGEMENT AND UNMET NEEDS
Montesinos, P; (...); Sierra, J
Meeting Abstract. 2018
Current status of acute myeloid leukaemia in Spain: Results from a Delphi study on its epidemiology, disease management and unmet clinical needs.
Montesinos P, Gil A, Sierra J
Letter. 10.1016/j.medcli.2020.04.032. 2020
Current Status of CPX-351 Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Alotaibi, Shaykhah; (...); Aljurf, Mahmoud
Article. 10.1016/j.clml.2022.02.008. 2022
Current status of haematopoietic autologous stem cell transplantation in lymphoid malignancies: a European perspective
Hubel, K; (...); Corradini, P
Review. 10.1111/ejh.12362. 2015
CYTOGENETIC ANALYSIS IN REAL LIFE IN PATIENTS WITH MULTIPLE MYELOMA NEW DIAGNOSIS Results: FROM THE MULTIPLE MYELOMA STUDY GROUP OF THE VALENCIAN COMMUNITY (GREMI)
Gomez, Beltran Elena; (...); De la Rubia, Comos Javier
Meeting Abstract. 2020
Cytogenetic Assessment and Risk Stratification in Myelofibrosis with Optical Genome Mapping.
Diaz-Gonzalez, Alvaro; (...); Such, Esperanza
Article. 10.3390/cancers15113039. 2023
Cytokine response as a biomarker for early diagnosis and outcome prediction of stem cell transplant recipients and acute leukemia patients with invasive aspergillosis.
Puerta-Alcalde, Pedro; (...); Garcia-Vidal, Carolina
Article. 10.1093/mmy/myac038. 2022
Cytomegalovirus DNA load monitoring in stool specimens for anticipating the occurrence of intestinal acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: Is it of any value?
Bueno F; (...); Navarro D
Article. 10.1111/tid.13440. 2020
Cytomegalovirus DNAemia in hematological patients undergoing CD19-directed CAR-T cell therapy: should it be systematically monitored?
Solano de la Asuncion, Carlos; (...); Navarro, David
Letter. 10.1016/j.cmi.2023.05.010. 2023
Cytomegalovirus-specific T-cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib.
Solano de la Asuncion, Carlos; (...); Navarro, David
Letter. 10.1111/bjh.17732. 2021
Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes
Greenberg, PL; (...); Haase, D
Letter. 10.1182/blood-2016-07-728766. 2016
Cytotoxic Natural Killer Subpopulations as a Prognostic Factor of Malignant Pleural Effusion
Lara, SH; (...); Suarez-Varela, MM
Article. 10.1007/s00408-018-0186-7. 2019
Challenges in Clinical Metaproteomics Highlighted by the Analysis of Acute Leukemia Patients with Gut Colonization by Multidrug-Resistant Enterobacteriaceae
Rechenberger, J; (...); Kuster, B
Article. 10.3390/proteomes7010002. 2019
Challenges in the diagnosis and treatment of secondary acute myeloid leukemia
Ossenkoppele, G, Montesinos, P
Review. 10.1016/j.critrevonc.2019.03.003. 2019
Challenges of phase III trial design for novel treatments in diseases with no standard treatment: The AZA-001 myelodysplasia study model
Fenaux P; (...); Hellstrom-Lindberg E
Article. 10.1016/j.leukres.2013.10.014. 2014
Changes in health-related quality of life in patients with newly diagnosed acute myeloid leukemia receiving ivosidenib plus azacitidine or placebo plus azacitidine.
Schuh, Andre C.; (...); Montesinos, Pau
Meeting Abstract. 2022
Changes in nutritional status, body composition and associated symptomatology in hospitalized patients undergoing bone marrow transplantation: prospective longitudinal study
Cabanas-Alite, L; (...); Pinana, LL
Article. 10.14306/renhyd.25.2.1098. 2021
CHANGES IN THE HEMATIC AND SERUM GROUP IN PATIENTS SUBJECTED TO TRANSPLANTATION OF HEMATOPOIETIC PROGENITORS WITH ABO MAYOR INCOMPATIBILITY
Balsera, MS; (...); Sanz, M. A.
Meeting Abstract. 2017
Characteristics and management of primary and other immune thrombocytopenias: Spanish registry study
JUAN PALAU BARGUES; (...); Sanz MA
Article. 10.1080/10245332.2017.1311442. 2017
Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants.
Cicconi, L; (...); Abla, O
Article. 10.1038/s41408-021-00561-w. 2021
Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols.
Sobas M; (...); PETHEMA, HOVON, PALG, GATLA cooperative groups
Article. 10.1111/ejh.13346. 2020
Characteristics and Outcome of Early T Cell Precursor ALL (ETP-ALL) Patients Treated with High-Risk Spanish Pethema Protocols
Genesca, E; (...); Ribera, JM
Meeting Abstract. 10.1182/blood-2018-99-114559. 2018
Characteristics and Outcome of Older Patients with Acute Promyelocytic Leukemia Front-Line Treated with or without Arsenic Trioxide - an International Collaborative Study
Kayser, S; (...); Montesinos, P
Meeting Abstract. 10.1182/blood-2018-99-111768. 2018
Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4
Kayser, Sabine; (...); Schlenk, Richard F.
Meeting Abstract. 10.1182/blood-2021-150281. 2021
Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4.
Kayser, Sabine; (...); Schlenk, Richard F.
Meeting Abstract. 10.3324/haematol.2022.281137. 2022
Characteristics and outcome of patients with core binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study.
Kayser S; (...); Levis MJ
Article. 10.3324/haematol.2021.278645. 2022
Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia.
Martinez-Cuadron, David; (...); On Behalf Of The Pethema Group
Article. 10.3390/cancers14112817. 2022
Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group
Palanques-Pastor, Tomas; (...); Montesinos, Pau
Article. 10.1080/10428194.2021.1948031. 2021
Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient Cohort
Stahl, M; (...); Zeidan, AM
Meeting Abstract. 10.1182/blood-2018-99-112974. 2018
Characterization of a translocation that disrupts the COL4A5 gene in a girl with Alport syndrome by optical genome mapping
Orellana, Carmen; (...); Diaz, Alvaro
Meeting Abstract. 2024
CHARACTERIZATION OF CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA BY MEANS OF IMMUNOLOGICAL AND MOLECULAR TECHNIQUES: RESULTS OF THE GEPTT NATIONAL COLLECTION
Liquori, A.; (...); Gomez-Segui, I
Meeting Abstract. 2019
CHARACTERIZATION OF CHARACTERISTIC MORPHOLOGICAL ALTERATIONS IN PATIENTS WITH MDS/CMML AND GENE MUTATIONS OF SPLICING DIFFERENT TO SF3B1
Marco Ayala, J.; (...); Sanz, G.
Meeting Abstract. 2019
CHARACTERIZATION OF MUTATIONS ALTERING THE PROCESS OF SPLICING IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
Boluda-Navarro, M.; (...); Cervera, J.
Meeting Abstract. 2018
CHARACTERIZATION OF RECURRENTLY MUTATED GENES IN ACUTE MYELOID LEUKEMIA DE NOVO WITH NORMAL KARPOTYPE BY TARGETED MASSIVE SEQUENCING
Ibanez, M.; (...); Cervera, J.
Article. 2015
CHARACTERIZATION OF THE GENOMIC AND TRANSCRIPTOMIC PROFILE OF THE ACUTE MYELOID LEUKEMIA (AML) SUBGROUP "CHROMATIN-SPLICEOSOME"
Alessandro, Liquori; (...); Zamora Jose, Cervera
Meeting Abstract. 2020
Characterization of three new HLA Class I Alleles in Spanish Caucasians, HLA-A*02:620, HLA-B*27:150 and HLA-B*07:05:01:02
Balas, A; (...); Vicario, JL
Article. 10.1111/iji.12317. 2017
Characterization ofFLT3-ITD(mut)acute myeloid leukemia: molecular profiling of leukemic precursor cells
Travaglini, S; (...); Ottone, T
Article. 10.1038/s41408-020-00352-9. 2020
Chemotherapy or Allogeneic Transplantation in High-Risk Philadelphia Chromosome-Negative Adult Lymphoblastic Leukemia.
Ribera JM; (...); Orfao A
Article. 10.1182/blood.2020007311. 2020
Chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study.
Bastos-Oreiro, Mariana; (...); Barba, Pere
Article. 10.1002/hem3.70077. 2025
CHOOSING THE APPROPRIATE DENOMINATOR FOR COUNTING BM BLASTS
Arenillas, L; (...); Florensa, L
Meeting Abstract. 10.1016/S0145-2126(17)30121-2. 2017
CHROMOSOMAL ABERRATIONS IN THERAPY-RELATED MYELODYSPLASTIC SYNDROMES - RELATIONS TO PRIMARY DISEASE, THERAPY AND PROGNOSTIC SIGNIFICANCE
Nomdedeu, M; (...); Haase, D
Meeting Abstract. 10.1016/S0145-2126(17)30161-3. 2017
Chromosomal Abnormalities and Prognosis in NPM1 -Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts.
Angenendt, L; (...); Schliemann, C
Article. 10.1200/JCO.19.00416. 2019
Chromosome 8 Abnormalities (8p Losses and 8q Gains) in Patients with Chronic Lymphocytic Leukemia (CLL) and Del(17p)
Blanco, Gonzalo; (...); Espinet, Blanca
Article. 2014
Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation.
Caballero JC; (...); Díez Campelo M
Article. 10.1007/s00277-019-03751-6. 2019
Chronic liver disease-associated severe thrombocytopenia in Spain: Results from a retrospective study using machine learning and natural language processing.
Calleja-Panero, Jose Luis; (...); Gonzalez Calvo, Jose
Article. 10.1016/j.gastrohep.2023.05.010. 2023
Chronic Myelomonocytic Leukemia ( CMML) with AML Typical Mutations ( NPM1, FLT3 or CEBPA) Identify a High-Risk CMML Group Independent of Molecular-Cpss
Castano-Diez, Panelsandra; (...); Diaz-Beya, Marina
Meeting Abstract. 10.1182/blood-2023-173311. 2023
CHRONOLOGICAL AGE AS A PROGNOSTIC FACTOR IN PATIENTS WITH MULTIPLE MYELOMA NEW DIAGNOSIS NOT CANDIDATED FOR TRANSPLANTATION
Martinez Elena, Meseguer; (...); Comos Javier, De la Rubia
Meeting Abstract. 2021
Chronological age as a prognostic factor in transplant-ineligible patients with newly diagnosed Multiple Myeloma
Garcia Ruiz, Raquel; (...); de la Rubia, Javier
Meeting Abstract. 2021
Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT.
Vincent, Laure; (...); Beksac, Meral
Letter. 10.1038/s41409-021-01560-y. 2022
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.
Moreau, Philippe; (...); Goldschmidt, Hartmut
Letter. 10.1038/s41408-023-00805-x. 2023
Data-Driven Multiparameter Flow Cytometry (MFC) Classification of Blast Differentiation in Elderly Patients with Acute Myeloid Leukemia (AML)
Gonzalez, Carmen; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2023-180646. 2023
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes.
Komrokji RS; (...); Della Porta MG
Article. 10.1016/S2352-3026(24)00251-5. 2024
Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review
Megias-Vericat, JE; (...); Montesinos, P
Review. 10.1080/17512433.2019.1573668. 2019
Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia (vol 11, 16867, 2021)
Lozano, Maria L.; (...); Vicente, Vicente
Article. 10.1038/s41598-021-95732-x. 2021
Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia.
Lozano ML; (...); Vicente V
Article. 10.1038/s41598-019-53209-y. 2019
Decitabine as Salvage Therapy after Azacitidine in AML
De La Fuente, A; (...); Montesinos, P
Meeting Abstract. 2019
Decitabine versus intensive chemotherapy induction for older patients with acute myeloid leukaemia: a futile but successful trial.
Montesinos, Pau, Sossa-Melo, Claudia
Article. 10.1016/S2352-3026(23)00308-3. 2023
DEEP INTRONIC MUTATIONS IN THE RUNX1 AND FLT3 GENES PRODUCE OPENING SPLICING IN PATIENTS WITH MYELODYSPLASIC SYNDROMES
Mireia, Boluda-Navarro; (...); Jose, Cervera
Meeting Abstract. 2021
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard and high risk myeloma.
Goicoechea I; (...); Paiva B
Article. 10.1182/blood.2020006731. 2020
DEEP SEQUENCING OF 23 GENES DESIGNATED BY TCGA STUDY IN ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE
Ibanez, M.; (...); Cervera, J.
Meeting Abstract. 2016
Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies
Burgos, Leire; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2021-150092. 2021
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies.
Burgos, Leire; (...); Paiva, Bruno
Article. 10.1200/JCO.22.01916. 2023
Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials
Lahuerta, JJ; (...); GEM (Grupo Español de Mieloma)
Article. 10.1200/JCO.2016.69.2517. 2017
Depth of Response of Isatuximab (Isa) plus Carfilzomib (K) and Dexamethasone (d) in Relapsed Multiple Myeloma: IKEMA Updated Analysis
Joseph, Mikhael; (...); Meletios, A. Dimopoulos
Article. 2022
Depth of response of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma: IKEMA updated analysis
Hajek, Roman; (...); Dimopoulos, Meletios A.
Meeting Abstract. 2022
DESCRIPTION OF THE CYTOOGENETIC ANOMALIES OF A SERIES OF PATIENTS OF THE SEHOP-PETHEMA 2013 PEDIATRIC PROTOCOL FOR THE TREATMENT OF B-LINE
Hidalgo Gomez, G.; (...); Ortega, M.
Meeting Abstract. 2018
DESCRIPTIVE STUDY OF THE RECORD OF THROMBOTIC MICROANGIOPATHY IN A SINGLE CENTRE
Romero Dominguez, S.; (...); Sanz Alonso, M. A.
Meeting Abstract. 2015
Design and Validation of a Custom Next-Generation Sequencing Panel in Pediatric Acute Lymphoblastic Leukemia.
Gil, Jose Vicente; (...); Barragan, Eva
Article. 10.3390/ijms24054440. 2023
DESIGN AND VALIDATION OF AN ACUTE LYMPHOBLASTIC LEUKEMIA-TARGETED NEXT-GENERATION SEQUENCING PANEL
Gil, JV.; (...); Llop, M.
Meeting Abstract. 2023
Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia
Roboz GJ; (...); Kantarjian H
Article. 10.2217/fon.15.326. 2016
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA.
Sanchez, Ricardo; (...); Martinez-Lopez, Joaquin
Article. 10.1038/s41598-022-17271-3. 2022
DETECTION OF MINIMAL RESIDUAL DISEASE (EMR) IN ACUTE MYELOID LEUKEMIA THROUGH HIGH DEPTH SEQUENCE
De La Fuente, EO; (...); Ayala, R.
Meeting Abstract. 2017
DETECTION OF MUTATIONS IN BCR-ABL1 WITH A SENSITIVITY OF 1% IN PATIENTS WITH PH plus LEUKEMIAS
Perez, RS; (...); Lopez, JM
Meeting Abstract. 2018
Detection of plasmid-mediated colistin resistance, mcr-1 gene, in Escherichia coli isolated from high-risk patients with acute leukemia in Spain
Lalaoui, R; (...); Rolain, JM
Article. 10.1016/j.jiac.2019.03.007. 2019
Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study.
Stojkov I; (...); Siebert U
Article. 10.1182/bloodadvances.2022008360. 2023
Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation.
Hernández-Boluda JC; (...); Yakoub-Agha I
Article. 10.1038/s41375-020-0815-z. 2020
Determinants of Survival in Myelofibrosis Patients Undergoing Allogeneic Hematopoietic Cell Transplantation: A Study by the Chronic Malignancies Working Party of EBMT
Hernandez-Boluda, JC; (...); Yakoub-Agha, I
Meeting Abstract. 2020
DETERMINATION OF THE CHALLENGES AND OPPORTUNITIES ASSOCIATED WITH PLATELET TRANSFUSION IN THE MANAGEMENT OF PATIENTS WITH SEVERE THROMBOCYTOPENIA ASSOCIATED WITH CHRONIC LIVER DISEASE
Jarque, Ramos, I; (...); Shepherd, Moreno J.
Meeting Abstract. 2020
DETERMINING THE EPIDEMIOLOGY, PATIENT FLOW, TREATMENT AND UNMET NEEDS OF PATIENTS WITH CHRONIC LIVER DISEASE-ASSOCIATED SEVERE THROMBOCYTOPENIA UNDERGOING INVASIVE PROCEDURES IN SPAIN
Andrade, R.; (...); Shepherd, J.
Meeting Abstract. 2019
Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale
Bonanad S; (...); GAH Group
Article. 10.1016/j.jgo.2015.03.003. 2015
Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry.
Shouval R; (...); Nagler A
Article. 10.1016/S2352-3026(20)30394-X. 2021
DEVELOPMENT AND VALIDATION OF A MCDA FRAMEWORK FOR EVALUATION AND DECISION-MAKING OF ORPHAN DRUGS IN SPAIN
Poveda, J. L.; (...); Vitoria, I
Meeting Abstract. 2019
Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia.
Article. 10.1182/blood-2012-08-452938. 2013
Development and validation of an MCDA framework for evaluation and decision-making of orphan drugs in Spain
Badia, X; (...); Poved, JL
Article. 10.1080/21678707.2019.1652163. 2019
DEVELOPMENT OF A CELLULAR MODEL OF ACUTE MYELOID LEUKEMIA THROUGH CRISPR/CAS 9 TECHNOLOGY
Romero, EG; (...); Zamora, JVC
Meeting Abstract. 2017
Development of a core outcome set for myelodysplastic syndromes - a Delphi study from the EUMDS Registry Group.
Rochau U; (...); Stauder R
Article. 10.1111/bjh.16654. 2020
DEVELOPMENT OF A MASSIVE SEQUENCING TEST FOR THE SIMULTANEOUS DETECTION OF POTENTIAL MUTATIONS AND CHROMOSOMAL ALTERATIONS IN PATIENTS WITH MYELODISPLASIC SYNDROMES
Liquori, A.; (...); Zamora, JVC
Meeting Abstract. 2017
Development, Implementation and Assessment of Molecular Diagnostics by Next Generation Sequencing in Personalized Treatment of Cancer: Experience of a Public Reference Healthcare Hospital.
Simarro J; (...); Palanca S
Article. 10.3390/cancers11081196. 2019
Dexamethasone does not prevent malignant cell reintroduction in leukemia patients undergoing ovarian transplant: risk assessment of leukemic cell transmission by a xenograft model
Diaz-Garcia, C; (...); Pellicer, A
Article. 10.1093/humrep/dez115. 2019
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Döhner H; (...); Bloomfield, CD
Review. 10.1182/blood-2016-08-733196. 2017
Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults Recommendations From the European Hematology Association and the European LeukemiaNet
Itzykson, R; (...); European LeukemiaNet
Article. 10.1097/HS9.0000000000000150. 2018
DIAGNOSIS OF NOONAN SYNDROME AFTER STUDY OF NGS BY ESSENTIAL THROMBOCITEMIA
Marco Ayala, J.; (...); Sanz, M. A.
Meeting Abstract. 2018
Diagnostic screening of paroxysmal nocturnal hemoglobinuria: Prospective multicentric evaluation of the current medical indications
Morado, M; (...); PNH working group of the Iberian Society of Cytometry (SIC)
Article. 10.1002/cyto.b.21480. 2017
Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia
Megias-Vericat, JE; (...); Spanish PETHEMA Grp
Article. 10.4084/MJHID.2019.016. 2019
Different Clinical Implications of Kinase Domain BCR-ABL1 Variants Detected in Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia Patients
Sanchez, Ricardo; (...); Martinez-Lopez, Joaquin
Meeting Abstract. 10.1182/blood-2019-127069. 2019
Differential diagnosis of myelodysplastic syndrome: anemia associated with copper deficiency
Villalba, A, Senent, L
Editorial Material. 10.1182/blood-2017-11-818013. 2018
Differentiation stage of myeloma plasma cells: biological and clinical significance
Paiva B; (...); San-Miguel JF
Article. 10.1038/leu.2016.211. 2017
Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib - pooled analysis from clinical trials.
Montesinos P; (...); DiNardo CD
Article. 10.1182/bloodadvances.2023011914. 2024
Differentiation Syndrome with Lower-intensity Treatments for Acute Myeloid Leukemia.
Fathi, Amir T; (...); de Botton, Stephane
Review. 10.1002/ajh.26142. 2021
Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS
Miyazaki, Y; (...); Greenberg, PL
Article. 10.1016/j.leukres.2018.08.022. 2018
Disease Characteristics and International Prognostic Scoring Systems (IPSS, IPSS-R, IPSS-M) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Participating in Two Randomized, Double-Blind, Placebo-Controlled Studies with Intravenous Sabatolimab Added to Hypomethylating Agents (HMA) (STIMULUS-MDS1 and MDS2)
Santini, Valeria; (...); Zeidan, Amer M.
Meeting Abstract. 10.1182/blood-2022-160282. 2022
Disruption of NIPBL/Scc2 in Cornelia de Lange Syndrome provokes cohesin genome-wide redistribution with an impact in the transcriptome
Garcia, P; (...); Queralt, E
Article. 10.1038/s41467-021-24808-z. 2021
Disseminated toxoplasma infection after hematopoietic stem cell transplantation with myositis and encephalitis.
Asensi Cantó P; (...); Guerreiro M
Article. 10.1111/tid.14067. 2023
Distinct mutational pattern of myelodysplastic syndromes with and without 5q-treated with lenalidomide
Adema, V; (...); Sole, F
Letter. 10.1111/bjh.16558. 2020
DNA methylation map in circulating leukocytes mirrors subcutaneous adipose tissue methylation pattern: a genome-wide analysis from non-obese and obese patients
Crujeiras, AB; (...); Martinez, JA
Article. 10.1038/srep41903. 2017
DNA methylation signatures associated with pathogenesis Crohn's disease-related genes
Tatay, IM; (...); Beltran, B
Meeting Abstract. 2019
Do Guidelines Influence Diagnostic and Therapeutic Practice in Immune Thrombocytopenia? Results of a Multicenter Retrospective Study
Luisa Lozano, Maria; (...); Vicente Garcia, Vicente
Meeting Abstract. 10.1182/blood-2019-125557. 2019
Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?
Article. 10.1182/bloodadvances.2019000680. 2019
Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?
Suárez EU; (...); Montesinos P
Article. 10.1007/s00277-024-05840-7. 2024
Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database
Azibeiro Melchor, Raul; (...); Ossenkoppele, Gert J.
Meeting Abstract. 10.1182/blood-2021-150766. 2021
Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Hutchings, Martin; (...); Subklewe, Marion
Meeting Abstract. 10.1182/blood-2023-173302. 2023
Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape.
Solana-Altabella, Antonio; (...); Montesinos, Pau
Article. 10.1080/17512433.2023.2174523. 2023
Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia
Megías-Vericat JE; (...); Montesinos P
Review. 10.1007/s00277-020-04186-0. 2020
Duodopa nasoduodenal tube at intrabronchial position.
Rosello, IA; (...); Navarro, PA
Editorial Material. 10.1016/j.redar.2017.12.011. 2018
Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories
Pfeilstocker, Michael; (...); Greenberg, Peter L.
Meeting Abstract. 10.1182/blood-2022-158671. 2022
Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes
Itzykson, R; (...); European MDS Registry Members
Article. 10.1182/bloodadvances.2018020495. 2018
Early radiological response as predictor of overall survival in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor mutations
Salvador-Coloma, C; (...); Juan, O
Article. 10.21037/jtd.2018.02.30. 2018
Early-Onset Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) without SF3B1 Mutations in Adults: Enrichment with Germline Variants in Genes Responsible for Congenital Sideroblastic Anemias
Jauregui, Sandra Novoa; (...); Jerez, Andres
Meeting Abstract. 10.1182/blood-2023-185836. 2023
EASIX AS A PREDICTOR INDEX FOR NEUROLOGICAL COMPLICATIONS AFTER ANTI-CD19 CAR-T CELL THERAPY IN AGGRESSIVE B-CELL LYMPHOMAS: A STUDY FROM THE GETHTC GROUP
Pena Domingo, Marta; (...); Sureda, Anna
Meeting Abstract. 2023
EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases
Article. 10.1038/bmt.2013.190. 2014
Economic Burden of Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients: A Spanish Multicenter, Retrospective Study
Vazquez, L; (...); Solano, C
Meeting Abstract. 2020
Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant
Solano C; (...); Bow EJ
Article. 10.1111/myc.12552. 2017
Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome
Cañigral C; (...); Sanz MA
Letter. 10.1007/s00277-013-1970-3. 2014
Editorial introductions
Curigliano, Giuseppe; (...); Mateos, Maria-Victoria
Editorial Material. 10.1097/CCO.0000000000001001. 2023
Editorial: Infectious diseases and hematology: diagnosis and management
Gonzalez-Lopez, Tomas Jose; (...); Di Micco, Pierpaolo
Editorial Material. 10.3389/fmed.2024.1385874. 2024
Editorial: Pediatric acute lymphoblastic leukemia: what's next?
Gil, J. V., Ribera, J., LLop, M.
Editorial Material. 10.3389/fped.2023.1358139. 2024
Effect of autologous umbilical cord blood transfusion in the development of retinopathy of prematurity: randomized clinical trial - study protocol.
Torrejon-Rodriguez L; (...); Aguar Carrascosa M
Article. 10.3389/fped.2023.1269797. 2023
Effect of Caplacizumab in the Recovery of ADAMTS13 Level in Patients with Autoimmune Thrombotic Thrombocytopenic Purpura. Analysis from the Spanish Registry (REPTT)
Eva Mingot, Maria; (...); Del Rio Garma, Julio
Meeting Abstract. 10.1182/blood-2023-182876. 2023
Effect of CD8(+) Cell Content on Umbilical Cord Blood Transplantation in Adults with Hematological Malignancies
Moscardó F; (...); Sanz GF
Article. 10.1016/j.bbmt.2014.06.038. 2014
Effect of Consolidation with Allogeneic Hematopoietic Cell Transplant Versus No Consolidation in Patients with Non-Hodgkin Lymphomas Treated with Bispecific Antibodies
Losi, Giulia; (...); Mussetti, Alberto
Meeting Abstract. 10.1182/blood-2024-202933. 2024
Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML).
Dinardo, CD; (...); Dohner, H
Meeting Abstract. 2020
Effect of gilteritinib on survival in patients with FLT3-mutated (FLT3(mut+)) relapsed/refractory (RR) AML who have common AML co-mutations or a high FLT3-ITD allelic ratio.
Levis, MJ; (...); Bahceci, E
Meeting Abstract. 2019
EFFECT OF MISSENSE MUTATIONS IN THE SPLICING OF PATIENTS WITH ACUTE MYELOID LEUKAEMIA
Morote-Faubel, M.; (...); Cervera, J.
Meeting Abstract. 2019
Effect of olutasidenib (FT-2102) on complete remissions in patients with relapsed/refractory (R/R) mIDH1 acute myeloid leukemia (AML): Results from a planned interim analysis of a phase 2 clinical trial.
De Botton, Stephane; (...); Fenaux, Pierre
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.7006. 2021
EFFECT OF PREGNANCY IN THE CLINICAL COURSE OF PREGNANT WOMEN WITH PTI AND THEIR OFFSPRING. RESULTS OF A SERIES OF SPANISH CASES WITH 263 PREGNANCIES IN PRIMARY PTI
Lopez, TJG; (...); Hermida, G.
Meeting Abstract. 2017
Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation A Randomized Clinical Trial
Bastidas, A; (...); ZOE-HSCT Study Grp Collaborators
Article. 10.1001/jama.2019.9053. 2019
Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia
García-Delgado R; (...); Sanz G
Article. 10.1016/j.leukres.2014.03.004. 2014
Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis
Salmerón J; (...); Quiles R
Article. 10.3748/wjg.v21.i30.9163. 2015
EFFECTIVENESS AND SAFETY OF THE INFUSION OF DONOR LYMPHOCYTES AFTER HAPLOIDENTICAL TRANSPLANTATION OF HEMATOPOYETIC PROGENITOR CELLS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE: MULTICENTRIC RETROSPECTIVE STUDY OF THE HEMATOPETIC SPANISH TRIPASHOLE GROUP
Martin-Sanchez, Guillermo; (...); Bermudez, Aranzazu
Meeting Abstract. 2020
EFFECTIVENESS AND TOXICITY OF THE USE OF INOTUZUMAB (INO) IN PATIENTS WITH RESISTANT OR RECALLING (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (LAL). STUDY OF PATIENTS INCLUDED IN INO'S EXPANDED USE PROGRAM
Ribera Santasusana, J. M.; (...); Valero, M.
Meeting Abstract. 2021
Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors' reply
Bernal, T; (...); Sanz, G
Letter. 10.1038/leu.2015.339. 2016
Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry
Bernal T; (...); Spanish Society of Hematology
Article. 10.1038/leu.2015.115. 2015
Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment
Palanques-Pastor T; (...); Poveda Andrés JL
Article. 10.1159/000517813. 2021
EFFECTS OF B-MYB ABERRANT EXPRESSION ON HEMATOPOIETIC PROGENITOR CELL GROWTH AND DETECTION OF GENETIC VARIATIONS THAT MAY MODIFY ITS PROTEIN FUNCTION
Dolz, S.; (...); Sanz, M.
Article. 2013
Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: A randomised controlled trial
Meeting Abstract. 2018
Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study Group
Pleyer, Lisa; (...); Greil, Richard
Meeting Abstract. 10.1182/blood-2019-123941. 2019
Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial.
Zeiser R; (...); Chen YB
Article. 10.1016/S2352-3026(21)00367-7. 2022
Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301) : a randomised, multicentre, double-blind, phase 3 trial
Zeiser, Robert; (...); Chen, Yi-Bin
Article. 10.1016/S2352-3026(21)00367-7. 2022
Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia
Ribera, JM; (...); PETHEMA Group, Spanish Society of Hematology
Article. 10.1080/10428194.2017.1397661. 2018
Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial
Cortes, JE; (...); Levis, MJ
Meeting Abstract. 10.1182/blood-2018-99-110439. 2018
Efficacy and Safety of Single-Agent Quizartinib (Q), Potent and SeleEfficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM-R Trial
Cortes, JE; (...); Levis, MJ
Meeting Abstract. 2019
Efficacy and Safety of Single-Agent Quizartinib, a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) With FLT3-Internal Tandem Duplication (FLT3-ITD) - Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM-R Trial
Jonas, BA; (...); Levis, MJ
Meeting Abstract. 10.1016/j.clml.2019.07.097. 2019
Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) in the Real-World Setting in Spain: An Update of the Venares Study
Ferra, Christelle; (...); Baltasar, Patricia
Meeting Abstract. 10.1182/blood-2022-162186. 2022
Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real World Setting in Spain: The Venares Study
Baltasar, Patricia; (...); Ferra, Christelle
Meeting Abstract. 10.1182/blood-2021-147685. 2021
Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma.
Crochet, Gilles; (...); Houot, Roch
Article. 10.1182/blood.2024024526. 2024
Efficacy of Chimeric Antigen Receptor T-Cell Therapy Is Not Impaired By Previous Bispecific Antibody Treatment in Patients with Large B-Cell Lymphoma
Iacoboni, Gloria; (...); Morschhauser, Franck
Meeting Abstract. 10.1182/blood-2023-185035. 2023
EFFICACY OF IBRUTINIB IN THE TREATMENT OF LINFOPROLIFERATIVE SYNDROMES: EXPERIENCE IN REAL LIFE OF THE VALENCIAN COMMUNITY
Martin, EMD; (...); Castera, MJT
Meeting Abstract. 2018
El nuevo reto en oncologia: la secuenciacion NGS y su aplicacion a la medicina de precision.
Calabria I; (...); Castel V
Article. 10.1016/j.anpedi.2016.05.006. 2016
Elotuzumab plus bortezomib and dexamethasone (EBd) versus bortezomib and dexamethasone (Bd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM)-2-year follow-up
Palumbo, A; (...); Jakubowiak, A
Article. 2016
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.
Peffault de Latour R; (...); Risitano AM
Article. 10.1056/NEJMoa2109965. 2022
ELTROMBOPAG ADDED TO STANDARD IMMUNOSUPPRESSION IMPROVES RESPONSE RATE IN SEVERE APLASTIC ANEMIA: RESULTS OF THE MULTICENTER PHASE III PROSPECTIVE RANDOMIZED RACE TRIAL
Risitano, A. M.; (...); de latour, R. Peffault
Meeting Abstract. 2021
ELTROMBOPAG ADDED TO STANDARD IST IS SUPERIOR TO IST ALONE AS FRONT-LINE TREATMENT FOR SEVERE APLASTIC ANEMIA: FINAL 2-YEAR ANALYSIS OF EBMT-SAAWP RACE STUDY
Risitano, Antonio Maria; (...); de Latour, Regis Peffault
Meeting Abstract. 2024
Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice
González-López TJ; (...); González-Porras JR
Article. 10.1111/ejh.12725. 2016
Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia.
Solana-Altabella, Antonio; (...); Montesinos, Pau
Article. 10.1080/14728214.2021.2009800. 2022
Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial.
Smith CC; (...); Bahceci E
Article. 10.1182/blood-2019-122620. 2019
Emerging strategies for the treatment of older patients with acute myeloid leukemia
Sanz MA; (...); Venditti A
Review. 10.1007/s00277-016-2666-2. 2016
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
DiNardo CD; (...); Döhner H
Article. 10.1016/S1470-2045(21)00494-0. 2021
Enasidenib vs conventional care in mutant-IDH2 relapsed/refractory acute myeloidleukemia: a randomized, phase 3 trial.
de Botton, Stephane; (...); DiNardo, Courtney D.
Article. 10.1182/blood.2021014901. 2022
Engaging Innate Immunity By AFM28, an Innate Cell Engager (ICE®) Targeting CD123-Positive Leukemic Cells in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Safety and Efficacy Results of a First-in-Human Phase 1 Study
Montesinos, Pau; (...); Recher, Christian
Meeting Abstract. 10.1182/blood-2024-194356. 2024
Engraftment kinetics and graft failure after single umbilical cord blood transplantation using a myeloablative conditioning regimen
Ruggeri A; (...); Netcord
Article. 10.3324/haematol.2014.109280. 2014
Enhancing Cytogenetic Diagnostics: Incorporating Optical Genome Mapping in the Laboratory Routine
Diaz-Gonzalez, Alvaro; (...); Such, Esperanza
Meeting Abstract. 10.1182/blood-2023-180691. 2023
Enhancing roasted pepper quality sustainably: Impact of biodegradable mulches
Guerra, Marcos; (...); Casquero, Pedro Antonio
Article. 10.1016/j.jafr.2024.101393. 2024
Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R)
Calvo, X; (...); Florensa, L
Article. 10.1002/ajh.24732. 2017
Epidemiology of Hereditary Thrombotic Thrombocytopenic Purpura (TTP) in Spain: Preliminary Results of a Study of the Spanish TTP Registry (REPTT)
Segui, Ines Gomez; (...); Garma, Julio Del Rio
Meeting Abstract. 2024
Epigenetic alterations leading to TMPRSS4 promoter hypomethylation and protein overexpression predict poor prognosis in squamous lung cancer patients
Villalba M; (...); Calvo A
Article. 10.18632/oncotarget.8045. 2016
Epigenetic and sex differences in opioid use disorder in chronic pain: A real-world study linked with OPRM1 DNA methylation.
Agullo, Laura; (...); Peiro, Ana M.
Article. 10.1111/adb.13422. 2024
Epigenetic control of influenza virus: role of H3K79 methylation in interferon-induced antiviral response
Marcos-Villar, L; (...); Nieto, A
Article. 10.1038/s41598-018-19370-6. 2018
Epigenetic crosstalk: a molecular language in human metabolic disorders.
Martinez-Jimenez CP, Sandoval J
Article. 2015
Epigenetic characterization of the inflammatory hidradenitis suppurativa phenotype
Martorell, Antonio; (...); Sandoval, Juan
Meeting Abstract. 2023
Epigenetic inactivation of the p53-induced long noncoding RNA TP53 target 1 in human cancer
Diaz-Lagares A; (...); Esteller M
Article. 10.1073/pnas.1608585113. 2016
Epigenetic Regulation of Early- and Late-Response Genes in Acute Pancreatitis
Sandoval J; (...); López-Rodas G
Article. 10.4049/jimmunol.1502378. 2016
Epigenetic Regulation of microRNAs in Cancer: Shortening the Distance from Bench to Bedside
Pajares MJ; (...); Sandoval J
Review. 10.3390/ijms22147350. 2021
Epigenetic Silencing of Tumor Suppressor miR-124 Directly Supports STAT3 Activation in Cutaneous T-Cell Lymphoma.
García-Colmenero L; (...); Gallardo F
Article. 10.3390/cells9122692. 2020
Epigenetics and Oxidative Stress in Aging
Guillaumet-Adkins, A; (...); Sandoval, J
Review. 10.1155/2017/9175806. 2017
Epigenetics of Inflammatory Bowel Disease: Unraveling Pathogenic Events
Mateos, Beatriz; (...); Sandoval, Juan
Review. 10.1093/crocol/otz017. 2019
Epigenome profiling reveals aberrant DNA methylation signature in GATA2 deficiency.
Marin-Bejar, Oskar; (...); Giorgetti, Alessandra
Article. 10.3324/haematol.2022.282305. 2023
Epstein-Barr virus-associated posttransplant lymphoproliferative disorder after allogeneic stem cell transplantation
Review. 10.1097/CCO.0000000000000119. 2014
ERCC6L2 in Early-Onset Adult Myelodysplastic Syndrome without Pre-Existing Disorder
Carrillo-Tornel, Salvador; (...); Jerez, Andres
Meeting Abstract. 10.1182/blood-2022-168759. 2022
Erythrocyte deformability and aggregation in homozygous sickle cell disease
Vayá A; (...); Barragán E
Article. 10.3233/CH-131717. 2014
Erythrocyte deformability and hereditary elliptocytosis
Article. 10.3233/CH-141889. 2014
Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes
Calvo X; (...); Florensa L
Article. 10.1038/modpathol.2016.146. 2016
Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome
Garelius, HKG; (...); Hellström-Lindberg E
Article. 10.1111/joim.12579. 2017
Escalated dosing schedules of CC-486 for patients experiencing first acute myeloid leukemia (AML) relapse: Results from the phase III QUAZAR AML-001 maintenance trial.
Dohner, H; (...); Roboz, GJ
Meeting Abstract. 2020
Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the EBMT.
Sanz, Jaime; (...); Ciceri, Fabio
Article. 10.1038/s41409-023-02075-4. 2023
European Perspective on Multiple Myeloma Treatment Strategies in 2014
Ludwig H; (...); Palumbo A
Article. 10.1634/theoncologist.2014-0042. 2014
Evaluation of a disease risk index for adult patients undergoing umbilical cord blood transplantation for haematological malignancies
Paviglianiti, A; (...); Rocha, V
Article. 10.1111/bjh.14962. 2017
EVALUATION OF ANTI-LEUKEMIC IN VITRO TREATMENT WITH DEXAMETHASONE OF OVARIAN CORTEX PRIOR TO TRANSPLANTATION.
Diaz-Garcia, C.; (...); Pellicer, A.
Article. 10.1016/j.fertnstert.2015.07.815. 2015
Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial
Lopez Cadenas, Felix; (...); Diez-Campelo, Maria
Meeting Abstract. 10.1182/blood-2022-168718. 2022
Evaluation of minimal residual disease in relapsed/refractory multiple myeloma patients treated with venetoclax or placebo in combination with bortezomib and dexamethasone: BELLINI study analyses.
Moreau, P; (...); Kumar, S
Meeting Abstract. 2020
EVALUATION OF THE EFFECT OF DIFFERENT LIGANDS OF TLRS IN THE PROLIFERATION AND DIFFERENTIATION OF ACUTE MYELOID LEUKEMIA CELLS
Fernandez, JG; (...); Ribate, EV
Meeting Abstract. 2017
EVALUATION OF THE MUTATION OF FLT3 IN ACUTE MYELOID LEUKAEMIA: RESULTS OF THE DELPHI QUESTIONNAIRE OF THE SPANISH GROUP
Gomez-Casares, M. T.; (...); Sierra, J.
Meeting Abstract. 2019
EVALUATION OF THE RETRO-TRANSCRIPTION Q-LAMP TEST: A NEW METHOD FOR ULTRA-FAST IDENTIFICATION OF BCR-ABL FUSION TRANSCRITES
Sargas, C.; (...); Barragan, E.
Meeting Abstract. 2019
Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia
Mosquera Orgueira, Adrian; (...); Perez Encinas, Manuel Mateo
Article. 10.3389/fonc.2022.968340. 2022
Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoeitic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years.
Bazarbachi A; (...); Mohty M
Article. 10.1158/1078-0432.CCR-20-3134. 2020
Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications
Remacha ÁF; (...); Sanz G
Article. 10.1007/s00277-014-2274-y. 2015
Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)
Labrador, Jorge; (...); Manuel Alonso-Dominguez, Juan
Meeting Abstract. 10.1182/blood-2022-163016. 2022
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry.
Labrador, Jorge; (...); Montesinos, Pau
Article. 10.1002/cncr.35431. 2024
Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients.
Boluda B; (...); Montesinos P
Article. 10.1080/10428194.2021.1938031. 2021
Evolving treatment patterns and outcomes in older patients (=60 years) with AML: changing everything to change nothing?
Martínez-Cuadrón D; (...); Montesinos P
Article. 10.1038/s41375-020-01058-4. 2020
Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host Disease.
Montoro J; (...); Papadopoulos EB
Article. 10.1016/j.bbmt.2019.10.003. 2020
Ex vivo T-cell depletion vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft-vs-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation.
Montoro, Juan; (...); Sanz, Jaime
Article. 10.1111/ejh.13529. 2021
Excess Mortality in Low-Risk MDS Can be Explained By MDS and AML Related Causes of Death
Madry, K; (...); Smith, A
Meeting Abstract. 10.1182/blood-2018-99-115928. 2018
Excess mortality in the myelodysplastic syndromes
Nomdedeu, M; (...); Spanish MDS Group
Article. 10.1002/ajh.24606. 2017
Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with hematological malignancies.
Gudiol C; (...); de la Cámara R
Article. 10.1016/j.eimc.2019.01.013. 2020
Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015)
Expert Panel of GESIDA and the National AIDS Plan; (...); Rivero A
Article. 10.1016/j.eimc.2015.03.017. 2015
Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm
Menezes J; (...); Cigudosa JC
Article. 10.1038/leu.2013.283. 2014
EXPERIENCE IN THE DONATION OF HEMATOPOYETIC PROGENITORS (PH) OF PERIPHERAL BLOOD OF MINOR DONORS
Dominguez Hernandez, L.; (...); Gomez Segui, I
Meeting Abstract. 2019
Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Pemmaraju, Naveen; (...); Daver, Naval
Meeting Abstract. 10.1182/blood-2021-146666. 2021
EXPLOITING CUTTING-EDGE TECHNOLOGIES TO ANALYZE LOSS OF HLA IN A GLOBAL MULTICENTRIC COHORT OF POST-TRANSPLANTATION RELAPSES: PRELIMINARY RESULTS FROM THE HLALOSS COLLABORATIVE STUDY
Vago, Luca; (...); Fleischhauer, Katharina
Meeting Abstract. 2018
Exploiting Cutting-Edge Technologies to Analyze Loss of HLA in a Global Multicentric Cohort of Post-Transplantation Relapses: Preliminary Results from the HLALOSS Collaborative Study
Vago, Luca; (...); Fleischhauer, Katharina
Meeting Abstract. 2018
EXPLOITING CUTTING-EDGE TECHNOLOGIES TO ANALYZE LOSS OF HLA IN A MULTICENTRIC COHORT OF POST-TRANSPLANTATION RELAPSES: RESULTS FROM THE HLALOSS GLOBAL COLLABORATIVE STUDY
Vago, L.; (...); Fleischhauer, K.
Meeting Abstract. 2018
Exploring Potential Molecular Mechanisms of Drug Response in FLT3-ITD Negative AML Patients Treated with Quizartinib Vs Placebo Plus Standard Chemotherapy in the Quiwi Trial
Mosquera Orgueira, Adrian; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2023-180710. 2023
Exploring the potential of optical genome mapping in soft-tissue and bone tumours
Mayordomo Aranda, E.; (...); Such Taboada, E.
Meeting Abstract. 2024
EXTRACORPOREAL PHOTOPHERESIS IN GRAFT-VERSUS-HOST DISEASE.
Canto, Pedro Asensi; (...); Segui, Ines Gomez
Article. 10.1016/j.jtct.2023.07.001. 2023
Extracorporeal photopheresis vs standard therapies for steroid-refractory chronic graft-vs-host disease: Pharmacoeconomic assessment of hospital resource use in Spain.
Boluda, Blanca; (...); Montesinos, Pau
Article. 10.1002/jca.21901. 2021
Ex-vivo T-cell depleted peripheral blood stem cell transplantation from HLA-matched sibling donors for the treatment of severe aplastic anemia
Cano-Ferri, I.; (...); Sanz, G.
Meeting Abstract. 2015
Factor XIII deficiency in two Spanish families with a novel variant in gene F13A1 detected by next-generation sequencing; symptoms and clinical management.
Moret A; (...); Bonanad S
Article. 10.1007/s11239-020-02065-z. 2020
Factors Associated With Survival in Secondary Acute Myeloid Leukemia in Colombia
Sossa, Claudia; (...); Marcela Cuervo, Diana
Meeting Abstract. 2023
Factors influencing platelet transfusion refractoriness in patients undergoing allogeneic hematopoietic stem cell transplantation
Solves P; (...); Carpio N
Article. 10.1007/s00277-017-3168-6. 2018
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial.
Ribera JM; (...); Sancho JM
Article. 10.3324/haematol.2023.283342. 2024
Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group
Ribera, JM; (...); Spanish Soc Hematology
Article. 10.1016/j.leukres.2015.11.012. 2016
Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis
Fox, ML; (...); Valcarcel, D
Article. 10.1080/10428194.2020.1788015. 2020
Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients
Hernandez-Boluda, JC; (...); GELMC
Article. 10.1038/s41408-018-0125-0. 2018
Features of cytomegalovirus DNAemia and virus-specific T-cell responses in allogeneic hematopoietic stem-cell transplant recipients during prophylaxis with letermovir.
Gimenez, Estela; (...); Navarro, David
Article. 10.1111/tid.14021. 2023
Female Sex Effect on Anti-CD19 CART Cell Therapy for Relapsed/Refractory B-Cell Lymphoma: A Grupo Espanol De Trasplante y Terapia Celular (GETH-TC) Study
Fabbri, Nicole; (...); Mussetti, Alberto
Meeting Abstract. 10.1182/blood-2023-185721. 2023
Fertility rescue and ovarian follicle growth promotion by bone marrow stem cell infusion
Herraiz, S; (...); Pellicer, A
Article. 10.1016/j.fertnstert.2018.01.004. 2018
FINAL ANALYSIS OF GLOBAL SURVIVAL OF THE FIRST TEST IN PATIENTS WITH MULTIPLE NEW DIAGNOSTIC MYELOMA
Oriol, A.; (...); Benboubker, L.
Meeting Abstract. 2017
Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Ayyappan, Sabarish; (...); Prince, H. Miles
Meeting Abstract. 10.1182/blood-2023-179818. 2023
FINAL RESULTS OF THE LAL-RI 08 PROTOCOL FOR ADOLESCENTS AND YOUNG ADULTS (AAJ) WITH LYMPHOBLASTIC ACUTE LEUKEMIA (LAL) OF STANDARD RISK (RE)
Santasusana, JMR; (...); Vale, AODCE
Meeting Abstract. 2018
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes.
Zeidan, Amer M.; (...); Santini, Valeria
Article. 10.1038/s41375-022-01724-9. 2022
First report of PhALLCON: A phase 3 study comparing ponatinib (pon) vs imatinib (im) in newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL).
Jabbour, Elias; (...); Ribera, Josep-Maria
Meeting Abstract. 2023
First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia
Jabbour, Elias; (...); Ribera, Jose-Maria
Meeting Abstract. 2023
First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia.
Salamero, Olga; (...); Somervaille TCP
Article. 10.1200/JCO.19.03250. 2020
FITNESS ASSESSMENT IN ACUTE MYELOID LEUKEMIA: RECOMMENDATIONS FROM AN EXPERT PANEL ON BEHALF OF EUROPEAN LEUKEMIA NET.
Venditti, Adriano; (...); Ossenkoppele, Gert J
Article. 10.1182/bloodadvances.2024013744. 2025
FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk
Spina M; (...); FLORENCE Study Group
Article. 10.1093/annonc/mdv317. 2015
FLT3 mutation Assay Laboratory Cross Validation: Results from the CALGB 10603/Ratify Trial in Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML)
Thiede, C; (...); Dohner, K
Meeting Abstract. 10.1182/blood-2018-99-112127. 2018
Fluorescence in situ hybridization of TP53 for the detection of chromosome 17 abnormalities in myelodysplastic syndromes
Sánchez-Castro J; (...); Solé F
Article. 10.3109/10428194.2015.1028053. 2015
Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia
Pallarès V; (...); Casanova, I
Article. 10.3390/cancers10110436. 2018
Follow-up of patients with FLT3-mutated R/R AML in the phase 3 ADMIRAL trial.
Perl, Alexander E.; (...); Levis, Mark J.
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.7013. 2021
Follow-up of Patients With FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukaemia in the Phase 3 ADMIRAL Trial
Perl, Alexander E.; (...); Levis, Mark J.
Meeting Abstract. 2022
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.
Perl AE; (...); Levis MJ
Article. 10.1182/blood.2021011583. 2022
Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice.
Gonzalez-Lopez, Tomas Jose; (...); Garcia-Donas Gabaldon, Gloria
Article. 10.1182/blood.2024024250. 2024
Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia
Genesca, E; (...); Ribera, JM
Article. 10.1186/s13045-018-0639-8. 2018
FREQUENCY AND CLINICAL IMPACT OF CDKN2A/B GENE LOCUS IN AN ADULT T-ALL COHORT OF PATIENTS ENROLLED IN THE SPANISH PETHEMA GROUP PROTOCOLS
Genesca, E; (...); Ribera, JM
Meeting Abstract. 2017
Frequency and Impact of Somatic Mutations Alone or in Combination on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Large Study on Behalf of the EBMT Acute Leukemia Working Party
Bazarbachi, Ali; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2024-204672. 2024
FREQUENCY AND IMPACT OF SOMATIC MUTATIONS ON OUTCOMES OF ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: FROM THE EBMT ACUTE LEUKEMIA WORKING PARTY
Bazarbachi, Ali; (...); Mohty, Mohamad
Meeting Abstract. 2024
Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia
Motllo C; (...); PETHEMA Group, Spanish Society of Hematology
Article. 10.1080/10428194.2017.1326596. 2018
Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols
Motlló C; (...); PETHEMA Group, Spanish Society of Hematology
Article. 10.1080/10428194.2016.1177182. 2017
Frequency of dicentrics and contamination levels in Ukrainian children and adolescents from areas near Chernobyl 20 years after the nuclear plant accident.
Montoro, A.; (...); Villaescusa, JI.
Article. 2013
Frequency, Clinical Characteristics and Outcome of Adults With Acute Lymphoblastic Leukemia and COVID 19 Infection in the First vs. Second Pandemic Wave in Spain.
Ribera, Josep-Maria; (...); Pinana, Jose-Luis
Article. 10.1016/j.clml.2021.06.024. 2021
Frequency, characteristics and outcomes of Lymphoproliferative Disorders After Allogeneic Stem Cell Transplant: results of a multicenter study from the Grupo Espanol de Trasplante Hematopoyetico (GETH)
Garcia Cadenas, Irene; (...); Solano, Carlos
Meeting Abstract. 2018
Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH)
Garcia-Cadenas, I; (...); Spanish Grp Blood & Marrow Tran
Article. 10.1111/ejh.13226. 2019
FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study
Cortes, JE; (...); Baer, MR
Meeting Abstract. 10.1182/blood-2018-99-114126. 2018
FUNCTIONAL CLASSIFICATION OF DEEP INTRONIC VARIANTS IN PATIENTS WITH ACUTE MYELOBLASTIC LEUKEMIA
Liquori, A.; (...); Cervera Zamora, J.
Meeting Abstract. 2019
FUNCTIONAL RECLASSIFICATION THROUGH MINIGENE TESTS OF MISSENSE VARIANTS WITH EFFECT ON SPLICING IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
Morote-Faubel, Mireya; (...); Cervera, Jose
Meeting Abstract. 2020
FUNCTIONAL STUDY OF SILENCED HMGCR GENE IN CELL LINES OF ACUTE MYELOID LEUKEMIA PATIENTS
De Matteo, B; (...); Zamora, JVC
Meeting Abstract. 2017
Further psychometric validation of the GAH scale: Responsiveness and effect size
Cruz-Jentoft, AJ; (...); GAH Group
Article. 10.1016/j.jgo.2016.12.008. 2017
G9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1.
Exposito, Francisco; (...); Calvo, Alfonso
Article. 10.1038/s41419-024-07156-w. 2024
GAH SCALE PREDICTS TREATMENT TOLERABILITY IN OLDER PATIENTS (> 65 YEARS) DIAGNOSED WITH HEMATOLOGICAL MALIGNANCIES
Bonanad, S; (...); de la Rubia, J
Meeting Abstract. 2017
GAM: General Auxetic Metamaterial with Tunable 3D Auxetic Behavior Using the Same Unit Cell Boundary Connectivity
Ben-Yelun, Ismael; (...); Saucedo-Mora, Luis
Article. 10.3390/ma16093473. 2023
Gastric Bleeding in Stem Cell Transplantation: A Focus on Gastric Vascular Ectasia Under Post-Transplant Cyclophosphamide, Sirolimus, and Mycophenolate Mofetil Prophylaxis.
Eirís J; (...); Sanz J
Article. 10.1016/j.jtct.2024.10.009. 2024
Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 Maintenance Therapy in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Trial
Ravandi, Farhad; (...); Dombret, Herve
Meeting Abstract. 2020
Gastrointestinal events and management strategies for patients with acute myeloid leukemia (AML) in first remission receiving oral azacitidine (Oral-AZA) in the randomized, placebo-controlled, phase 3 QUAZAR AML-001 maintenance trial
Pfeilstocker, M.; (...); Dombret, H.
Meeting Abstract. 2021
Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia.
Mosquera Orgueira A; (...); Bello López JL
Article. 10.1371/journal.pone.0247093. 2021
Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology
D'Amico, Saverio; (...); Della Porta, Matteo Giovanni
Meeting Abstract. 10.1182/blood-2024-209541. 2024
GENES BELONGING TO THE SWI/SNF CHROMATIN REMODELING COMPLEXES ARE MUTATED AT HIGH FREQUENCY IN RARE T(11;17)(Q23;Q21)/ZBTB16-RARA ACUTE MYELOID LEUKEMIA PATIENTS
Fabiani, E.; (...); Voso, M. T.
Meeting Abstract. 2020
Genome wide DNA methylation profiling identifies specific epigenetic features in high-risk cutaneous squamous cell carcinoma.
Hervás-Marín D; (...); Sandoval J
Article. 10.1371/journal.pone.0223341. 2019
GENOME-WIDE ANALYSIS OF SINGLE NUCLEOTIDE POLYMORPHISM (SNPS) IN PATIENTS WITH DE NOVO ACUTE MYELOID LEUKEMIA WITH NORMAL KARYOTYPE
Ibanez, M.; (...); Cervera, J.
Meeting Abstract. 2016
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (vol 13, 2, 2022)
Lin, Wei-Yu; (...); Allan, James M.
Article. 10.1038/s41467-021-27679-6. 2022
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.
Lin WY; (...); Allan JM
Article. 10.1038/s41467-021-26551-x. 2021
Genome-Wide DNA Methylation in Early-Onset-Dementia Patients Brain Tissue and Lymphoblastoid Cell Lines.
Ramos-Campoy, Oscar; (...); Antonell, Anna
Article. 10.3390/ijms25105445. 2024
Genome-wide DNA methylation pattern in visceral adipose tissue differentiates insulin-resistant from insulin-sensitive obese subjects
Crujeiras, A. B.; (...); Fernandez-Real, J. M.
Article. 10.1016/j.trsl.2016.07.002. 2016
Genome-wide DNA methylation profiling in anorexia nervosa discordant identical twins.
Iranzo-Tatay, C.; (...); Rojo-Moreno, L.
Article. 10.1038/s41398-021-01776-y. 2022
GENOMIC ANALYSIS OF PML/RARA BREAKPOINTS IN PAIRED DIAGNOSIS/RELAPSE SAMPLES OF PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA TREATED WITH ALL-TRANS RETINOIC ACID AND CHEMOTHERAPY
Iaccarino, L.; (...); Lo-Coco, F.
Meeting Abstract. 2017
GENOMIC AND TRANSCRIPTOMIC CHARACTERIZATION OF MYELODYSPLASTIC SYNDROMES/MYELOPROLIFERATIVE NEOPLASMS
Acha, P.; (...); Sole, F.
Meeting Abstract. 10.1016/j.leukres.2023.107253. 2023
GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES
Bernard, E.; (...); Papaemmanuil, E.
Meeting Abstract. 10.1016/j.leukres.2023.107146. 2023
Genomic characterization of Citrobacter freundii strains coproducing OXA-48 and VIM-1 carbapenemase enzymes isolated in leukemic patient in Spain
Lalaoui, R; (...); Rolain, JM
Article. 10.1186/s13756-019-0630-3. 2019
Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea.
Alvarez-Larrán A; (...); Hernández-Boluda JC
Letter. 10.1038/s41375-020-0849-2. 2020
Genomic profiling of high-risk smoldering myeloma patients treated with a curative strategy: a biological study of the phase II GEM CESAR clinical trial
Medina, Alejandro; (...); Garcia-Sanz, Ramon
Meeting Abstract. 2023
Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials.
Gonzalez-Gil, Celia; (...); Genesca, Eulalia
Article. 10.3324/haematol.2022.281196. 2023
Genotype FBN1/Phenotype relationship in a cohort of patients with Marfan syndrome.
Hernándiz A; (...); Sepúlveda P
Article. 10.1111/cge.13879. 2020
Genotypic and Phenotypic Characteristics of Acute Promyelocytic Leukemia Translocation Variants.
Mannan A; (...); Aljurf M
Article. 10.1016/j.hemonc.2020.05.007. 2020
Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study.
de la Rubia J; (...); Bonanad, Santiago
Article. 10.1016/j.jgo.2022.10.016. 2022
GERMINAL PREDISPOSITION IN PATIENTS WITH MYELOID NEOPLASMS: ASSOCIATION BETWEEN MOLECULAR DISORDERS AND CLINICAL HISTORY
Marta, Santiago; (...); Jose, Cervera
Meeting Abstract. 2021
Germline and Acquired Genetic Variants in Myelodysplastic Syndromes in Young Adults without a Preexisting Disorder or Organ Dysfunction
Chen-Liang, TH; (...); Jerez, A
Meeting Abstract. 10.1182/blood-2018-99-116045. 2018
Germline assessment for alloHSCT candidates over 50 years: A 'Fast-Track' screening in myeloid neoplasms.
Torres-Esquius S; (...); Jerez A
Article. 10.1111/bjh.19460. 2024
Germline Predisposition in Myeloid Neoplasms Aged =50: A Novel Approach for Allogeneic Stem Cell -Transplantation Decision-Making
Torres-Esquius, Sara; (...); Jerez, Andres
Meeting Abstract. 10.1182/blood-2023-179234. 2023
GERMLINE PREDISPOSITION TO MYELOID MALIGNANCIES IN A CONSECUTIVE COHORT OF 183 PATIENTS
Santiago, M.; (...); Cervera-Zamora, J.
Meeting Abstract. 10.1016/j.leukres.2023.107247. 2023
Germline Predisposition to Pediatric Cancer, from Next Generation Sequencing to Medical Care.
Gargallo P; (...); Cañete A
Article. 10.3390/cancers13215339. 2021
Germline variant in Ctcf links mental retardation to Wilms tumor predisposition
Gargallo, Pablo; (...); Font de Mora, Jaime
Article. 10.1038/s41431-022-01105-x. 2022
GETH-CLL4: Long-term follow-up of a pilot trial evaluating the addition of ofatumumab to the conditioning regimen of patients with chronic lymphocytic leukemia undergoing allogeneic HCT
Montesinos, Pau; (...); Delgado, Julio
Meeting Abstract. 2018
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML.
Perl AE; (...); Levis MJ
Article. 10.1056/NEJMoa1902688. 2019
Gilteritinib prolongs survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukaemia who have common AML comutations or a high FLT3-internal tandem duplication allelic ratio
Levis, MJ; (...); Bahceci, E
Meeting Abstract. 2020
Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial
Perl, AE; (...); Levis, MJ
Meeting Abstract. 10.1158/1538-7445.AM2019-CT184. 2019
GILTERITINIB SIGNIFICANTLY PROLONGS OVERALL SURVIVAL IN PATIENTS WITH FLT3-MUTATED RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA: RESULTS FROM THE PHASE 3 ADMIRAL TRIAL
Perl, A. E.; (...); Levis, M. J.
Meeting Abstract. 2019
Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia: results from the phase 3 ADMIRAL trial
Perl, A. E.; (...); Levis, M. J.
Meeting Abstract. 2019
Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation.
Ballesta-López O; (...); Montesinos P
Review. 10.2217/fon-2020-0700. 2020
Glasdegib (GLAS) plus low-dose cytarabine (LDAC) in AML or MDS: BRIGHT AML 1003 final report and four-year overall survival (OS) follow-up.
Heuser, M; (...); Cortes, JE
Meeting Abstract. 2020
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial.
Sekeres MA; (...); Cortes JE
Article. 10.1038/s41375-023-02001-z. 2023
Glasdegib plus low-dose cytarabine in acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS): BRIGHT AML 1003 final report and 4-year overall survival follow-up
Heuser, M; (...); Cortes, JE
Meeting Abstract. 2020
Glasdegib Plus Low-Dose Cytarabine in Acute Myeloid Leukemia or Myelodysplastic Syndrome: BRIGHT AML 1003 Final Report and 4-Year Overall Survival Follow-Up
Heuser, Michael; (...); Cortes, Jorge E.
Meeting Abstract. 2020
Glasdegib with LDAC in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) Unsuitable for Intensive Chemotherapy: Effects on Transfusions and Marrow Recovery vs LDAC Alone
Wang, ES; (...); Cortes, JE
Meeting Abstract. 10.1016/j.clml.2019.07.114. 2019
Glomerulonephritis Secondary to Acute Promyelocytic Leukemia that Resolved after Induction Therapy.
Andres Regino, Carlos; (...); Angel Sanz, Miguel
Article. 10.1159/000528088. 2023
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: randomized phase 3 ASTRAL-2 trial.
Roboz GJ; (...); Döhner H
Article. 10.1182/bloodadvances.2023012062. 2024
GUIDELINES OF PRESCRIPTION IN FIRST LINE OF PATIENTS WITH MULTIPLE MYELOMA NOT CANDIDATES TO TRANSPLANTATION STRATIFIED BY AGE IN REAL LIFE IN SPAIN BETWEEN 2012 AND 2016
Cejalvo, M. J.; (...); Sarra, J.
Meeting Abstract. 2019
Guidelines of the Spanish ITP Group for the diagnosis, treatment and follow-up of patients with immune thrombopenia.
Lozano ML, Sanz MA, Vicente V
Article. 10.1016/j.medcli.2021.03.017. 2021
Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC)
López Rubio M; (...); Garcia-Marco JA
Article. 10.3109/10428194.2013.827187. 2014
Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML
Kwon M; (...); Diez-Martin JL
Article. 10.1038/bmt.2017.36. 2017
Haploidentical Donor Vs. Mismatch Unrelated Donor in Reduced Intensity Conditioning Transplant: A Study from the Spanish Group of Hematopoietic Transplant and Cell Therapy (GETH-TC)
Laura Fox, Maria; (...); Valcarcel, David
Meeting Abstract. 10.1182/blood-2022-167747. 2022
Haploidentical non-manipulated stem cell transplant in patients with non-hodgkin lymphoma: Spanish experience
Dorado, N; (...); Diez-Martin, JL
Meeting Abstract. 2019
Haploidentical stem cell donor choice for patients with acute myeloid leukemia: A study from the ALWP of the EBMT.
Sanz, Jaime; (...); Ciceri, Fabio
Article. 10.1182/bloodadvances.2023012133. 2024
Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with Non-Hodgkin Lymphoma: The Spanish Experience
Dorado, N; (...); Kwon, M
Meeting Abstract. 2020
Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide Therapy vs Other Donor Transplantations in Adults With Hematologic Cancers A Systematic Review and Meta-analysis
Gagelmann, N; (...); Kroger, N
Review. 10.1001/jamaoncol.2019.3541. 2019
Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler, Arnon; (...); Mohty, Mohamad
Article. 10.1097/HS9.0000000000000790. 2022
Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Nagler, Arnon; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2021-144558. 2021
Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation
Sobas, Marta; (...); Maria Hernandez-Rivas, Jesus
Meeting Abstract. 10.1182/blood-2021-149521. 2021
Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study
Solana-Altabella, Antonio; (...); Martinez-Cuadron, David
Article. 10.3390/cancers14081921. 2022
Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain.
Solana-Altabella A; (...); Montesinos P
Article. 10.1111/ejh.13604. 2021
Health-Related Quality of Life (HRQoL) during Treatment with Enasidenib (ENA) Plus Azacitidine (AZA) in Patients with Newly Diagnosed Mutant IDH2 (m IDH2) Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy (IC)
DiNardo, Courtney D.; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2021-147601. 2021
Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML).
Dinardo, Courtney Denton; (...); De Botton, Stephane
Meeting Abstract. 2022
Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study
Iskierka-Jazdzewska, Elzbieta; (...); Ivanescu, Cristina
Meeting Abstract. 10.1182/blood-2023-180743. 2023
Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study
Stauder, R; (...); de Witte, T
Article. 10.1038/s41375-018-0089-x. 2018
HEALTH-RELATEDQUALITYOF LIFE IS SUBSTANTIALLY IMPAIRED IN LOWER-RISK MDS WHEN COMPARED WITH REFERENCE POPULATIONS AND SIGNIFICANTLY AFFECTS OVERALL SURVIVAL
Stauder, R; (...); De Witte, T
Meeting Abstract. 10.1016/S0145-2126(17)30135-2. 2017
Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia.
Vega-Garcia N; (...); Camós M
Article. 10.3390/jpm10040244. 2020
Hematologic improvements with ivosidenib plus azacitidine compared to placebo plus azacitidine in patients with newly diagnosed acute myeloid leukemia.
Dohner, Hartmut; (...); De Botton, Stephane
Meeting Abstract. 2022
Hematologic neoplasms: interpreting lung findings in chest computed tomography.
Calvillo Batllés P; (...); Compte Torrero L
Article. 10.1016/j.rx.2015.07.003. 2015
Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China
Huang XJ; (...); Issaragrisil S
Article. 10.18632/oncotarget.15655. 2017
Hematopoietic Stem cell transplant in Aplastic anemia in patients older than 40 years: The experience of the Spanish Group of Hematopoietic Stem Cell Transplant (GETH)
Yanez, Lucrecia; (...); Solano, Carlos
Meeting Abstract. 2018
Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission.
Sanz, Jaime; (...); Marrow Transplantation (EBMT)
Article. 10.1038/s41409-020-01162-0. 2020
Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT.
Ruggeri A; (...); Nagler A
Article. 10.1038/s41409-019-0582-5. 2019
HIDDEN MDS: A PROSPECTIVE STUDY TO CONFIRM OR EXCLUDE MDS IN PATIENTS WITH ANEMIA OF UNCERTAIN ETIOLOGY
Bastida Bermejo, J. M.; (...); Diez-Campelo, M.
Meeting Abstract. 2016
Hidden myelodysplastic syndrome (MDS): A prospective study to confirm or exclude MDS in patients with anemia of uncertain etiology
Bastida, JM; (...); Diez-Campelo, M
Article. 10.1111/ijlh.12933. 2019
High Delta Np73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia
Lucena-Araujo AR; (...); Rego EM
Article. 10.1182/blood-2015-01-623330. 2015
High Heterogeneity of Multidrug-Resistant Enterobacteriaceae Fecal Levels in Hospitalized Patients Is Partially Driven by Intravenous $\beta$-Lactams.
Djukovic, Ana; (...); Ubeda, Carles
Article. 2020
High heterogeneity of multidrug-resistant Enterobacteriaceae fecal levels in hospitalized patients is partially driven by intravenous beta-lactams.
Djukovic A; (...); Ubeda C
Article. 10.1128/AAC.01415-19. 2020
High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance
Garcia-Marco, JA; (...); GELLC Study Grp
Article. 10.3324/haematol.2018.204891. 2019
Higher survival following transplantation with a mismatched unrelated donor with posttransplant cyclophosphamide-based graft-versus-host disease prophylaxis than with double unit umbilical cord blood in patients with acute myeloid leukemia in first complete remission: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Baron, Frederic; (...); Ciceri, Fabio
Article. 10.1002/ajh.27466. 2024
High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience
Rodriguez-Otero, Paula; (...); Gutierrez, Norma
Meeting Abstract. 2023
High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience
Gonzalez-Calle, Veronica; (...); Gutierrez, Norma C.
Article. 10.1002/hem3.70031. 2024
History of Acute Promyelocytic Leukemia.
Article. 10.2991/chi.k.210703.001. 2021
How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
de Arriba de la Fuente, Felipe, Montes Gaisan, Carmen, de la Rubia Comos, Javier
Review. 10.3390/cancers15010155. 2023
How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia
Review. 10.1182/blood-2013-10-512640. 2014
Human Mesenchymal Stem Cells Growth and Osteogenic Differentiation on Piezoelectric Poly(vinylidene fluoride) Microsphere Substrates
Sobreiro-Almeida, R.; (...); Sempere, A.
Article. 10.3390/ijms18112391. 2017
Hypermethylation of the alternative AWT1 promoter in hematological malignancies is a highly specific marker for acute myeloid leukemias despite high expression levels
Guillaumet-Adkins A; (...); Monk D
Article. 10.1186/1756-8722-7-4. 2014
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort.
Stahl M; (...); Zeidan AM
Article. 10.1182/bloodadvances.2018016121. 2018
Iadademstat in Combination with Azacitidine Generates Robust and Long Lasting Responses in AML Patients (ALICE Trial)
Salamero, Olga; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2021-152183. 2021
Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study.
Salamero, Olga; (...); Montesinos, Pau
Article. 10.1016/S2352-3026(24)00132-7. 2024
Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC).
Abrisqueta, Pau; (...); Bosch, Francesc
Article. 10.1016/j.eclinm.2024.102642. 2024
IBRUTINIB IN COMBINATION WITH R-GEMOX-D IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA IN RECALLING OR REFRACTORY: PHASE II STUDY OF THE GELTAMO GROUP
Rey, Bua Beatriz; (...); Martin, A.
Meeting Abstract. 2020
Idasanutlin Plus Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia: Results of the MIRROS Trial.
Konopleva, Marina Y.; (...); Wei, Andrew H.
Article. 10.1182/bloodadvances.2021006303. 2022
Idelalisib for Relapsed/Refractory Follicular Lymphoma: Retrospective Study from Spanish Lymphoma Group Geltamo (GELT-IDE-2018-02)
Sancho, Juan-Manuel; (...); Guillermo Armando, Lopez
Meeting Abstract. 10.1182/blood-2019-125921. 2019
Identification of a Novel Synthetic Lethal Vulnerability in Non-Small Cell Lung Cancer by Co-Targeting TMPRSS4 and DDR1
Redin, E; (...); Calvo, A
Meeting Abstract. 10.1016/j.jtho.2019.08.1485. 2019
Identification of a novel synthetic lethal vulnerability in non-small cell lung cancer by co-targeting TMPRSS4 and DDR1
Villalba, Maria; (...); Calvo, Alfonso
Article. 10.1038/s41598-019-51066-3. 2019
Identification of an episignature of human colorectal cancer associated with obesity by genome-wide DNA methylation analysis.
Crujeiras, AB; (...); Tinahones, FJ
Article. 10.1038/s41366-018-0065-6. 2019
Identification of Epigenetic Methylation Signatures With Clinical Value in Crohn's Disease.
Moret-Tatay I; (...); Beltrán B
Article. 10.14309/ctg.0000000000000083. 2019
Identification of epigenetic silencing of the SFRP2 gene in colorectal cancer as a clinical biomarker and molecular significance
Boughanem, Hatim; (...); Macias-Gonzalez, Manuel
Article. 10.1186/s12967-024-05329-x. 2024
Identification of Leukemia-Associated Immunophenotypes by Databaseguided Flow Cytometry Provides a Highly Sensitive and Reproducible Strategy for the Study of Measurable Residual Disease in Acute Myeloblastic Leukemia
Pinero, Paula; (...); Tarin, Fabian
Article. 10.3390/cancers14164010. 2022
Identifying prognostic gene panels in acute myeloid leukemia.
Sanchez-Garcia, Joaquin; (...); Montesinos, Pau
Article. 10.1080/17474086.2023.2193322. 2023
IDH1-mutated relapsed or refractory AML: current challenges and future prospects
Megias-Vericat, JE; (...); Montesinos, P
Review. 10.2147/BLCTT.S177913. 2019
IDIOPATHIC UPPER GASTROINTESTINAL BLEEDING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: AN UNPRECEDENTED COMPLICATION
Eiris, Juan; (...); Balaguer-Rosello, Aitana
Meeting Abstract. 2024
IFISTRATEGY: Spanish National Survey of Invasive Fungal Infection in Hemato-Oncologic Patients.
Vallejo, Carlos; (...); Peman, Javier
Article. 10.3390/jof9060628. 2023
IgG antibody response to pneumococcal-conjugated vaccine (Prevenar®13) in children with immunodeficiency disorders.
Garrido-Jareño M; (...); Pemán-García J
Article. 10.1007/s00430-022-00759-0. 2023
IgG subclasses quantitation: Analytical performance of The Binding Site SPA(PLUS)(R) human assay and comparison with Siemens BNII (R) assay
Sarnago, A; (...); Fuster, O
Article. 10.1016/j.clinbiochem.2017.09.004. 2018
IKZF1 Deletions Are Markers of Treatment Resistance in Adult Ph-Negative B-Cell Acute Lymphoblastic Leukemia Patients Treated within the Ongoing Risk-Adapted Pethema LAL19 Trial
Ribera, Jordi; (...); Ribera, Josep-Maria
Meeting Abstract. 10.1182/blood-2022-162159. 2022
Imaging features and clinical data-based network analysis of CAR-T treated B- cell lymphoma patients in relation to their TP53 mutation status
Estepa-Fernandez, A.; (...); Alberich-Bayarri, A.
Meeting Abstract. 2024
Imiquimod inhibits growth and induces differentiation of myeloid leukemia cell lines
Villamon, E; (...); Gil, ML
Article. 10.1186/s12935-018-0515-1. 2018
Immune biomarkers of survival and infection-related mortality in multiple myeloma (MM) patients treated with lenalidomide and dexamethasone (Rd)
Maia, Catarina; (...); Paiva, Bruno
Meeting Abstract. 2022
Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)
Maia, Catarina; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2022-163058. 2022
Immune reconstitution after single-unit umbilical cord blood transplantation using anti-thymoglobulin and myeloablative conditioning in adults with hematological malignancies.
Article. 10.1007/s00277-024-05758-0. 2024
Immune Reconstitution Profiling Suggests Antiviral Protection After Transplantation with Omidubicel: a Phase 3 Substudy.
Szabolcs, Paul; (...); Horwitz, Mitchell E.
Article. 10.1016/j.jtct.2023.04.018. 2023
Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis
Paiva B; (...); Spanish Myeloma Group
Article. 10.1182/blood-2015-10-662320. 2016
IMMUNE THROMBOCYTOPENIA AND PREGNANCY: A SPANISH CASE SERIES OF 270 PREGNANCIES IN PRIMARY ITP.
Gonzalez-Lopez, TJ; (...); Porras, JRG
Meeting Abstract. 2017
Immune thrombotic thrombocytopenic purpura in older patients: Results from the Spanish TTP Registry (REPTT).
Gomez-Segui, I; (...); de la Rubia Comos, J
Article. 10.1111/bjh.19109. 2023
Immunobiology of cytomegalovirus infection in patients with haematological malignancies undergoing treatment with small molecule inhibitors.
de la Asuncion Carlos, Solano; (...); Navarro, David
Letter. 10.1111/bjh.18655. 2023
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma
Perez, C; (...); Programa Estudio Terapeutica Hemop
Article. 10.1182/blood.2019004537. 2020
Immunohaematological events related to changes in haematic and seric ABO group in patients undergoing haematopoietic stem cell transplantation with major ABO mismatch.
Santiago, M; (...); Solves, P
Letter. 10.1111/tme.12538. 2019
Immunohistochemical, genetic and epigenetic profiles of hereditary and triple negative breast cancers. Relevance in personalized medicine
Murria R; (...); Bolufer P
Article. 2015
Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease.
Lakhwani S; (...); Hernández MT
Article. 10.1007/s00277-024-06031-0. 2024
Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease
Lakhwani, Sunil; (...); Hernandez, Miguel-Teodoro
Meeting Abstract. 10.1182/blood-2022-166826. 2022
Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer
Salvador-Coloma, C; (...); de Mora, JF
Article. 10.1016/j.ejca.2020.08.020. 2020
Immunosuppressive profiles in liquid biopsy predict response to neoadjuvant chemotherapy in triple negative breast cancer
Salvador-Coloma, C; (...); Santaballa, A
Meeting Abstract. 10.1158/1538-7445.SABCS18-P3-11-16. 2019
Immunotherapy in multiple myeloma.
Asensi Cantó P, Arnao Herraiz M, de la Rubia Comos J
Article. 10.1016/j.medcli.2023.11.019. 2024
Immunotherapy May be Preferable to Chemotherapy As Second-Line Treatment for POD24 Follicular Lymphoma (FL) Patients
Serna, Angel; (...); Abrisqueta, Pau
Meeting Abstract. 10.1182/blood-2024-207871. 2024
Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1080/10428194.2016.1231405. 2017
Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy
Eapen M; (...); Rocha V
Article. 10.1182/blood-2013-05-506253. 2014
IMPACT OF ALLELIC STATUS OF TP53 MUTATIONS IN ACUTE MYELOID LEUKEMIA (AML)
Ibanez, Mariam; (...); Sanz, Guillermo
Meeting Abstract. 2020
Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in First Complete Remission (CR1) in Addition to FLT3 Inhibition With Quizartinib in Acute Myeloid Leukemia (AML) With FLT3-Internal Tandem Duplication (FLT3-ITD): Results from the QuANTUM-First Trial
Schlenk, Richard F.; (...); Erba, Harry P.
Meeting Abstract. 2023
Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3-Internal Tandem Duplication: Results from the Quantum-First Trial
Schlenk, Richard F.; (...); Erba, Harry P.
Meeting Abstract. 10.1182/blood-2022-169011. 2022
IMPACT OF ALLO-HCT IN FIRST COMPLETE REMISSION (CR1) IN ADDITION TO FLT3 INHIBITION WITH QUIZARTINIB IN AML WITH FLT3-ITD: RESULTS FROM THE QUANTUM-FIRST TRIAL
Schlenk, Richard F.; (...); Erba, Harry P.
Meeting Abstract. 2023
IMPACT OF BUSULFAN, ETOPOSIDE AND HIGH-DOSE ARA-C (BEA) CONDITIONING FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN AML
Sanz, Jaime; (...); Ciceri, Fabio
Meeting Abstract. 2023
Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols.
Barba P; (...); Ribera JM
Article. 10.1097/HS9.0000000000000810. 2023
Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1080/10428194.2020.1839650. 2020
Impact of CTLA4 genotype and other immune response gene polymorphisms on outcomes after single umbilical cord blood transplantation
Cunha R; (...); Eurocord, Cord Blood Committee Cellular Therapy–Immunobiology Working Party of t
Article. 10.1182/blood-2016-06-722249. 2017
IMPACT OF CYTOGENETIC ABNORMALITIES DEFINING AML MYELODYSPLASIA-RELATED (WHO AND ICC 2022) IN FIRST LINE DECITABINE IN UNFIT AML PATIENTS
de la Fuente, Adolfo; (...); Tormo, Mar
Meeting Abstract. 2023
Impact of Cytogenetic Risk on Outcomes of Non-T Cell Depleted Haploidentical Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia.
Nagler, Arnon; (...); Mohty, Mohamad
Article. 10.1016/j.jtct.2022.08.018. 2022
Impact of FLT3-ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study.
Ayala, Rosa; (...); Montesinos, Pau
Article. 10.3390/cancers14235799. 2022
Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study
Matteuzzi, Tommaso; (...); Bullinger, Lars
Meeting Abstract. 10.1182/blood-2021-152215. 2021
Impact of HLA mismatch direction on outcomes after umbilical cord blood transplantation for hematological malignant disorders: a retrospective Eurocord-EBMT analysis
Cunha R; (...); Rocha V
Article. 10.1038/bmt.2013.120. 2014
Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party
Rubio, MT; (...); Nagler, A
Article. 10.1186/s13045-016-0389-4. 2017
Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An Analysis from a Large International Patient Cohort
Stahl, M; (...); Zeidan, AM
Meeting Abstract. 10.1182/blood-2018-99-112495. 2018
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia.
Paiva B; (...); PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) coop
Article. 10.1038/s41375-021-01126-3. 2021
Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission.
Nagler, Arnon; (...); Mohty, Mohamad
Article. 10.1111/bjh.18765. 2023
Impact of minimal residual disease on outcomes after umbilical cord blood transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia: an analysis on behalf of Eurocord, Cord Blood Committee and the Acute Leukaemia working party of the European group for Blood and Marrow Transplantation
Tucunduva L; (...); Rocha V
Article. 10.1111/bjh.12970. 2014
Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1038/tpj.2017.19. 2018
Impact of natural-killer immune reconstitution on the development of cytomegalovirus infection, non-relapse mortality, and graft versus host disease after allogeneic stem cell transplantation
Rodriguez-Veiga, R.; (...); Sanz, M. A.
Meeting Abstract. 2015
Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1097/FPC.0000000000000286. 2017
Impact of NPM1/FLT3-ITD genotypes defined by the2017 European LeukemiaNet in patients with acute myeloid leukemia.
Döhner K; (...); Bloomfield CD
Article. 10.1182/blood.2019002697. 2020
Impact of Patient Selection and Management over Different Time Periods on the Outcome of Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
Torrent, Anna; (...); Barba, Pere
Meeting Abstract. 10.1182/blood-2023-186388. 2023
IMPACT OF POSTTRANSPLANT CYCLOPHOSPHAMIDE ON TRANSFUSION REQUIREMENTS IN HLA MATCHED SIBLING PERIPHERAL BLOOD STEM CELL TRANSPLANTATION.
Marco-Ayala, Javier; (...); Solves, Pilar
Article. 10.1016/j.jtct.2023.01.009. 2023
Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma.
Martinez, Carmen; (...); Garcia-Sanz, Ramon
Article. 10.1007/s00277-022-05011-6. 2022
Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study
Redondo AM; (...); Martín A
Article. 10.1111/bjh.12676. 2014
Impact of red blood cell transfusion dose density on progression-free survival in lower-risk myelodysplastic syndromes patients.
de Swart L; (...); EUMDS Registry Participants
Article. 10.3324/haematol.2018.212217. 2020
IMPACT OF RED BLOOD CELL TRANSFUSIONS ON SURVIVAL IN LOWER-RISK MDS PATIENTS INCLUDED IN THE EUROPEAN LEUKEMIANET MDS (EUMDS) REGISTRY
de Swart, L; (...); de Witte, T
Meeting Abstract. 10.1016/S0145-2126(17)30393-4. 2017
Impact of SCHOLAR-1 criteria on CAR-T cell therapy efficacy in aggressive B lymphoma. A real-world GELTAMO/GETH study.
Oreiro MB; (...); García-Sancho AM
Article. 10.1016/j.jtct.2023.08.026. 2023
Impact of Scholar-1 Refractoriness Criteria on the Efficacy of CAR-T Therapy in Aggressive B Cell Lymphoma, Compared with Non-Refractory Patients: A Real World Geltamo/Geth Study
Bastos-Oreiro, Mariana; (...); Martin Garcia-Sancho, Alejandro
Meeting Abstract. 10.1182/blood-2022-166329. 2022
Impact of SNP array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases
Palomo L; (...); Zamora L
Article. 10.1002/ajh.24227. 2016
Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7.
Crisà E; (...); Mufti GJ
Article. 10.1038/s41375-020-0728-x. 2020
Impact of t(11;14) according to induction regimen in newly diagnosed transplant-eligible multiple myeloma patients: long term follow-up of GEM05MENOS65 and GEM2012 PETHEMA/GEM studies
Moreno, David; (...); Rosinol, Laura
Meeting Abstract. 2021
IMPACT OF THE TREATMENT OF THE PURE APLASIA OF THE RED SERIES; EXPERIENCE IN A CENTER
Marco, Ayala Javier; (...); Solves, Alcaina Pilar
Meeting Abstract. 2020
Impact of transplant eligibility and availability of a human leukocyte antigen-identical matched related donor on outcome of older patients with acute lymphoblastic leukemia
Barba P; (...); Ribera JM
Article. 10.3109/10428194.2015.1014365. 2015
Impact of Transporter Genes Polymorphisms in Standard Induction of Acute Myeloid Leukemia
Eduardo Megias, Juan; (...); Angel Sanz, Miguel
Meeting Abstract. 2015
Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry.
Hoeks M; (...); EUMDS Registry Participants
Article. 10.3324/haematol.2018.212332. 2020
Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia.
Kayser, Sabine; (...); Schlenk, Richard F.
Article. 10.3324/haematol.2022.282127. 2023
Impact on Outcomes of Human Leukocyte Antigen Matching by Allele-Level Typing in Adults with Acute Myeloid Leukemia Undergoing Umbilical Cord Blood Transplantation
Article. 10.1016/j.bbmt.2013.10.016. 2014
Impact-AML: A European Master Framework for Cohort Studies and Pragmatic Clinical Trials in Relapse or Refractory Acute Myeloid Leukemia
Marconi, Giovanni; (...); Martinelli, Giovanni
Meeting Abstract. 10.1182/blood-2023-184745. 2023
IMPLEMENTATION OF DIAGNOSIS AND CENTRALIZED FOLLOW-UP BY FLOW CYTOMETRY IN ACUTE MYELOID LEUKAEMIA (AML) IN CHILDREN IN THE NOPHO-DBH-AML-2012 CLINICAL TRIAL: PRELIMINARY RESULTS
Torrebadell, M.; (...); Fernandez, J. M.
Meeting Abstract. 2019
IMPLEMENTATION OF MASSIVE SEQUENCING TECHNOLOGIES TO THE DETECTION OF MUTATIONS IN THE ABL KINASE DOMAIN OF BCR-ABL REORDERING
Simarro, CS; (...); Gonzalez, EB
Meeting Abstract. 2017
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (vol 26, pg 1549, 2020)
Bernard, Elsa; (...); Elias, Harold K
Article. 10.1038/s41591-021-01367-w. 2021
Implications ofTP53allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Bernard, E; (...); Papaemmanuil, E
Article. 10.1038/s41591-020-1008-z. 2020
Improved outcomes in allo-HCT for multiple myeloma patients with thiotepa-busulfan-fludarabine conditioning regimen and post-transplant cyclophosphamide, sirolimus and mycophenolate mofetil
de la Rubia, Javier; (...); Sanz, Miguel
Meeting Abstract. 2023
Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity.
Onecha E; (...); Ayala R
Article. 10.1111/bjh.16432. 2020
In silico validation of serum protein profile in long- and short-term glioblastoma survivors: A proteomic approach to prognostic factors
Bruixola, G.; (...); Reynes, G.
Meeting Abstract. 10.1016/S0959-8049(16)31646-X. 2015
In vitro all-trans retinoic acid sensitivity of acute myeloid leukemia blasts with NUP98/RARG fusion gene
Letter. 10.1007/s00277-014-2073-5. 2014
IN VIVO MODELS FOR THE FUNCTIONAL STUDY OF CO-OCCURRING GENETIC AND EPIGENETIC MUTATIONS IN MYELODYSPLASTIC SYNDROMES
Martinez-Valiente, C.; (...); Sanjuan-Pla, A.
Meeting Abstract. 2018
IN VIVO MODELS TO STUDY THE COOPERATION BETWEEN SPLICING AND DNA METHYLATION IN MYELODYSPLASTIC SYNDROMES
Martinez-Valiente, Cristina; (...); Sanjuan-Pla, Alejandra
Meeting Abstract. 2020
INCIDENCE AND CHARACTERISTICS OF BACTERIAL INFECTIONS DURING THE THERAPY OF INDUCTION IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH NEW DRUGS. STUDY OF 67 PATIENTS FROM A SINGLE CENTRE
Martinez Garcia, M. F.; (...); Sanz Alonso, M. A.
Meeting Abstract. 2015
INCIDENCE AND CHARACTERISTICS OF POST-TRANSPLANT ALLOGENIC LYMPHOPROLIFERATIVE SYNDROMES. EXPERIENCE OF SPANISH GROUP OF HEMATOPOIETIC TRANSPLANT (GETH)
San Segundo, LY; (...); Solano, C.
Meeting Abstract. 2017
Incidence and Management of Aplastic Anemia in Spain (IMAS). An Ambispective Study of Biodonostia / Pethema
Vallejo, C; (...); Jarque, I
Meeting Abstract. 2020
Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group
Ribera, Josep-Maria; (...); Feliu, Evarist
Article. 10.1002/cncr.32156. 2019
Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis.
Rodríguez-Veiga R; (...); Sanz GF
Article. 10.1007/s00277-019-03744-5. 2019
Incidence and prognostic impact of U2AF1 mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion.
Castillo MI; (...); Díaz TM
Article. 10.1002/cam4.6300. 2023
Incidence and Risk Factors for Development of Cardiac Toxicity in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia
Boluda, Blanca; (...); Montesinos, Pau
Article. 10.3390/cancers15082267. 2023
Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis
Montesinos P; (...); Sanz MA
Article. 10.1038/bmt.2015.181. 2015
Incidence of HLA Loss in a Global Multicentric Cohort of Post-Transplantation Relapses: Results from the Hlaloss Collaborative Study
Vago, L; (...); Fleischhauer, K
Meeting Abstract. 10.1182/blood-2018-99-112142. 2018
Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy
Kelleher, N; (...); Spanish Soc Hematology
Article. 10.3109/10428194.2015.1040013. 2016
Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS
Sirenko, Maria; (...); Papaemmanuil, Elli
Meeting Abstract. 10.1182/blood-2022-162397. 2022
Incidence, Diagnosis, and Outcome of Acquired Thrombotic Thrombocytopenic Purpura (aTTP): A Nationwide Survey By the Spanish Apheresis Group
Izquierdo, Maria Cristina Pascual; (...); Salinas, Ramon
Meeting Abstract. 10.1182/blood-2019-123258. 2019
Incidence, diagnosis, and outcome of immune-mediated thrombotic thrombocytopenic purpura: A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura
Pascual-Izquierdo, C; (...); Salinas, R
Article. 10.1002/jca.21894. 2021
Incidence, risk factors and therapy response of acute graft-versus-host disease after myeloablative hematopoietic stem cell transplantation with posttransplant cyclophosphamide.
Asensi Cantó P; (...); Sanz J
Article. 10.1038/s41409-024-02391-3. 2024
Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients
Pinana JL; (...); Sanz MA
Article. 10.1007/s00277-013-1872-4. 2014
Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients
Pinana, JL; (...); Navarro, D
Article. 10.1111/tid.13158. 2019
Incidence, risk factors, and outcomes of BK hemorrhagic cystitis in hematopoietic stem cell transplantation from HLA-matched and haploidentical donors with post-transplant cyclophosphamide.
Chorao, Pedro; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2024.12.006. 2024
Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience.
Sobas, Marta; (...); Montesinos, Pau
Article. 10.1007/s00277-023-05582-y. 2023
INCORPORATION OF DARATUMUMAB IN COMBINATION TO THE THERAPEUTIC PANORAMA OF PATIENTS WITH MULTIPLE MYELOMA IN RECAIDA: RESULTS OF HABITUAL CLINICAL PRACTICE IN SPAIN. GEMINI STUDY
Rios-Tamayo, R.; (...); Mateos Manteca, M., V
Meeting Abstract. 2019
Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials
Barba, P; (...); Ribera, JM
Article. 10.1111/ejh.13178. 2019
In-depth analysis of responders in the phase 3 PhALLCON trial of ponatinib vs imatinib in newly diagnosed Ph plus ALL.
Jabbour, Elias; (...); Ribera-Santasusana, Jose-Maria
Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.6533. 2024
In-depth Responder Analysis of PhALLCON, a Phase 3 Trial of Ponatinib Versus Imatinib in Newly Diagnosed Ph plus ALL
Jabbour, Elias; (...); Ribera-Santasusana, Jose-Maria
Meeting Abstract. 10.1016/S2152-2650(24)00426-9. 2024
Individualized Prophylactic Treatment with Recombinant Factor VIII in Severe or Moderate Haemophilia a Patients. Association Between Pharmacokinetic Parameters and Clinical Variables
Megias-Vericat, Juan Eduardo; (...); Bonanad, Santiago
Meeting Abstract. 10.1182/blood.V128.22.3802.3802. 2016
Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study
Labrador, Jorge; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2022-162591. 2022
Infections of the Central Nervous System after Untelated Donor Umbilical Cord Blood Transplantation or Human teukocyte Antigen-Matched Sibling Transplantation
Balaguer Rosello A; (...); Sanz, J
Article. 10.1016/j.bbmt.2016.10.005. 2017
INFECTIONS OF THE CENTRAL NERVOUS SYSTEM IN THE ALOGENIC TRANSPLANTATION OF HEMATOPOYETIC PROGENITORS
Balaguer Rosello, A.; (...); Sanz Caballer, J.
Meeting Abstract. 2018
Infectious Complications after Umbilical Cord-Blood Transplantation from Unrelated Donors.
Montoro, J; (...); Sanz, J
Review. 10.4084/MJHID.2016.051. 2016
Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: A systematic review and meta-analysis of observational studies
Megías-Vericat JE; (...); Aliño SF
Review. 10.1038/tpj.2014.80. 2015
Influence of age and gender on red blood cell distribution width
Letter. 10.1515/cclm-2014-0756. 2015
Influence of Age on Treatment with Thrombopoietin Receptor Agonists in Patients with Immune Thrombocytopenia; A Retrospective Multicenter Study
Luisa Lozano, Maria; (...); Vicente Garcia, Vicente
Meeting Abstract. 10.1182/blood-2019-122237. 2019
Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1080/10428194.2017.1323267. 2017
Influence of inflammatory and lipidic parameters on red blood cell distribution width in a healthy population
Vayá A; (...); Romagnoli M
Article. 10.3233/CH-141862. 2015
Influence of lipids on blood and plasma viscosity
Letter. 10.3233/CH-141890. 2014
Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1097/FPC.0000000000000431. 2021
Influence of Polymorphisms Related to Drug Metabolism in Allogeneic Bone Marrow Transplantation
Santiago, M; (...); Alino, S
Meeting Abstract. 2021
Influence of Single Nucleotide Polymorphisms in Anthracycline Metabolism Pathway in Standard Induction of Acute Myeloid Leukemia
Eduardo Megias, Juan; (...); Angel Sanz, Miguel
Meeting Abstract. 2015
Influence of TP53 Gene Mutations and its Allelic Status in Myelodysplastic Syndromes with Isolated 5q Deletion.
Montoro, Maria Julia; (...); Valcarcel, David
Article. 10.1182/blood.2024023840. 2024
Infusion of Haploidentical Stem Cell after Consolidation in Younger Patients with Acute Myeloid Leukemia: Preliminary Results of a Phase I-II Study
Boluda, Blanca; (...); Sanz, Miguel A.
Meeting Abstract. 10.1182/blood.V128.22.1614.1614. 2016
INHIBITORS OF THE MUTATED DEHYDROGENASE (MIDH), IVOSIDENIB OR ENASIDENIB, IN COMBINATION WITH AZACITINE (AZA) IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
Montesinos, P; (...); Vyas, P
Meeting Abstract. 2018
IN-SILICO AND IN VITRO STUDY OF MUTATIONS THAT ALTER THE SPLICING PROCESS IN PATIENTS WITH MYELODISPLASIC SYNDROMES
Boluda-Navarro, M.; (...); Cervera, J.
Meeting Abstract. 2019
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia.
Simoes C; (...); Paiva B
Article. 10.1182/bloodadvances.2022008141. 2023
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia
Elena C; (...); Cazzola M
Article. 10.1182/blood-2016-05-714030. 2016
Integrative and comparative genomic analyses identify clinicallyrelevant pulmonary carcinoidgroups and unveil the supra-carcinoids.
Alcala N; (...); Fernandez-Cuesta L
Article. 10.1038/s41467-019-11276-9. 2019
INTENSIVE CHEMOTHERAPY VERSUS DECITABINE FIRST LINE LAM OVER 60 YEARS OLD
De la Fuente, A.; (...); Montesinos, P.
Meeting Abstract. 2019
INTERLABORATORY STUDY OF MUTATIONS DETECTION IN MYELOID NEOPLASMS THROUGH NEW GENERATION SEQUENCING
Rodriguez, CF; (...); Bellosillo, B
Meeting Abstract. 2017
Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study
Lucena-Araujo AR; (...); Rego EM
Article. 10.1007/s00277-014-2142-9. 2014
International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Roboz GJ; (...); Giles FJ
Article. 10.1200/JCO.2013.52.8562. 2014
INTRACHROMOSOMAL AMPLIFICATION OF CHROMOSOME 21 (IAMP21): STUDY IN A SERIES OF 894 LLA-B OF PEDIATRIC AND 74 LLA-B OF ADULT
Hidalgo Gomez, G.; (...); Ortega, M.
Meeting Abstract. 2018
Intravenous Acetaminophen for Analgesia: Back to Square One
Fuster-Lluch, O, Zapater-Hernandez, P, Geronimo-Pardo, M
Letter. 10.1002/jcph.982. 2017
Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Nagler A; (...); Mohty M
Article. 10.3324/haematol.2014.105197. 2014
Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma
Blanes, M; (...); de la Rubia, J
Letter. 10.1007/s00277-019-03663-5. 2019
Intravenous Busulfan-Melphalan vs Melphalan as Preparative Regimen for Newly Diagnosed Multiple Myeloma: Long-Term Follow-Up of a Case-Control Study
Blanes, M; (...); de la Rubia, J
Meeting Abstract. 10.1016/j.clml.2019.09.473. 2019
Intravenous busulphan plus melphalan versus melphalan alone as conditioning regimen for newly diagnosed patients with multiple myeloma: Long-term follow-up of a matched case-controlled study
Blanes, M; (...); de la Rubia, J
Meeting Abstract. 2019
Invasive fungal disease in patients undergoing umbilical cord blood transplantation after myeloablative conditioning regimen
Montoro, J; (...); Pinana, JL
Article. 10.1111/ejh.13202. 2019
INVASIVE FUNGAL INFECTION IN ADULT PATIENTS SUBMITTED TO UMBILICAL CORD BLOOD TRANSPLANTATION
Montoro, J.; (...); Pinana, J. L.
Meeting Abstract. 2018
Invasive mould disease in haematological patients
Ruiz-Camps, I, Jarque, I
Review. 10.1016/j.riam.2014.06.002. 2014
Invasive yeast infections in neutropenic patients
Camps, IR, Jarque, I
Review. 10.1016/j.riam.2015.11.001. 2016
Investigation of HLA loss relapse after allogeneic stem cell transplantation in a global multicentric cohort (HLALOSS Consortium)
Fleischhauer, K; (...); Vago, L
Meeting Abstract. 2018
Is erythrocyte sedimentation rate a useful inflammatory marker independently of the hematocrit? Comparison results with plasma viscosity
Letter. 10.3233/CH-141864. 2014
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma according to prior lines of treatment and refractory status: IKEMA subgroup analysis.
Hajek, Roman; (...); Dimopoulos, Meletios A.
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.8034. 2021
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis.
Dimopoulos, Meletios A.; (...); Hajek, Roman
Article. 10.1002/ajh.26602. 2022
Isohaemagglutinin production after minor ABO incompatible umbilical cord blood transplantation
Letter. 10.1111/tme.12386. 2017
Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial
Puig, Noemi; (...); Victoria Mateos, Maria
Meeting Abstract. 10.1182/blood-2023-182964. 2023
Itacitinib and Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravitas-309
Im, Annie; (...); Pavletic, Steven Z.
Meeting Abstract. 10.1182/blood-2022-169605. 2022
ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in preliminary results
Ghobrial, Irene; (...); Mateos, Maria-Victoria
Meeting Abstract. 2021
Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.
Montesinos, Pau; (...); Dohner, Hartmut
Article. 10.1056/NEJMoa2117344. 2022
Ivosidenib and Azacitidine in IDH1-Mutated AML. Reply.
Montesinos, Pau, de Botton, Stephane, Dohner, Hartmut
Letter. 10.1056/NEJMc2206489. 2022
Ivosidenib plus Azacitidine vs Placebo plus Azacitidine in Patients With Newly-Diagnosed Acute Myeloid Leukemia: Updated Long-term Efficacy and Safety Results From the AGILE Study
de Botton, Stephane; (...); Doehner, Hartmut
Meeting Abstract. 2023
Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial
Rosinol, Laura; (...); Blade Creixenti, Joan
Meeting Abstract. 10.1182/blood-2021-146798. 2021
JUVENILE MYELOMONOCITIC LEUKEMIA IN PATIENTS WITH NOONAN SYNDROME AND NOONAN-LIKE SYNDROMES: EXPERIENCE OF THE SPANISH YOUTH MYELOMONOCITIC LEUKEMIA REGISTRATION
Arques Martinez, L.; (...); Catala Temprano, A.
Meeting Abstract. 2019
Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations
Blanco, G; (...); Espinet, B
Article. 10.18632/oncotarget.13106. 2016
Killer Cell Immunoglobulin-Like Receptor Ligand Matching and Outcomes after Unrelated Cord Blood Transplantation in Acute Myeloid Leukemia
Rocha, V; (...); Ctr Int Blood Marrow Transplant Re
Article. 10.1016/j.bbmt.2016.04.007. 2016
Kinetics of Complete Remission (CR) and CR Duration and Its Impact on Overall Survival (OS) and Event-Free Survival (EFS) in Quantum-First
Montesinos, Pau; (...); Dombret, Herve
Meeting Abstract. 10.1182/blood-2023-187286. 2023
Kinetics of Torque Teno virus DNA in stools may predict occurrence of acute intestinal graft versus host disease early after allogeneic hematopoietic stem cell transplantation.
Bueno F; (...); Navarro D
Article. 10.1111/tid.13507. 2020
Label-free DNA-methylation detection by direct ds-DNA fragment screening using poly-purine hairpins
Huertas, CS; (...); Lechuga, LM
Article. 10.1016/j.bios.2018.08.027. 2018
ladademstat Combination with Azacitidine Is a Safe and Effective Treatment in First Line Acute Myeloid Leukemia. Final Results of the Alice Trial
Salamero, Olga; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2022-168945. 2022
LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors.
Cruz, David; (...); Gallardo, David
Article. 10.3389/fimmu.2023.1066393. 2023
Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin Lymphoma
Camacho-Arteaga, Lina; (...); Agusti, Antonia
Article. 10.1001/jamanetworkopen.2024.61683. 2025
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Benboubker L; (...); FIRST Trial Team
Article. 10.1056/NEJMoa1402551. 2014
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.
Rosinol, Laura; (...); Blade, Joan
Article. 10.1182/blood.2022019531. 2023
LENALIDOMIDE IN COMBINATION WITH R-ESHAP IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMAS (DLBCL) REFRACTORY OR IN RELAPSE: STUDY PHASE 2 OF THE GELTAMO SPANISH GROUP
Baile, M.; (...); Martin, A. A.
Meeting Abstract. 2017
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO.
Martin Garcia-Sancho, A.; (...); Caballero, D.
Article. 10.1111/bjh.18989. 2023
Lenalidomide induced reversible parkinsonism, dystonia, and dementia in subclinical Creutzfeldt-Jakob disease
Argente-Escrig, H; (...); Bataller, L
Letter. 10.1016/j.jns.2018.08.027. 2018
Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial
Mateos, MV; (...); Miguel, JFS
Article. 10.1016/S1470-2045(16)30124-3. 2016
Lineage switch from B lymphoblastic leukemia with KMT2A-rearranged to mixed-phenotype acute leukemia under daratumumab
Marco-Ayala, J; (...); Peris, MLS
Editorial Material. 10.5045/br.2020.2020059. 2020
Live donor kidney transplantation. Situation analysis and roadmap.
de la Oliva Valentín M; (...); Domínguez-Gil B
Article. 10.1016/j.nefroe.2022.02.002. 2022
Long Term Discontinuation of Eltrombopag after Remission in Primary Immune Thrombocytopenia: 8-Year Follow-up Data from 15 Spanish Centers
Jose Gonzalez-Lopez, Tomas; (...); Sanz, Miguel A.
Meeting Abstract. 10.1182/blood-2019-129274. 2019
Long Term Survival Analysis of Multiple Myeloma Patients Receiving Induction Therapy plus Autologous STEM CELL Trasplantation, Comparing Velcade-Dexametasone to Alkylating Polichemotherapy As Induction Therapy
Caceres, S; (...); Burgues, JMMB
Meeting Abstract. 10.1182/blood-2018-99-116924. 2018
Longitudinal outcome over four decades of allogeneic stem cell transplantation: a single center experience.
Sanz, Miguel Angel; (...); Sanz, Jaime
Article. 10.1038/s41409-024-02319-x. 2024
Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice.
Gomez, E; (...); Fernandez-Rodriguez, C M
Article. 10.1111/apt.18004. 2024
Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy
Martínez-Cuadrón D; (...); Sanz MA
Article. 10.1038/leu.2017.178. 2018
Long-term outcome of second allogeneic hematopoietic stem cell transplantation (HSCT2) for primary graft failure in patients with acute leukemia in remission: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler, Arnon; (...); Mohty, Mohamad
Article. 10.1038/s41409-023-02012-5. 2023
Long-Term Outcome of Second Allogeneic Stem Cell Transplantation (HSCT2) for Primary Graft Failure in Patients with Acute Leukemia in Remission: A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Nagler, Arnon; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2022-156231. 2022
Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study
Rodriguez-Arboli, E; (...); GETH Grp Espanol Trasplante Hemato
Article. 10.1016/j.jtct.2020.12.029. 2021
Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries.
Recher, Christian; (...); Montesinos, Pau
Article. 10.1038/s41375-021-01425-9. 2022
Long-term survival of CML patients who received autologous HCT before and after the tyrosine kinase inhibitors ERA. Study on behalf of the EBMT CMWP
Michallet, M; (...); Yakoub-Agha, I
Meeting Abstract. 2019
Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial.
Wei, Andrew H.; (...); Roboz, Gail J.
Letter. 10.1002/ajh.26847. 2023
Low-Dose Cytarabine With or Without Glasdegib in Newly Diagnosed Patients with Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial
Papayannidis, C; (...); Cortes, JE
Meeting Abstract. 10.1016/j.clml.2019.07.111. 2019
Low-dose cytarabine with or without glasdegib in newly diagnosed patients with acute myeloid leukemia: Long-term analysis of a phase 2 randomized trial.
Smith, BD; (...); Cortes, JE
Meeting Abstract. 2019
LYFOMA POST-TRANSPLANT TYPE BURKITT: CLINICAL CHARACTERISTICS AND PRONOSTICAS IN A MULTICENTRAL STUDY
Varela, SB; (...); Bosch, F.
Meeting Abstract. 2017
Lymphocyte Subpopulations in Community-Acquired Pneumonia: Role of Cell-Mediated Immunity
Mendez, R; (...); Menendez, R
Meeting Abstract. 2018
Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation
de Koning, Coco; (...); Nierkens, Stefan
Article. 10.1038/s41409-021-01417-4. 2021
LYMPHOPENIA IS HIGHLY PREVALENT IN MDS AND PROVIDES ADDITIONAL PROGNOSTIC INFORMATION FOR IPSS-R VERY-LOW AND LOW-RISK PATIENTS. AN ANALYSIS FROM THE EU-MDS REGISTRY
Silzle, T.; (...); Smith, A.
Meeting Abstract. 2021
Lymphopenia is highly prevalent in MDS and provides prognostic information for IPSS-R (very)-low-risk patients. An analysis from the EU-MDS registry
Silzle, T.; (...); Smith, A.
Meeting Abstract. 2021
Lymphopenic community-acquired pneumonia is associated with a dysregulated immune response and increased severity and mortality
Mendez, R; (...); Torres, A
Article. 10.1016/j.jinf.2019.04.006. 2019
Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML - Results of the European Harmony Alliance
Hernandez Sanchez, Alberto; (...); Bullinger, Lars
Meeting Abstract. 10.1182/blood-2022-167138. 2022
Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform
Hernandez Sanchez, Alberto; (...); Bullinger, Lars
Meeting Abstract. 10.1182/blood-2023-183029. 2023
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study.
Zeidner, Joshua F; (...); Vyas, Paresh
Article. 10.1182/blood.2024027408. 2025
Male genital GvHD: a hidden complication following haematopoietic stem cell transplantation
Montoro, J; (...); Balaguer-Rosello, A
Editorial Material. 10.1111/bjh.17019. 2020
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet
Sanz, MA; (...); Lo-Coco, F
Article. 10.1182/blood-2019-01-894980. 2019
Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee.
Onida F; (...); Pleyer L
Article. 10.1182/blood.2023023476. 2024
Management of Adult Patients with Primary Immune Thrombocytopenia (ITP) in Clinical Practice: A Consensus Approach of the Spanish ITP Expert Group.
Mingot-Castellano ME; (...); González Porras JR
Article. 10.1155/2019/4621416. 2019
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial
Ravandi, F; (...); Dombret, H
Article. 10.1186/s13045-021-01142-x. 2021
Management of chronic liver disease-associated severe thrombocytopenia in Spain: a view from the experts
Calleja-Panero, JL; (...); Gil, A
Article. 10.17235/reed.2020.6895/2020. 2020
Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study.
Stahl M; (...); Zeidan AM
Article. 10.1038/s41375-020-0783-3. 2020
Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry, a Unique Prospective Real-World Dataset
Bowen, David; (...); de Witte, Theo M.
Meeting Abstract. 10.1182/blood-2021-150322. 2021
Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry: A Report on 197 Cases
Smoljanovic, Inga Mandac; (...); Bowen, David
Meeting Abstract. 10.1182/blood-2022-167716. 2022
Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation.
Brissot E; (...); Mohty M
Article. 10.1038/s41409-020-0970-x. 2020
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus.
Buske C; (...); Passamonti F
Article. 10.1016/j.esmoop.2022.100403. 2022
MASS SEQUENCING DIRECTED TO THE STUDY OF REARRANGEMENTS AND CHANGES IN GENIC EXPRESSION IN ACUTE MYELOID LEUKEMIA
Sargas Simarro, C.; (...); Barragan Gonzalez, E.
Meeting Abstract. 2019
Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma.
Puig, Noemi; (...); Mateos, Maria-Victoria
Article. 10.1182/bloodadvances.2021006762. 2022
MATCHED RELATED VERSUS MATCHED UNRELATED VERSUS HAPLOIDENTICAL DONORS IN FLT3-ITD + AML PATIENTS IN CR1: A STUDY FROM THE EBMT ACUTE LEUKEMIA WORKING PARTY
Brissot, Eolia; (...); Ciceri, Fabio
Meeting Abstract. 2024
Maternal and fetal outcomes in pregnant women with acute promyelocytic leukemia
Article. 10.1007/s00277-015-2372-5. 2015
Maternal imprinting on cognition markers of wild type and transgenic Alzheimer's disease model mice.
Zamarbide, M; (...); Perez-Mediavilla, A
Article. 10.1038/s41598-018-24710-7. 2018
MDS Diagnosis: Many Patients May Not Require Bone Marrow Examination
Oster, HS; (...); Mittelman, M
Meeting Abstract. 10.1182/blood-2018-99-111838. 2018
Measurable Residual Disease (MRD) Testing for Acute Leukemia in EBMT Transplant Centers: A Survey on Behalf of The ALWP of the EBMT
Nagler, A; (...); Mohty, M
Meeting Abstract. 2020
Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT.
Nagler, Arnon; (...); Mohty, Mohamad
Article. 10.1038/s41409-020-01005-y. 2021
Measurable Residual Disease Assessed by Flow-Cytometry Is a Stable Prognostic Factor for Pediatric T-Cell Acute Lymphoblastic Leukemia in Consecutive SEHOP Protocols Whereas the Impact of Oncogenetics Depends on Treatment.
Vega-García N; (...); Camós M
Article. 10.3389/fped.2020.614521. 2021
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.
Paiva B; (...); GEM (Grupo Español de Mieloma)
Article. 10.1200/JCO.19.01231. 2020
Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial.
Simoes C; (...); Montesinos P
Article. 10.1182/bloodadvances.2020003195. 2021
MethCORR modelling of methylomes from formalin-fixed paraffin-embedded tissue enables characterization and prognostication of colorectal cancer
Mattesen, TB; (...); Bramsen, JB
Article. 10.1038/s41467-020-16000-6. 2020
Methods for analysis of specific DNA methylation status.
Pajares MJ; (...); Sandoval J
Article. 10.1016/j.ymeth.2020.06.021. 2020
Methylation of tumor suppressor genes is related with copy number aberrations in breast cancer
Murria R; (...); Bolufer P
Article. 2015
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial.
Voso MT; (...); Lo-Coco F
Article. 10.1182/bloodadvances.2020002904. 2020
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Stone, RM; (...); Döhner H
Article. 10.1056/NEJMoa1614359. 2017
Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial
Sierra, Jorge; (...); Venditti, Adriano
Article. 10.1182/bloodadvances.2023009847. 2023
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.
Larson RA; (...); Stone RM
Article. 10.1038/s41375-021-01179-4. 2021
Minimal Residual Disease Detection By Single Cell DNA Sequencing Technology: A Feasible Approach for Clinical Application and Identification of the Landscape of MRD Clones
Alfonso Pierola, Ana; (...); Prosper, Felipe
Meeting Abstract. 10.1182/blood-2023-188865. 2023
Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia
Vidriales, MB; (...); PETHEMA Programa Estudio Terapeuti
Article. 10.1016/j.leukres.2015.10.002. 2016
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients
Paiva B; (...); Grupo Español de Mieloma
Article. 10.1182/blood-2016-03-705319. 2016
miRNAs Regulation and Its Role as Biomarkers in Endometriosis
Marí-Alexandre J; (...); Sandoval J
Review. 10.3390/ijms17010093. 2016
MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine +/- idasanutlin in relapsed or refractory acute myeloid leukemia
Montesinos, P; (...); Fenaux, P
Article. 10.2217/fon-2020-0044. 2020
MIRROS: An ongoing randomized phase 3 trial of idasanutlin plus ARA-C in patients with relapsed or refractory acute myeloid leukemia.
Montesinos, P; (...); Fenaux, P
Meeting Abstract. 2019
Mismatched Unrelated Donor Transplantation with Ptcy-Based Gvhd Prophylaxis Is Associated with Better Survival Than Double Unit Umbilical Cord Blood Transplantation in Patients with AML in First CR: A Study from the ALWP of the EBMT
Baron, Frederic; (...); Ciceri, Fabio
Meeting Abstract. 10.1182/blood-2023-186293. 2023
MODELING OF IDH2 GENE MUTATIONS IN THE CAENORHABDITIS ELEGANS ORGANISM. DEVELOPMENT OF A NEW STUDY MODEL
Gonzalez-Romero, E.; (...); Cervera-Zamora, J.
Meeting Abstract. 2021
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes.
Sirenko, Maria; (...); Papaemmanuil, Elli
Article. 10.1182/blood.2023023723. 2024
MOLECULAR APPROACH TO CHRONIC LYMPHOPROLIFERATIVE SYNDROMES IN THE DAILY CLINICAL PRACTICE OF A SINGLE CENTER
Mariam, Ibanez; (...); Irene, Luna
Meeting Abstract. 2021
Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH(1) Acute Myeloid Leukemia
De Botton, Stephane; (...); Fenaux, Pierre
Meeting Abstract. 10.1182/blood-2021-144912. 2021
MOLECULAR CHARACTERIZATION OF ACUTE LEUKAEMIA OF CHILD, ADOLESCENT AND YOUNG ADULT THROUGH MASSIVE GUIDED SEQUENCING
Llop Garcia, M.; (...); Barragan Gonzalez, E.
Meeting Abstract. 2019
MOLECULAR CHARACTERIZATION OF CELLULAR MODELS OF ACUTE MYELOBLASTIC LEUKEMIA (AML) BY MASS SEQUENCING
Navarro, MB; (...); Cervera, J
Meeting Abstract. 2017
Molecular Characterization of Clinical Response and Relapse in Patients with IDH1m ND-AML Treated with Ivo plus AZA in the AGILE Study
Doehner, Hartmut; (...); De Botton, Stephane
Meeting Abstract. 10.1182/blood-2022-159473. 2022
Molecular characterization of clinical response in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib plus azacitidine compared to placebo plus azacitidine.
De Botton, Stephane; (...); Dohner, Hartmut
Meeting Abstract. 2022
MOLECULAR CHARACTERIZATION OF MULTIPLE MYELOMA PATIENTS BY USING A SINGLE ENRICHMENT PANEL IDENTIFYING SNVS, INDELS, CNVS AND TRANSLOCATIONS
Juan Manuel, Rosa-Rosa; (...); Joaquin, Martinez-Lopez
Meeting Abstract. 2021
MOLECULAR CHARACTERIZATION OF PATIENTS WITH HEREDITARY MYELOID NEOPLASIAS THROUGH MASS SEQUENCING
Pardo-Lorente, N.; (...); Cervera, J.
Meeting Abstract. 2018
MOLECULAR CHARACTERIZATION OF VARIANTS THAT ALTER SPLICING (VAS) IN PATIENTS WITH MYELODYSPLASIC SYNDROMES
Boluda-Navarro, M.; (...); Cervera, J.
Meeting Abstract. 2020
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results
Rücker FG; (...); Doehner, Konstanze
Article. 10.1038/s41375-021-01323-0. 2021
Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry.
Sargas, Claudia; (...); On Behalf Of Pethema Group
Article. 10.3390/cancers15020438. 2023
Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.
Ribera J; (...); Ribera JM
Article. 10.1002/gcc.22788. 2019
Molecular remission as a therapeutic objective in acute promyelocytic leukemia
Cicconi, L; (...); Lo-Coco, F
Review. 10.1038/s41375-018-0219-5. 2018
Molecular Taxonomy of Myelodysplastic Syndromes and Its Clinical Implications
Bernard, Elsa; (...); Papaemmanuil, Elli
Meeting Abstract. 10.1182/blood-2023-186863. 2023
Molecular Taxonomy of Myelodysplastic Syndromes and its Clinical Implications.
Bernard, Elsa; (...); Papaemmanuil, Elli
Article. 10.1182/blood.2023023727. 2024
Monitoring drug activity of dabigatran and rivaroxaban by thrombin generation using the calibrated automated thrombinoscope
Moret, A.; (...); Bonanad, S.
Meeting Abstract. 2015
MONITORING MINIMUM RESIDUAL DISEASE (EMR) THROUGH NGS CONFIRMS PROGNOSTIC VALUE
De La Fuente, EO; (...); Diaz, RA
Meeting Abstract. 2018
MRD ANALYSIS BY NEXT-GENERATION SEQUENCING APPROACH FOR ACUTE MYELOID LEUKEMIA FOLLOW-UP
De la Fuente, EO; (...); Ayala, R
Meeting Abstract. 2017
MTHFR and VDR Polymorphisms Improve the Prognostic Value of MYCN Status on Overall Survival in Neuroblastoma Patients
Olivera, GG; (...); Herrero, MJ
Article. 10.3390/ijms21082714. 2020
Multi- Omics Exploration of Adaptive Mechanism to BTK Inhibition By Ibrutinib in CLL Identified TMBIM6/BI-1 As a Poor Prognosis Variable and Potential Therapeutic Target
Medina, Daniel; (...); Crespo, Marta
Meeting Abstract. 10.1182/blood-2023-185683. 2023
Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials.
Lin, Chenyu; (...); Horwitz, Mitchell E.
Article. 10.1016/j.jtct.2023.01.031. 2023
Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3(mut+)) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort
Esteve, J; (...); Bahceci, E
Meeting Abstract. 10.1182/blood-2018-99-110976. 2018
Multicentre Implementation of Next Generation Sequencing to Acute Myeloid Leukemia Patients in PETHEMA Spanish Collaborative Group
Sargas, C; (...); Barragan, E
Meeting Abstract. 2019
Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group
Ramos, F; (...); Spanish Group for Myelodysplastic Syndromes (GESMD)
Article. 10.1002/ajh.24813. 2017
Multimodal analysis identifies microbiome changes linked to stem cell transplantation-associated diseases
Artacho, Alejandro; (...); Ubeda, Carles
Article. 10.1186/s40168-024-01948-0. 2024
MULTINATIONAL STUDY ASSESSING TREATMENT PATTERNS, OUTCOMES, AND HEALTHCARE RESOURCE UTILIZATION IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH REFRACTORY/RESISTANT CYTOMEGALOVIRUS INFECTION, OR INTOLERANCE TO ANTI-CYTOMEGALOVIRUS THERAPIES
Papanicolaou, Genovefa; (...); Hirji, Ishan
Meeting Abstract. 2023
Multi-omics comparative analyses of pulmonary typical carcinoids, atypical carcinoids, and large-cell neuroendocrine carcinoma
Leblay, N; (...); Fernandez-Cuesta, L
Meeting Abstract. 10.1158/1538-7445.AM2018-5358. 2018
Multiomics Characterization of Normal CD34+Hematopoietic Progenitor Cells (HPC) and Blasts in the Bone Marrow (BM) and Peripheral Blood (PB) of Patients with Acute Myeloid Leukemia (AML)
Simoes, Catia; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2023-185760. 2023
Multiple Congenital Anomalies-Hypotonia-Seizures Syndrome 2 Caused by a Novel PIGA Variant Not Associated with a Skewed X-Inactivation Pattern
Gabaldon-Albero, Alba; (...); Martinez, Francisco
Article. 10.3390/genes15060802. 2024
Multiple phenotypes and epigenetic profiles in a three-generation family history with GATA2 deficiency.
Romero-Moya, Damia; (...); Giorgetti, Alessandra
Article. 10.1038/s41375-025-02519-4. 2025
Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score
Falantes J; (...); Sanz G
Article. 10.1016/j.leukres.2014.10.004. 2015
Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion
Sánchez-García J; (...); Sanz GF
Article. 10.1111/bjh.12876. 2014
Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML).
Dinardo, CD; (...); Vyas, P
Meeting Abstract. 10.1200/JCO.2018.36.15_suppl.7042. 2018
MUTATIONAL PROFILE ENABLES THE IDENTIFICATION OF A HIGH RISK SUBGROUP IN MYELODYSPLASTIC SYNDROMES WITH ISOLATED TRISOMY 8
Toribio Castello, S. M.; (...); Del Rey, M.
Meeting Abstract. 10.1016/j.leukres.2023.107189. 2023
Mutational Profile Enables the Identification of a High-Risk Subgroup in Myelodysplastic Syndromes with Isolated Trisomy 8.
Toribio-Castelló S; (...); Hernández-Rivas JM
Article. 10.3390/cancers15153822. 2023
MUTATIONAL PROFILE IN PATIENTS DIAGNOSED WITH LOW-RISK SMD WITHOUT THE RINGED SIDEROBLASTS
Abaigar, M; (...); Campelo, MD
Meeting Abstract. 2018
Mutational profile of ZBTB16-RARA-positive acute myeloid leukemia
Fabiani E; (...); Voso MT
Article. 10.1002/cam4.3904. 2021
MUTATIONS IN BCR-ABL1 IN PATIENTS WITH PH LEUKAEMIAS. CORRELATION WITH CLINICAL DATA
Sanchez Perez, R.; (...); Martinez-Lopez, J.
Meeting Abstract. 2019
Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes
Cedena, MT; (...); Martinez-Lopez, J
Article. 10.18632/oncotarget.22157. 2017
Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia
Forero-Castro, M; (...); Hernandez-Rivas, JM
Article. 10.1038/bjc.2017.152. 2017
Mutually-Exclusive Pathways between IKZF1 plus and RAS Mutations and TP53 double-Hit Alterations Lead Relapse in B-Other, Ph-like and Hyperdiploidy Genetic Groups in Adult B- Cell Acute Lymphoblastic Leukemia
Navas Acosta, Josgrey Del Valle Del Valle; (...); Hernandez-Rivas, Jesus Maria
Meeting Abstract. 10.1182/blood-2023-182163. 2023
Myeloablative cord blood transplantation in adults with acute leukemia: comparison of two different transplant platforms.
Sanz J; (...); Brunstein C
Article. 10.1016/j.bbmt.2013.09.015. 2013
Myeloablative Unrelated Cord Blood Transplantation in Adolescents and Young Adults with Acute Leukemia.
Hayashi H; (...); Eurocord, Cellular Therapy & Immunobiology Working Party, and Paediatric Disease
Article. 10.1016/j.bbmt.2019.07.031. 2019
Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations
Martin, I; (...); Tormo, M
Article. 10.1111/bjh.17675. 2021
MYELODYSPLASTIC SYNDROMES WITH 20Q DELETION: INCIDENCE, PROGNOSTIC VALUE AND THERAPEUTIC IMPACT OF CHROMOSOMAL ALTERATIONS OF THE ASXL1 GENE AND GENETIC MUTATIONS
Martin, Castillo, I; (...); Tormo, Diaz M.
Meeting Abstract. 2020
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Fenaux P; (...); ESMO Guidelines Working Group
Article. 10.1093/annonc/mdu180. 2014
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Fenaux, P; (...); ESMO Guidelines Comm
Article. 10.1016/j.annonc.2020.11.002. 2021
NATIONAL EXPERIENCE WITH THE USE OF VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
Labrador, J.; (...); Montesinos, P.
Meeting Abstract. 2020
National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies
Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis
Meeting Abstract. 10.1182/blood-2022-169938. 2022
NEDD9, an independent good prognostic factor in intermediate-risk acute myeloid leukemia patients
Pallares, V; (...); Mangues, R
Article. 10.18632/oncotarget.18537. 2017
Negative impact on clinical outcome of the mutational co-occurrence of SF3B1 and DNMT3A in refractory anemia with ring sideroblasts (RARS)
Martin, I; (...); Sanz, G
Article. 10.1080/10428194.2016.1246725. 2017
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project.
Sargas C; (...); Montesinos P
Article. 10.3324/haematol.2020.263806. 2021
NEUROLOGIC COMPLICATIONS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH CALCINEURIN-FREE GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS
Balaguer Rosello, Aitana; (...); Sanz, Jaime
Meeting Abstract. 2023
New Cases and Mutations in SEC23B Gene Causing Congenital Dyserythropoietic Anemia Type II.
Musri, Melina Mara; (...); Sanchez, Mayka
Article. 10.3390/ijms24129935. 2023
New challenges of advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2023.11.008. 2024
NEW MODEL TO QUANTIFY THE IN VITRO PHARMACOLOGICAL ACTIVITY OF BI-SPECIFIC ANTIBODIES IN HAEMATOLOGIC MALIGNANCIES
Primo, D.; (...); Ballesteros, J.
Meeting Abstract. 2017
New mutations found by Next-Generation Sequencing screening of Spanish patients with Nemaline Myopathy
Moreau-Le Lan, S; (...); Pedrola, L
Article. 10.1371/journal.pone.0207296. 2018
Next generation sequencing in bleeding disorders: two novel variants in the F5 gene (Valencia-1 and Valencia-2) associated with mild factor V deficiency.
Moret, A; (...); Bonanad, S
Article. 10.1007/s11239-019-01911-z. 2019
Next-Generation DNA Sequencing-Based Gene Panel for Diagnosis and Genetic Risk Stratification in Onco-Hematology
Gargallo P; (...); Calabria I
Article. 10.3390/cancers14081986. 2022
NGS ANALYSIS AND IMPACT OF VARIANT ALLELIC FREQUENCY AT RELAPSE AND REFRACTORINESS STATUS IN AML PATIENTS
De la Fuente, EO; (...); Ayala, R
Meeting Abstract. 2017
NGS ANALYSIS IN ADULTS GREATER THAN 65 YEARS DIAGNOSED OF ACUTE MYELOID LEUKEMIA IN LOW INTENSITY TREATMENTS
Garcia, AB; (...); Lopez, JM
Meeting Abstract. 2017
NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial.
Rosa-Rosa, Juan Manuel; (...); Martinez-Lopez, Joaquin
Article. 10.3390/cancers14205169. 2022
Nicord Single Unit Expanded Umbilical Cord Blood Transplantation (UCBT): Final Results of a Multicenter Phase I/II Trial
Horwitz, ME; (...); Sanz, G
Meeting Abstract. 10.1016/j.bbmt.2017.12.628. 2018
Nivolumab for Heavily Pretreated Relapsed/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain (Spanish Group of Lymphoma and Bone Marrow Transplantation, GELTAMO)
Martinez, C; (...); Garcia-Sanz, R
Meeting Abstract. 10.1182/blood-2018-99-115774. 2018
NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy.
Hurtado-Navarro L; (...); Ferrer-Marín F
Article. 10.1016/j.xcrm.2023.101329. 2023
No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group.
Castano-Bonilla, Tamara; (...); Montesinos, Pau
Article. 10.1155/2022/3132941. 2022
Noninfectious Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation
Balaguer-Rosello, A; (...); Sanz, Jaime
Article. 10.1016/j.bbmt.2019.05.024. 2019
Non-infectious neurologic complications after allogeneic hematopoietic stem cell transplantation (ALLO-HSCT)
Balaguer Rosello, Aitana; (...); Sanz, Jaime
Meeting Abstract. 2019
Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT.
Nagler, Arnon; (...); Mohty, Mohamad
Article. 10.1038/s41409-021-01537-x. 2022
Non-T Depleted Haploidentical Stem Cell Transplantation in Aml Patients Achieving First Complete Remission After One Vs Two Induction Courses: A Study From The ALWP/EBMT
Nagler, A; (...); Mohty, M
Meeting Abstract. 2021
Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT.
Nagler, Arnon; (...); Mohty, Mohamad
Article. 10.1186/s13045-023-01450-4. 2023
Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT (16, 58, 2023)
Nagler, Arnon; (...); Mohty, Mohamad
Correction. 10.1186/s13045-023-01501-w. 2023
Novel Agents May be Preferable to Standard Chemotherapy in Second-Line for Early Relapsing Follicular Lymphoma (FL) Patients
Serna, Angel; (...); Abrisqueta Costa, Pau
Meeting Abstract. 10.1182/blood-2023-186019. 2023
Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective.
De Witte T; (...); Smith A
Article. 10.3324/haematol.2020.266817. 2020
Novel microgel culture system as semi-solid three-dimensional in vitro model for the study of multiple myeloma proliferation and drug resistance
Clara-Trujillo S; (...); Gómez Ribelles JL
Article. 10.1016/j.bioadv.2022.212749. 2022
Novel real-time polymerase chain reaction assay for simultaneous detection of recurrent fusion genes in acute myeloid leukemia.
Dolz S; (...); Sanz MA
Article. 10.1016/j.jmoldx.2013.04.003. 2013
Obesity is a risk factor for acute promyelocytic leukemia: evidence from population and cross-sectional studies studies and correlation with flt3 mutations and polyunsaturated fatty acid metabolism.
Mazzarella L; (...); Pelicci PG
Article. 10.3324/haematol.2019.223925. 2020
OBSERVATIONAL CLINICAL TRIAL FOR THE VALIDATION OF A TEST OF PRECISION MEDICINE IN ACUTE MYELOID LEUKEMIA
Montesinos, P.; (...); Sanz, M.
Meeting Abstract. 2017
Observational study to describe the impact of treatment combinations with Daratumumab versus other alternative regimens in patients with relapsed / refractory multiple myeloma. Spain real world evidence (RWE) data. GeminiS study
Tamayo, RR; (...); Mateos, MV
Meeting Abstract. 10.1016/j.clml.2019.09.245. 2019
Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
Kim, Won-Seog; (...); Walewski, Jan
Meeting Abstract. 10.1182/blood-2022-158406. 2022
Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial
Cabrero M; (...); Caballero D
Article. 10.1038/s41409-023-02171-5. 2024
Ofatumumab as Part of Reduced Intensity Conditioning in High Risk b-cell Lymphoma Patients: Results from a Prospective Multicenter Phase-II Trial
Cabrero, M; (...); Caballero, D
Meeting Abstract. 2020
OLD MATCHED SIBLING DONOR VERSUS YOUNG HAPLOIDENTICAL DONOR FOR ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA TRANSPLANTED IN FIRST REMISSION
Poire, Xavier; (...); Ciceri, Fabio
Meeting Abstract. 2024
Older MRD vs. younger MUD in patients older than 50 years with AML in remission using post-transplant cyclophosphamide.
Piemontese S; (...); Ciceri F
Article. 10.1038/s41375-024-02359-8. 2024
Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia
Cortes, Jorge E.; (...); Wei, Andrew H.
Meeting Abstract. 10.1182/blood-2021-144905. 2021
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML.
de Botton, Stephane; (...); Cortes, Jorge
Article. 10.1182/bloodadvances.2022009411. 2023
Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial
Cortes, Jorge E.; (...); De Botton, Stephane
Meeting Abstract. 10.1182/blood-2022-167330. 2022
Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study
Watts, Justin M.; (...); Cortes, Jorge E.
Meeting Abstract. 10.1182/blood-2019-123920. 2019
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
Watts, Justin M.; (...); Cortes, Jorge E.
Article. 10.1016/S2352-3026(22)00292-7. 2022
Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial
Cortes, Jorge E.; (...); Olutasidenib Combination Therapy Study Grp
Article. 10.1186/s13045-024-01657-z. 2025
Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML).
Cortes J; (...); Watts JM
Article. 10.1080/10428194.2024.2333451. 2024
Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study.
Horwitz, ME; (...); Sanz, G
Article. 10.1182/blood.2021011719. 2021
One or two umbilical cord blood cell units? Caveat emptor
Sanz J, Gale RP
Article. 10.1038/bmt.2016.277. 2017
Optimised molecular genetic diagnostics of Fanconi anaemia by whole exome sequencing and functional studies.
Bogliolo M; (...); Surralles J
Article. 10.1136/jmedgenet-2019-106249. 2020
OPTIMIZATION OF THE EFFICIENCY OF GENETIC EDITING OF HEMAPOYETIC PROGENITOR CELLS USING CRISPR/CAS9 RIBONUCLEOPROTEINS
Martinez-Valiente, C.; (...); Sanjuan-Pla, A.
Meeting Abstract. 2019
Optimizing Outcomes of Acute Leukemia After Transplants with Single Unrelated Cord Blood Units Selected According to Current International Recommendations for Cell Dose and HLA Match
Rafii, H; (...); Gluckman, E
Meeting Abstract. 2020
Oral Azacitidine (Oral-AZA) improves Overall Survival (OS) and Relapse-free Survival (RFS) for patients with Acute Myeloid Leukemia (AML) in first remission after Intensive Chemotherapy (IC), regardless of amount of consolidation received: Results of the QUAZAR AML-001 maintenance trial
Dohner, H.; (...); Ravandi, F.
Meeting Abstract. 2021
Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukaemia (AML) in First Remission after Intensive Chemotherapy (IC): Long-Term Overall Survival (OS) Results from the Phase 3 QUAZAR AML-001 Trial
Wei, Andrew; (...); Roboz, Gail
Meeting Abstract. 2022
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
Wei AH; (...); Roboz GJ
Article. 10.1056/NEJMoa2004444. 2020
Oral cancers preceded by Proliferative Verrucous Leukoplakia exhibit distinctive molecular features.
Herreros-Pomares A; (...); Bagan J
Article. 10.1111/odi.14550. 2023
Osteogenic differentiation of human mesenchymal stem cells on electroactive substrates.
Tamaño-Machiavello MN; (...); Ribelles JLG
Article. 10.1016/j.heliyon.2024.e28880. 2024
Outcome of a Real-Life Population of Patients With Acute Promyelocytic Leukemia Treated According to the PETHEMA Guidelines: The Polish Adult Leukemia Group (PALG) Experience.
Sobas M; (...); Giebel S
Article. 10.1016/j.clml.2019.09.616. 2020
Outcome of Acute Myeloid Leukemia with Inv(3)(Q21q26.2)/ T(3;3)(Q21;Q26.2). Experience of the Spanish PETHEMA and CETLAM Groups
Sitges, M; (...); CETLAM Cooperative Grp
Meeting Abstract. 2019
Outcome of Allogeneic Stem Cell Transplantation in FLT3-TKD-Mutated AML - a Study on Behalf of the Acute Leukemia Working Party of the EBMT
Heinicke, Thomas; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2023-174233. 2023
Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients
Ferrà C; (...); Ribera JM
Article. 10.3109/10428194.2014.930849. 2015
Outcome of Human Parainfluenza Virus infection in allogeneic stem cell transplantation recipients: possible impact of ribavirin therapy.
Perez, Ariadna; (...); Pinana, Jose Luis
Article. 10.1007/s15010-024-02213-0. 2024
Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents
Park, Sophie; (...); Fenaux, Pierre
Letter. 10.1016/j.leukres.2020.106472. 2020
OUTCOME OF LOWER-RISK PATIENTS WITH MYELODYSPLASTIC SYNDROMES WITHOUT 5Q DELETION AFTER FAILURE OF ERYTHROPOIESIS STIMULATING AGENTS
Park, S; (...); Fenaux, P
Meeting Abstract. 10.1016/S0145-2126(17)30162-5. 2017
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents
Park S; (...); Fenaux P
Article. 10.1200/JCO.2016.71.3271. 2017
Outcome of older (=70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study.
Kayser S; (...); Montesinos P
Article. 10.1038/s41375-020-0758-4. 2020
Outcome of older (>= 70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study (vol 34, pg 2333, 2020)
Kayser, Sabine; (...); Montesinos, Pau
Correction. 10.1038/s41375-021-01358-3. 2021
Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
Middeke JM; (...); Schetelig J
Article. 10.1182/blood-2013-12-544957. 2014
Outcome of patients with chronic myeloid leukemia and a low-risk score: allogeneic hematopoietic stem cell transplantation in the era of targeted therapy. A report from the EBMT Chronic Malignancies Working Party
Koenecke, C; (...); Finke, J
Letter. 10.1038/bmt.2016.97. 2016
Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry
Martinez-Cuadron, David; (...); Montesinos, Pau
Article. 10.3324/haematol.2022.282506. 2024
Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes.
Caballero, Juan Carlos; (...); Diez Campelo, Maria
Article. 10.1177/20406207231218157. 2024
Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials
Ribera, JM; (...); PETHEMA Grp
Article. 10.1002/hon.2910. 2021
Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy
Socie, Gerard; (...); Mohty, Mohamad
Article. 10.1038/s41409-023-02127-9. 2024
Outcomes for Patients with Late-Stage Mutant-IDH2 (m IDH2) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treated with Enasidenib Vs Other Lower-Intensity Therapies in the Randomized, Phase 3 IDHentify Trial
DiNardo, Courtney D.; (...); de Botton, Stephane
Meeting Abstract. 10.1182/blood-2021-147593. 2021
Outcomes in Chemotherapy-Ineligible Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Plus Azacitidine: A Pooled Analysis
Venditti, Adriano; (...); Pullarkat, Vinod
Meeting Abstract. 10.1182/blood-2023-182045. 2023
Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study
Giagounidis A; (...); Fenaux P
Article. 10.1111/ejh.12380. 2014
Outcomes of CAR-T Cell Therapy for Large B Cell Lymphoma in Patients of 70 Years and Older: Multicentric Experience on Behalf of Geth-TC/Geltamo
Bailen, Rebeca; (...); Barba, Pere
Meeting Abstract. 10.1182/blood-2023-185858. 2023
OUTCOMES OF CAR-T CELL THERAPY FOR LARGE B CELL LYMPHOMA IN PATIENTS OF 70 YEARS AND OLDER: MULTICENTRIC REAL WORLD EXPERIENCE
Bailen, Rebeca; (...); Barba, Pere
Meeting Abstract. 2023
Outcomes of graft failure after umbilical cord blood transplantation in acute leukemia: a study from Eurocord and the Acute Leukemia Working Party of the EBMT.
Baron F; (...); Mohty M
Article. 10.1038/s41409-023-02000-9. 2023
Outcomes of Patients with Hodgkin Lymphoma Receiving Brentuximab Vedotin (BV) As Maintenance Therapy after ASCT According to Previous Exposure to BV. a Retrospective Analysis of the EBMT Lymphoma Working Party in Collaboration with Geltamo, FIL, Lysarc, and Turkish Lymphoma Group
Munoz, Maria Carmen Martinez; (...); Balari, Anna Sureda
Meeting Abstract. 10.1182/blood-2024-205007. 2024
Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis Who Did Not Undergo Intensive Chemotherapy: Results from a Large International Database
Shallis, RM; (...); Zeidan, AM
Meeting Abstract. 10.1182/blood-2018-99-119755. 2018
Outcomes of subsequent neoplasms after umbilical cord blood transplantation in Europe.
Rafii, Hanadi; (...); Gluckman, Eliane
Article. 10.1182/bloodadvances.2022007941. 2022
Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT
Paviglianiti, A; (...); Mohty, M
Article. 10.3324/haematol.2015.138917. 2016
Overactivation of the NLRP3 Inflammasome in Chronic Myelomonocytic Leukemia KRAS Mutated Patients Can be Detected By the Apoptosis- Associated Speck-like Protein (ASC) and Reverted By IL1 beta Inhibitors
Hurtado-Navarro, Laura; (...); Marin, Francisca Ferrer
Meeting Abstract. 10.1182/blood-2021-153686. 2021
Oxidative Stress in the Pathogenesis of Crohn's Disease and the Interconnection with Immunological Response, Microbiota, External Environmental Factors, and Epigenetics
Alemany-Cosme, E; (...); Beltran, B
Review. 10.3390/antiox10010064. 2021
Oxygen Load Influences DNA Methylation in Preterm Infants upon Delivery Room Stabilization
Vento, M.; (...); Sandoval, J.
Meeting Abstract. 2017
P-137: ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in preliminary results (vol 21, pg S109, 2021)
Ghobrial, Irene M.; (...); Mateos, Maria-Victoria
Correction. 10.1016/j.clml.2022.03.011. 2022
p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)
Saft L; (...); Hellström-Lindberg E
Article. 10.3324/haematol.2013.098103. 2014
Panel Sequencing for Clinically Oriented Variant Screening and Copy Number Detection in Chronic Lymphocytic Leukemia Patients
Ibanez, Mariam; (...); Luna I
Article. 10.3390/diagnostics12040953. 2022
Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study
Ocio EM; (...); PETHEMA Group
Article. 10.3324/haematol.2015.129577. 2015
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
San-Miguel, JF; (...); Richardson, PG
Article. 10.1016/S1470-2045(14)70440-1. 2014
PAN-STAKEHOLDER CORE OUTCOME SET (COS) DEFINITION FOR HEMATOLOGICAL MALIGNANCIES IN THE FRAMEWORK OF THE EU PROJECT, HARMONY: THE HEALTHCARE ALLIANCE FOR RESOURCEFUL MEDICINE OFFENSIVE AGAINST NEOPLASMS IN HEMATOLOGY
Lang, K.; (...); Bullinger, L.
Meeting Abstract. 2023
Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies within the Framework of Harmony and Harmony PLUS Projects
Lang, Katharina M.; (...); Bullinger, Lars
Meeting Abstract. 10.1182/blood-2022-157549. 2022
Pan-Stakeholder Core Outcome Set (COS) Definition for Selected Hematological Malignancies - Results of the Harmony Alliance
Lang, Katharina M.; (...); Bullinger, Lars
Meeting Abstract. 10.1182/blood-2021-145002. 2021
Paradoxical Findings in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors: Suboptimal Disease Control Perceived As Satisfactory
Gaya, Anna; (...); Vallejo, Carlos
Meeting Abstract. 10.1182/blood-2023-185939. 2023
Parasitic Infections in Hematopoietic Stem Cell Transplantation.
Article. 10.4084/MJHID.2016.035. 2016
Partial T Cell-Depleted Peripheral Blood Stem Cell Transplantation from HLA-Identical Sibling Donors for Patients with Severe Aplastic Anemia.
Sanz J; (...); Piñana JL
Article. 10.1016/j.bbmt.2019.08.020. 2020
Passenger lymphocyte syndrome in liver transplant recipients: a description of 12 cases
Article. 10.2450/2015.0148-14. 2015
Patient Reported Outcomes in Patients with Newly Diagnosed FLT3(mut+) acute Myeloid Leukemia Ineligible for Intensive Induction Chemotherapy from Lacewing: A Randomized Phase 3 Trial of Gilteritinib and Azacitidine Versus Azacitidine Alone
Wang, Eunice S.; (...); Shah, Manasee V.
Meeting Abstract. 10.1182/blood-2021-144977. 2021
Patient-reported Outcomes in Adults With Newly Diagnosed Ph plus Acute Lymphoblastic Leukemia Treated With Ponatinib or Imatinib in Combination With Reduced-Intensity Chemotherapy: Results From the Phase III PhALLCON Study
Ashaye, Ajibade; (...); Guo, Shien
Meeting Abstract. 2024
PATTERNS OF RESCUE TREATMENT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED IN THE FIRST LINE WITH AZACITIDINE AND DECITABIN: RESULTS OF THE PETHEMA AML REGISTRY
Jorge, Labrador; (...); Miguel-Angel, Sanz
Meeting Abstract. 2021
PCR-Based Strategy for Introducing CRISPR/Cas9 Machinery into Hematopoietic Cell Lines.
González-Romero E; (...); Vázquez-Manrique RP
Article. 10.3390/cancers15174263. 2023
Performance evaluation of low platelet count and platelet clumps detection on Mindray BC-6800 hematology analyzer
Letter. 10.1515/cclm-2015-0409. 2016
Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study
Rodriguez-Medina, C; (...); Fernandez, PM
Article. 10.1016/j.leukres.2020.106352. 2020
Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia
Stahl, M; (...); Zeidan, AM
Letter. 10.1080/10428194.2018.1468893. 2019
Personalized Survival Prediction of Patients With Acute Myeloblastic Leukemia Using Gene Expression Profiling
Orgueira, AM; (...); Lopez, JLB
Article. 10.3389/fonc.2021.657191. 2021
Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications
Sargas, Claudia; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2022-166639. 2022
PHARMACOECONOMIC ANALYSIS OF THE USE OF VORICONAZOLE, POSACONAZOLE AND MICAFUNGIN IN THE PRIMARY PROPHYLAXIS OF INVASIVE FUNGAL INFECTIONS IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTS IN SPAIN
Grau S; (...); Rubio-Terrés C
Meeting Abstract. 10.1016/j.jval.2015.09.1944. 2015
Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia
Megias-Vericat, JE; (...); Montesinos, P
Review. 10.2174/1389200218666171101124931. 2018
Pharmacogenomics and the treatment of acute myeloid leukemia
Megías-Vericat JE; (...); Aliño SF
Review. 10.2217/pgs-2016-0055. 2016
Pharmacokinetic Study of Intravenous Acetaminophen Administered to Critically Ill Multiple-Trauma Patients at the Usual Dosage and a New Proposal for Administration
Fuster-Lluch, O, Zapater-Hernandez, P, Geronimo-Pardo, M
Article. 10.1002/jcph.903. 2017
Pharmacologic evaluation of bispecific antibodies: A novel method to quantify their in vitro activity in hematologic samples.
Primo, D; (...); Ballesteros, J
Meeting Abstract. 2017
Pharmacological Profiles of Acute Myeloid Leukemia Treatments in Patient Samples by Automated Flow Cytometry: A Bridge to Individualized Medicine
Bennett TA; (...); Ballesteros J
Article. 10.1016/j.clml.2013.11.006. 2014
Phase 1 study of LP-108 as monotherapy and in combination with azacitidine in patients with relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).
Walker, Alison R.; (...); William Burke, Patrick
Meeting Abstract. 2022
Phase 1/2 study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in patients with IDH1/2-mutated acute myeloid leukemia: The DIAMOND-01 trial.
Martinelli, Giovanni; (...); Montesinos, Pau
Meeting Abstract. 2022
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia
Robak, T; (...); Jolles, S
Article. 10.1182/bloodadvances.2020002003. 2020
Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) - Preliminary Blinded Analysis of the European Sintra-REV Trial
Cadenas, FL; (...); Diez-Campelo, M
Meeting Abstract. 10.1182/blood-2018-99-119430. 2018
Phase 3 Trial of Gilteritinib Plus Azacitidine Vs Azacitidine for Newly Diagnosed FLT3mut+ AML Ineligible for Intensive Chemotherapy.
Wang, Eunice S.; (...); Tiu, V, Ramon
Article. 10.1182/blood.2021014586. 2022
Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy
Wang, Eunice S.; (...); Tiu, Ramon V.
Meeting Abstract. 10.1182/blood-2021-145379. 2021
Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.
Roboz, Gail J.; (...); Wei, Andrew H.
Letter. 10.1080/10428194.2021.2012667. 2022
Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide
Horwitz, ME; (...); Sanz, G
Article. 10.1200/JCO.18.00053. 2019
Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial
Cabrero, M; (...); Caballero, D
Article. 10.1016/j.bbmt.2016.10.003. 2017
Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia
Martínez-Cuadrón D; (...); Sanz MA
Article. 10.1007/s00277-013-1914-y. 2014
Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation
Vallejo C; (...); Jarque I
Article. 10.3324/haematol.2014.105908. 2014
Pilot Inter-Laboratory Comparison Study of Optical Genome Mapping Analysis for Cytogenomic Characterization of Hematological Malignancies: A Spanish Multicentric Study
Puiggros, Anna; (...); Espinet, Blanca
Meeting Abstract. 10.1182/blood-2022-166293. 2022
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.
Daver NG; (...); Kantarjian HM
Article. 10.1016/S1470-2045(23)00674-5. 2024
Pivekimab Sunirine (PVEK, IMGN632), a CD123-Targeting Antibody-Drug Conjugate, in Combination with Azacitidine and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia
Daver, Naval; (...); Sweet, Kendra
Meeting Abstract. 10.1182/blood-2023-173413. 2023
PLZF-RAR(alpha), NPM1-RAR(alpha), and Other Acute Promyelocytic Leukemia Variants: The PETHEMA Registry Experience and Systematic Literature Review
Sobas, M; (...); Montesinos, P
Review. 10.3390/cancers12051313. 2020
Ponalfil trial for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: Long-term results.
Ribera, Josep-Maria; (...); Garcia-Sanz, Ramon
Article. 10.1002/hem3.67. 2024
PONATINIB AND CHEMOTHERAPY IN YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA WITH PHILADELPHIA CHROMOSOME. RESULTS OF THE PONALFIL CLINICAL TRIAL WITH COMPLETE RECRUITMENT
Ribera, J. M.; (...); Garcia-Sanz, R.
Meeting Abstract. 2020
PONATINIB AND CHEMOTHERAPY IN YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WITH PHILADELPHIA CHROMOSOME. PRELIMINARY RESULTS OF THE PONALFIL CLINICAL TRIAL
Ribera Santasusana, J. M.; (...); Garcia-Sanz, R.
Meeting Abstract. 2019
PONATINIB AND CHEMOTHERAPY IN YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WITH PHILADELPHIC CHROMOSOME (LAL PH plus ). RESULTS OF THE PONALFIL CLINICAL TRIAL WITH MEDIUM 2-YEAR FOLLOW-UP
Ribera Santasusana, J. M.; (...); Garcia-Sanz, R.
Meeting Abstract. 2021
Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblstic Leukemia. Preliminary Results of Ponalfil Clinical Trial
Ribera, Josep-Maria; (...); Garcia-Sanz, Ramon
Meeting Abstract. 10.1182/blood-2019-125558. 2019
Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph plus ALL: Subgroup Analysis of the Phase 3 Phallcon Study
Aldoss, Ibrahim; (...); Jabbour, Elias
Meeting Abstract. 10.1182/blood-2023-179537. 2023
Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Jabbour, Elias; (...); Ribera, Jose-Maria
Article. 10.1001/jama.2024.4783. 2024
Ponatinib, Chemotherapy, and Transplant in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Ribera, Josep-Maria; (...); Garcia-Sanz, Ramon
Article. 10.1182/bloodadvances.2022007764. 2022
POOLED FECAL ALLOGENEIC MICROBIOTHERAPY FOR REFRACTORY GASTROINTESTINAL ACUTE GRAFT-VERSUSHOST DISEASE: RESULTS FROM THE EARLY ACCESS PROGRAM IN EUROPE
Malard, Florent; (...); Mohty, Mohamad
Meeting Abstract. 2024
Positive impact of ABCB1 polymorphisms in overall survival and complete remission in acute myeloid leukemia: a systematic review and meta-analysis
Megías-Vericat JE; (...); Aliño SF
Letter. 10.1038/tpj.2015.79. 2016
POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) VERSUS ANTI-THYMOCYTE GLOBULIN (ATG) VERSUS COMBINATION FOR GRAFT-VERSUS-HOST DISEASE PREVENTION IN HAPLOIDENTICAL TRANSPLANTATION FOR ADULT ACUTE MYELOID LEUKEMIA: A REPORT FROM THE EBMT
Bazarbachi, Abdul-Hamid; (...); Mohty, Mohamad
Meeting Abstract. 2023
Post-transplant cyclophosphamide after HLA identical compared to Haploidentical donor transplant in Acute Myeloid Leukemia: a study on behalf of GETH-TC.
Bailen, Rebeca; (...); Kwon, Mi
Article. 10.1016/j.jtct.2022.01.020. 2022
Post-Transplant Cyclophosphamide after HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of Geth-TC
Bailen, Rebeca; (...); Kwon, Mi
Meeting Abstract. 10.1182/blood-2021-150835. 2021
Post-transplant Cyclophosphamide after Matched Sibling and Matched Unrelated Compared to Haploidentical Donor Transplants in Patients with Acute Myeloid Leukemia, a Study on Behalf of Geth
Kwon, M; (...); Martin, JLD
Meeting Abstract. 2020
Post-Transplant Cyclophosphamide after Matched Sibling, Unrelated and Haploidentical Donor Transplants in Patients with Acute Myeloid Leukemia, a Comparative Study of the ALWP EBMT
Sanz, Jaime; (...); Nagler, Arnon
Meeting Abstract. 10.1182/blood-2019-125859. 2019
Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT.
Sanz J; (...); Acute Leukemia Working Party of the European Society for Blood and Marrow Transp
Article. 10.1186/s13045-020-00882-6. 2020
Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia.
Lazzari, Lorenzo; (...); Sanz, Jaime
Article. 10.1038/s41409-022-01725-3. 2022
Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT
Sanz, J; (...); Mohty, M
Article. 10.1186/s13045-021-01094-2. 2021
Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation.
Bailén R; (...); Díez-Martín JL
Article. 10.1007/s00277-020-04317-7. 2020
Post-transplant cyclophosphamide for GVHD prophylaxis in matched unrelated donor transplantation
Bailen, R; (...); Kwon, M
Meeting Abstract. 2019
Post-Transplant Cyclophosphamide for Gvhd Prophylaxis in Matched Unrelated Donor Transplantation Compared to ATG-Based Prophylaxis
Bailen, Rebeca; (...); Luis Diez-Martin, Jose
Meeting Abstract. 10.1182/blood-2019-124849. 2019
Post-transplant Cyclophosphamide in Acute Leukemia Patients Receiving more than 5/10 HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation from Related Donors: a Study on behalf of the ALWP of the EBMT.
Wieczorek, Michele; (...); Mohty, Mohamad
Letter. 10.1002/ajh.26782. 2022
Post-Transplant Cyclophosphamide in Acute Leukemia Patients Receiving More Than 5/10 HLA-Mismatched Allogeneic Stem Cell Transplantation: A Study on Behalf of the ALWP of the EBMT
Wieczorek, Michele; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2021-151087. 2021
Post-transplant cyclophosphamide separates graft-versus host disease (GVHD) and graft versus leukemia (gvl) effects after HLA- matched stem-cell transplantation (sct) for AML
Shimoni, A.; (...); Mohty, M.
Meeting Abstract. 2022
Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Haploidentical Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT
Battipaglia, Giorgia; (...); Ciceri, Fabio
Meeting Abstract. 10.1182/blood-2024-207391. 2024
Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Giebel, Sebastian; (...); Mohty, Mohamad
Article. 10.1002/cncr.35004. 2023
Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors
Brissot, E; (...); Mohty, M
Article. 10.1186/s13045-020-00923-0. 2020
Post-transplant cyclophosphamide versus antithymocyte globulin in patients with all treated in CR1 with allo-HCT from matched unrelated donors. A study from ALWP of the EBMT
Giebel, S.; (...); Mohty, M.
Meeting Abstract. 2022
Posttransplant cyclophosphamide versus anti-thymocyte globulin versus combination for graft-versus-host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party.
Bazarbachi, Abdul-Hamid; (...); Mohty, Mohamad
Article. 10.1002/cncr.35365. 2024
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in HLAMatched and Haploidentical Donor Transplants for Patients with Hodgkin disease: A Comparative Study of the LWP EBMT
Montoro, Juan; (...); Glass, Bertram
Meeting Abstract. 10.1182/blood-2023-179829. 2023
Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation
Dietrich, S; (...); EBMT Lymphoma Working Party
Letter. 10.1038/leu.2016.125. 2016
Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.
Article. 10.1080/10428194.2018.1474462. 2019
Posttransplant monomorphic Burkitt's lymphoma: clinical characteristics and outcome of a multicenter series
Bobillo, S; (...); Grp Espanol Linfomas Trasplante
Article. 10.1007/s00277-018-3473-8. 2018
Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Sahebi, Firoozeh; (...); Schonland, Stefan
Article. 10.1016/j.jtct.2021.09.008. 2021
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
Montoro, Juan; (...); Glass, Bertram
Article. 10.1016/j.jtct.2023.11.021. 2024
Potential survival benefit for patients receiving allogeneic hematopoietic stem cell transplantation after nivolumab therapy for relapse/refractory Hodgkin lymphoma: Real-life experience in Spain (Spanish Group of Lymphoma and Bone Marrow Transplantation, GELTAMO).
Martínez C; (...); García-Sanz R
Article. 10.1016/j.bbmt.2020.02.003. 2020
Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports.
Martínez-Cuadrón D; (...); Montesinos P
Article. 10.1007/s40261-019-00881-7. 2020
Practical guide to emergency treatment of thrombotic microangiopathy
Romero S; (...); Grupo de Microangiopatía Trombótica del Hospital Universitario y Politécnico La
Editorial Material. 10.1016/j.medcli.2018.01.013. 2018
Practice Patterns of Transplant Centers Regarding Maintenance Treatment Post Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia: A Survey on Behalf of the EBMT Acute Leukemia Working Party
Abou Dalle, Iman; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2023-187095. 2023
Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?
Megías-Vericat JE; (...); Montesinos P
Review. 10.1080/17474086.2020.1818559. 2020
Precision medicine in Ewing sarcoma: a translational point of view.
Gargallo P; (...); Cañete A
Review. 10.1007/s12094-020-02298-7. 2020
Precision Medicine Test Is Similar but Faster Than Conventional Cytogenetics Predicting Response in AML Patients and Provides Alternative Treatments
Ballesteros, J; (...); Montesinos, P
Meeting Abstract. 10.1182/blood-2018-99-115849. 2018
Predicting Malignant and Paramalignant Pleural Effusions by Combining Clinical, Radiological and Pleural Fluid Analytical Parameters
Herrera Lara S; (...); Morales Suárez-Varela M
Article. 10.1007/s00408-017-0032-3. 2017
Predicting survival, neurotoxicity and response in B-cell lymphoma patients treated with CAR-T therapy using an imaging features-based model
Ferrer-Lores, Blanca; (...); Alberich-Bayarri, Angel
Article. 10.1186/s13550-024-01172-9. 2024
Predictive Factors for Thrombopoietin Receptor Agonist Free Responses in Chronic ITP Patients: A Multicenter Retrospective Study with Long-Term Follow-up
Luisa Lozano, Maria; (...); Vicente Garcia, Vicente
Meeting Abstract. 10.1182/blood-2019-125580. 2019
Predictive value of 1q21 gain in multiple myeloma is strongly dependent on concurrent cytogenetic abnormalities and first-line treatment
Minguela, Alfredo; (...); Periago, Adela
Article. 2021
Predictive value of 1q21 gain in multiple myeloma is strongly dependent on concurrent cytogenetic abnormalities and first-line treatment.
Minguela, Alfredo; (...); Periago, Adela
Article. 2021
Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy
Abla, O; (...); Sanz, MA
Article. 10.1007/s00277-017-3042-6. 2017
PREDICTORS OF TREATMENT FREE RESPONSES WITH THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH PTI
Lozano Almela, M. L.; (...); Vicente, V.
Meeting Abstract. 2019
Preferential Genetic Pathways Lead to Relapses in Adult B-Cell Acute Lymphoblastic Leukemia
Navas-Acosta, Josgrey; (...); Hernandez-Rivas, Jesus Maria
Article. 10.3390/cancers16244200. 2024
PRELIMINARY ANALYSIS OF EFFICACY AND SAFETY OF SINTRA-REV CLINICAL TRIAL, LENALIDOMIDE VS PLACEBO PHASE 3 STUDY IN LOW/INT-1 MDS PATIENTS WITH DEL(5Q) AND TRANSFUSION INDEPENDENCY
Cadenas, FL; (...); Diez-Campelo, M
Meeting Abstract. 2017
Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC)
Abrisqueta, Pau; (...); Bosch, Francesc
Meeting Abstract. 10.1182/blood-2019-128470. 2019
Preliminary Safety and Efficacy of Bgb-11417, a Novel Bcl-2 Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)
Shortt, Jake; (...); Wei, Andrew H.
Meeting Abstract. 10.1182/blood-2022-166937. 2022
Presence of acute and chronic renal failure in patients with paroxysmal nocturnal hemoglobinuria: results of a retrospective analysis from the Spanish PNH Registry
Villegas, A; (...); Urbano, A
Article. 10.1007/s00277-017-3059-x. 2017
Pre-Transplant Somatic Co-Occurring Mutations (by next generation sequencing) in Acute Myeloid Leukemia: Frequency and Impact on Clinical Outcomes after Allogeneic Hematopoietic Cell Transplantation - a Large Study on Behalf of the EBMT Acute Leukemia Working Party
Bazarbachi, Ali; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2023-182823. 2023
Prevalence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort The PESA (Progression of Early Subclinical Atherosclerosis) Study
Fernández-Friera L; (...); Fuster V
Article. 10.1161/CIRCULATIONAHA.114.014310. 2015
Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia.
Cortes JE; (...); Wang ES
Review. 10.1186/s13045-020-00975-2. 2020
Primary and secondary immune thrombocytopenia (ITP): Time for a rethink.
Gonzalez-Lopez, Tomas Jose; (...); Fernandez-Fuertes, Fernando
Article. 10.1016/j.blre.2023.101112. 2023
Primary paraesophageal Ewing's sarcoma: an uncommon case report and literature review
Tarazona N; (...); Cervantes A
Article. 10.2147/OTT.S80879. 2015
Prognosis and Survival of Acute Myeloid Leukemia: Experience of a Single Center in Colombia
Sossa, CL; (...); Jimenez, SI
Meeting Abstract. 10.1182/blood-2018-99-119927. 2018
Prognosis Value of Measurable Residual Disease By Multiparameter Flow Cytotometry in Patients with Acute Myeloblastic Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation
Caballero, Teresa; (...); Perez-Simon, Jose A.
Meeting Abstract. 10.1182/blood-2021-151533. 2021
PROGNOSIS VALUE OF MINIMAL DETECTABLE DISEASE (MDD) BY 2(nd) GENERATION ALLOGENIC PRE-TRANSPLANTATION CYTOMETRY IN PATIENTS WITH ACUTE MYELOBLASTIC LEUKEMIA
Velazquez Teresa, Caballero; (...); Jose Antonio, Perez Simon
Meeting Abstract. 2021
Prognostic Factors and Treatment Strategy in Patients with Hodgkin Lymphoma and HIV Infection Treated with ABVD and CART: A Retrospective Study from Spanish Group Geltamo
Huguet, Maria; (...); Navarro, Jose-Tomas
Meeting Abstract. 10.1182/blood-2023-189756. 2023
Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study
Kanda, J; (...); Gluckman, E
Meeting Abstract. 2018
Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study.
Kanda J; (...); Gluckman E
Article. 10.1038/s41375-019-0534-5. 2020
Prognostic factors of overall (OS) and relapse-free survival (RFS) for patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy (IC): Multivariate analyses from the QUAZAR AML-001 trial of oral azacitidine (Oral-AZA).
Roboz, Gail J.; (...); Dohner, Hartmut
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.7014. 2021
Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/ TCF3-PBX1 treated with measurable residual disease-oriented protocols
Ribera, Jordi; (...); Ribera, Josep-Maria
Article. 10.1111/bjh.17844. 2021
Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS
de Swart, L; (...); de Witte, T
Article. 10.1016/j.leukres.2018.01.022. 2018
Prognostic Impact of Anthracycline Metabolism Gene Polymorphisms in Newly Diagnosed Acute Myeloid Leukemia Adults
Eduardo Megias, Juan; (...); Angel Sanz, Miguel
Article. 2014
Prognostic Impact of Cytarabine Pathway Gene Polymorphisms in Acute Myeloid Leukemia Adults Undergoing Induction Chemotherapy
Eduardo Megias, Juan; (...); Angel Sanz, Miguel
Article. 2014
Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes
Nomdedeu, M; (...); Costa, D
Article. 10.1002/gcc.22333. 2016
Prognostic impact of gene mutations in myelodysplastic syndromes with ring sideroblasts
Martin, I; (...); Sanz, G
Article. 10.1038/s41408-017-0016-9. 2017
Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603)
Rucker, FG; (...); Dohner, K
Meeting Abstract. 10.1182/blood-2018-99-116149. 2018
Prognostic impact of KMT2E transcript levels on outcome of patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukaemia study
Lucena-Araujo AR; (...); Rego EM
Article. 10.1111/bjh.12921. 2014
Prognostic Impact of NPM1 and FLT3 Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance
Dohner, Hartmut; (...); de Menezes, Daniel Lopes
Meeting Abstract. 10.1182/blood-2021-147465. 2021
Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.
Dohner, Hartmut; (...); Lopes de Menezes D
Article. 10.1182/blood.2022016293. 2022
Prognostic Impact of NPM1 and FLT3-ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study
Uriel Suarez, Edwin; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2022-167365. 2022
PROGNOSTIC IMPACT OF TRANSPORTER GENE POLYMORPHISMS IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA ADULTS
Megias Vericat, J. E.; (...); Sanz, M. A.
Article. 2015
Prognostic Significance of Complex Karyotype and Monosomal Karyotype in Adult Patients With Acute Lymphoblastic Leukemia Treated With Risk-Adapted Protocols
Motlló C; (...); Feliu E
Article. 10.1002/cncr.28950. 2014
Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols
Ribera J; (...); Ribera JM
Article. 10.1002/cncr.29579. 2015
Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens.
Castaño-Bonilla T; (...); Montesinos, P
Article. 10.1038/s41598-021-00050-x. 2021
Prognostic Value of Antigen Expression in Multiple Myeloma (MM): A Large GEM/Pethema Study Based in Four Consecutive Clinical Trials
Paiva, Bruno; (...); San Miguel, Jesus
Meeting Abstract. 2015
Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials
Arana P; (...); San Miguel JF
Article. 10.1038/leu.2017.320. 2018
Prognostic Value of Chromosome 1 Abnormalities in Myelodysplastic Syndrome
Ibarrondo, Paloma; (...); Batlle-Lopez, Ana
Article. 2014
PROGNOSTIC VALUE OF EARLY DROP IN PLATELETS IN LOWER-RISK MDS. A SUB-STUDY FROM THE EUROPEAN LEUKEMIANET LOWER-RISK MDS (EUMDS) REGISTRY
Itzykson, R; (...); de Witte, T
Meeting Abstract. 10.1016/S0145-2126(17)30132-7. 2017
Prognostic Value of Immune Profiling Multiple Myeloma Patients during Minimal Residual Disease Monitoring in the Pethema/GEM2010MAS65 Study
Arana, Paula; (...); San Miguel, Jesus
Meeting Abstract. 2015
Prognostic Value of Measurable Residual Disease in Patients with AML Undergoing HSCT: A Multicenter Study.
Caballero-Velazquez, Teresa; (...); Perez-Simon, Jose A.
Article. 10.3390/cancers15051609. 2023
Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma.
Tamariz-Amador, Luis-Esteban; (...); Troconiz, Inaki F.
Article. 10.1016/j.clml.2022.04.024. 2022
Progression-free survival at 2years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma
Jimenez-Ubieto, A; (...); GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) cooperative stu
Article. 10.1002/cam4.1217. 2017
Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study.
Muñoz-González JI; (...); Orfao A
Article. 10.1016/S2352-3026(20)30400-2. 2021
PROPOSED MOLECULAR CLASSIFICATION OF ACUTE MYELOBLASTIC LEUKEMIA (AML) BASED ON SPLICING EVENTS
Liquori, A.; (...); Cervera Zamora, J.
Meeting Abstract. 2021
Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies.
Sanz J; (...); Piñana JL
Article. 10.1016/j.bbmt.2019.10.014. 2020
Protein-Functionalized Microgel for Multiple Myeloma Cells' 3D Culture.
Marín-Payá JC; (...); Gomez Ribelles, Jose Luis
Article. 10.3390/biomedicines10112797. 2022
PTCy vs CNI-based GVHD prophylaxis in HLA-matched transplants for Hodgkin lymphoma: a study of the LWP of the EBMT.
Montoro J; (...); Glass B
Article. 10.1182/bloodadvances.2024013328. 2024
Publisher Correction: MethCORR modelling of methylomes from formalin-fixed paraffin-embedded tissue enables characterization and prognostication of colorectal cancer.
Mattesen TB; (...); Bramsen JB
Correction. 10.1038/s41467-020-16538-5. 2020
Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneumonia
Pinana, JL; (...); Navarro, D
Article. 10.1016/j.jinf.2019.02.009. 2019
Pulmonary invasive fungal disease after community acquire respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients: Results from a prospective observational study
Pinana, Jose; (...); Navarro, David
Meeting Abstract. 2019
PURE ERYTHROID SARCOMA IN A PEDIATRIC PATIENT. A CASE REPORT AND REVIEW OF THE LITERATURE
Manresa Manresa, P.; (...); Rodrigo, FT
Meeting Abstract. 2017
Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question.
Marco-Ayala J; (...); Solves P
Review. 10.1038/s41409-020-01124-6. 2021
Púrpura trombocitopénica trombótica inmune: sospecha y manejo básico en los servicios de urgencias. Revisión y consenso de un grupo de expertos de las sociedades científicas SEHH y SEMES.
Pascual-Izquierdo, Cristina; (...); de la Rubia Comos, Javier
Article. 10.55633/s3me/E099.2023. 2023
Purtscher-like retinopathy associated with dermatomyositis and hemophagocytic lymphohistiocytosis.
Barreiro-González A; (...); Azorín Villena I
Article. 10.1016/j.oftal.2017.03.009. 2018
qMetforminintreatment Overcomes AT-Resistance in Acute Promyelocytic Leukemia Foxo3A Expression
Pereira-Martins, DA; (...); Rego, EM
Meeting Abstract. 10.1182/blood-2018-99-115068. 2018
Quality of thawed plasma inactivated with methylene blue after 48-hour storage
Balaguer A; (...); Sanz MÁ
Letter. 10.1016/j.transci.2014.11.005. 2015
QUANTIFICATION OF CIRCULATING TUMOR CELLS IS THE MOST RELEVANT PROGNOSTIC FACTOR AT DIAGNOSIS IN PATIENTS WITH MULTIPLE MYELOMA, WHO ARE TRANSPLANT CANDIDATES, Abstracts
Juan-Jose, Garces; (...); Bruno, Paiva
Meeting Abstract. 2021
QuANTUM-First Trial: FLT3-Internal Tandem Duplication (FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Is Associated With Improved Overall Survival (OS)
Levis, Mark J.; (...); Perl, Alexander E.
Meeting Abstract. 2023
Quantum-First Trial: FLT3-ITD-Specific MRD Clearance Is Associated with Improved Overall Survival
Levis, Mark J.; (...); Perl, Alexander
Meeting Abstract. 10.1182/blood-2022-162739. 2022
Quantum-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed through Induction ( IND) and Consolidation CONS) Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (nd) FLT3-ITD+ AML Patients (pts)
Perl, Alexander; (...); Levis, Mark J.
Meeting Abstract. 10.1182/blood-2023-186785. 2023
QuANTUM-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication (FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed Through Induction and Consolidation Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (ND) FLT3-ITD+ AML Patients
Perl, Alexander E.; (...); Levis, Mark J.
Meeting Abstract. 2024
QuANTUM-First: Efficacy by Age in Newly Diagnosed (nd) Patients With FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication-Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML)
Erba, Harry P.; (...); Montesinos, Pau
Meeting Abstract. 2024
QuANTUM-First: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients (pts) with newly diagnosed (NDx) FLT3-ITD acute myeloid leukemia (AML)
Schlenk, R; (...); Erba, H
Meeting Abstract. 2017
QuANTUM-R: phase 3, randomised trial of Quizartinib in patients with FLT3-Internal tandem duplication (FLT3-ITD)-positive relapsed/refractory (R/R) acute myeloid meukaemia (AML)
Radsak, M. P.; (...); Levis, M. J.
Meeting Abstract. 2019
Quizartinib in FLT3-ITD-Mutated Relapsed/Refractory Acute Myeloid Leukemia: QuANTUM-R Trial Results
Cortes, JE; (...); Levis, MJ
Meeting Abstract. 10.1093/annonc/mdz374.003. 2019
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
Erba, Harry P.; (...); Schlenk, Richard F.
Article. 10.1016/S0140-6736(23)00464-6. 2023
Quizartinib prolongs Life compared to Placebo plus intensive Induction Therapy and Consolidation Therapy followed by Monotherapy Treatment in Patients aged 18-75 Years with newly diagnosed FLT3-ITD and AML
Schlenk, R.; (...); Erba, H.
Meeting Abstract. 2022
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
Cortes, JE; (...); Levis, MJ
Article. 10.1016/S1470-2045(19)30150-0. 2019
Rabbit antithymocyte globulin versus horse antithymocyte globulin for treatment of acquired aplastic anemia: a retrospective analysis
Vallejo C; (...); Rayón C
Article. 10.1007/s00277-015-2305-3. 2015
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
Cortes, JE; (...); Heuser, M
Article. 10.1038/s41375-018-0312-9. 2019
Randomized Phase 1-2 Study to Assess Safety and Efficacy of Low-Dose (LD) Oral Decitabine/ Cedazuridine (ASTX727) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients: Interim Safety Analysis
Garcia-Manero, Guillermo; (...); Yacoub, Abdulraheem
Meeting Abstract. 2023
RANDOMIZED PHASE 2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS
Garcia-Manero, G.; (...); Yacoub, A.
Meeting Abstract. 10.1016/j.leukres.2023.107270. 2023
Rapid and Robust CD4+and CD8+T-, NK-, B- and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation
Boelens, JJ; (...); Nierkens, S
Meeting Abstract. 10.1182/blood-2018-99-116700. 2018
Rapid and Robust CD4+and CD8+T-, NK-, B-Cell, Dendritic Cell, and Monocyte Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation
de Koning, Coco; (...); Boelens, Jaap-Jan
Meeting Abstract. 2019
RAPID DETECTION OF THE TRANSCRIBED PML-RARA DIRECTLY IN RNA IN ONE STEP BY MEANS OF RETRO-TRANSCRIPTION LOOP MEDIATED AMPLIFICATION (RT-Q-LAMP)
Sargas, C.; (...); Barragan, E.
Meeting Abstract. 2019
Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin or Placebo Plus Standard Chemotherapy
Voso, MT; (...); Lo-Coco, F
Meeting Abstract. 10.1182/blood-2018-99-114318. 2018
Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA plus )
Falantes, J; (...); European ALMA?+?Investigators
Article. 10.1080/10428194.2017.1365854. 2018
Real life outcomes of patients aged =75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry.
Salamero O; (...); PETHEMA and PALG Groups
Article. 10.1080/10428194.2019.1607327. 2019
Real world evaluation of teclistamab in patients with RRMM: results from the IMF immunotherapy database project
Costa, Luciano; (...); Wong, Sandy
Meeting Abstract. 2023
Real-life clinical practice in Spain in the setting of new drug availability for ITP treatment. A Delphi-based Spanish expert panel consensus.
Gonzalez-Lopez, Tomas Jose; (...); Jarque, Isidro
Article. 10.1080/09537104.2024.2336104. 2024
Real-Life Evidence of Treatment with Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Saiz-Rodriguez, M; (...); Pethema Grp
Meeting Abstract. 2021
REAL-LIFE EVIDENCE OF VENETOCLAX TREATMENT IN PATIENTS WITH ACUTE REPLAPSE OR REFRACTORY LEUKEMIA MYELOID
Jorge, Labrador; (...); Pau, Montesinos
Meeting Abstract. 2021
Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study).
Abrisqueta, Pau; (...); Villanueva, Miguel
Article. 10.1016/j.clml.2021.07.022. 2021
Real-world effectiveness of caplacizumab vs standard of care in immune thrombotic thrombocytopenic purpura.
Pascual Izquierdo, Maria Cristina; (...); Del Rio-Garma, Julio
Article. 10.1182/bloodadvances.2022008028. 2022
Real-World Experience in Extracorporeal photopheresisfor adults with graft-versus-host disease.
Asensi Cantó P; (...); Gómez-Seguí I
Article. 10.1016/j.jtct.2023.09.001. 2023
Real-world experience with CPX-351 in high-risk acute myeloid leukemia.
Lemoli, Roberto M., Montesinos, Pau, Jain, Akriti
Article. 10.1016/j.critrevonc.2023.103984. 2023
Real-World Outcomes Using Front-Line Midostaurine in Combination with Intensive Chemotherapy for Patients Aged = 60 Years Old with FLT3 Mutated Acute Myeloid Leukemia
Requena, Gaspar Aspas; (...); Matinez-Cuadron, David
Meeting Abstract. 10.1182/blood-2023-190128. 2023
Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes
Sauta, Elisabetta; (...); Della Porta, Matteo G.
Meeting Abstract. 10.1182/blood-2022-163634. 2022
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
Sauta, Elisabetta; (...); Della Porta, Matteo Giovanni
Article. 10.1200/JCO.22.01784. 2023
Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY study.
Hernandez-Sanchez, Alberto; (...); Bullinger, Lars
Article. 10.1038/s41375-024-02333-4. 2024
Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications - Results of the Harmony Alliance AML Database
Hernandez Sanchez, Alberto; (...); Bullinger, Lars
Meeting Abstract. 10.1182/blood-2022-167480. 2022
Reasons for noncompliance with the national guidelines for initial antiretroviral therapy of HIV-infected patients in Spain, 2010-2015
Gonzalez, J; (...); Cohort Spanish HIV Res Network Co
Article. 10.1016/j.eimc.2019.02.007. 2019
Recent advances in allogeneic transplantation for acute myeloid leukemia.
Montoro J, Balaguer-Roselló A, Sanz J
Article. 10.1097/CCO.0000000000000992. 2023
Reciprocal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemias: review of 5,654 patients with an evaluable karyotype.
Costa D; (...); Nomdedeu B
Article. 10.1002/gcc.22071. 2013
Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI).
Mingot-Castellano, Maria Eva; (...); Pascual-Izquierdo, Cristina
Article. 10.3390/jcm12206422. 2023
Recommendations for the diagnosis and treatment of patients with thrombotic thrombocytopenic purpura.
Mingot Castellano, Maria Eva; (...); Grp Espanol Aferesis GEA
Practice Guideline. 10.1016/j.medcli.2021.03.040. 2022
Recommendations for the study of monoclonal gammopathies in the clinical laboratory. A consensus of the Spanish Society of Laboratory Medicine and the Spanish Society of Hematology and Hemotherapy. Part I: update on laboratory tests for the study of monoclonal gammopathies.
Cardenas, Maria C.; (...); Cruz-Iglesias, Elena
Article. 10.1515/cclm-2023-0326. 2023
Recommendations for the study of monoclonal gammopathies in the clinical laboratory. A consensus of the Spanish Society of Laboratory Medicine and the Spanish Society of Hematology and Hemotherapy. Part II: methodological and clinical recommendations for the diagnosis and follow-up of monoclonal gammopathies
Cardenas, Maria C.; (...); Cruz-Iglesias, Elena
Article. 10.1515/cclm-2023-0325. 2023
Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease
Lakhwani, Sunil; (...); Hernandez, Miguel-Teodoro
Meeting Abstract. 10.1182/blood-2022-167247. 2022
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.
Lakhwani S; (...); Hernández MT
Article. 10.3324/haematol.2023.284154. 2024
Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients.
Spyridonidis A; (...); Mohty M
Article. 10.1038/s41409-020-0803-y. 2020
REDEFINING OUTCOMES IN IMMUNE TTP: AN INTERNATIONAL WORKING GROUP CONSENSUS REPORT.
Cuker A; (...); Scully M
Article. 10.1182/blood.2020009150. 2021
Reduced incidence of neurologic complications after allogeneic hematopoietic stem cell transplantation with calcineurin-free graft-versus-host disease prophylaxis.
Balaguer-Rosello, Aitana; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2023.07.008. 2023
Reduced Intensity (RIC) vs Myeloablative Conditioning (MAC) in Cord Blood Transplantation for AML (40-60 Years) Across Mismatched HLA Barriers - Analysis by Ctiwp/eurocord of EBMT
Sheth, V; (...); Ruggeri, A
Meeting Abstract. 2020
Reduced Levels of miR-145-3p Drive Cell Cycle Progression in Advanced High-Grade Serous Ovarian Cancer
Gonzalez-Canto, Eva; (...); Mari-Alexandre, Josep
Article. 10.3390/cells13221904. 2024
Reduced SLIT2 is Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in Acute Promyelocytic Leukemia.
Weinhäuser I; (...); Rego EM
Article. 10.3390/cancers12113134. 2020
Reduced-Intensity Conditioning With Fludarabine and Busulfan Versus Fludarabine and Melphalan for Patients With Acute Myeloid Leukemia: A Report From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Baron F; (...); Mohty M
Article. 10.1002/cncr.29163. 2015
Reduced-Intensity Versus Myeloablative Conditioning for Unrelated Cord Blood Transplantation in Adults with Acute Leukemia: A Report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy & Immunobiology Working Party of the European Group for Blood and Marrow Transplantation
Baron, Frederic; (...); Nagler, Arnon
Article. 2015
Reduced-Intensity versus Myeloablative Conditioning in Cord Blood Transplantation for Acute Myeloid Leukemia (40-60 years) across Highly Mismatched HLA Barriers-On Behalf of Eurocord and the Cellular Therapy & Immunobiology Working Party (CTIWP) of EBMT.
Sheth V; (...); Ruggeri A
Article. 10.1016/j.bbmt.2020.07.025. 2020
Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma.
Puig, Noemi; (...); Paiva, Bruno
Article. 10.3390/cancers13194924. 2021
Regions of homozygosity confer a worse prognostic impact in myelodysplastic syndrome with normal karyotype.
Mallo, Mar; (...); Sole, Francesc
Article. 10.1002/jha2.651. 2023
Relapse Prevention in Acute Myeloid Leukemia: The Role of Immunotherapy with Histamine Dihydrochloride and Low-Dose Interleukin-2.
Montesinos, Pau; (...); Heuser, Michael
Article. 10.3390/cancers16101824. 2024
Relationship of immunohistochemistry, copy number aberrations and epigenetic disorders with BRCAness pattern in hereditary and sporadic breast cancer
Estal, RM; (...); Gilabert, PB
Article. 10.1007/s10689-015-9864-2. 2016
Relevancia de la anfotericina B liposomal en el tratamiento de las infecciones fúngicas invasoras en pacientes oncohematológicos.
García-Vidal C, Vázquez L, Jarque I
Article. 10.1016/j.riam.2021.03.001. 2021
RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group.
Bastos-Oreiro M; (...); López-Guillermo A
Article. 10.1007/s00277-020-03918-6. 2020
REMOVAL OF GERMINAL LINE MUTATIONS IN PATIENTS WITH MDS AND AML: WHO SHOULD BE PERFORMED?
Santiago, Marta; (...); Cervera, Jose
Meeting Abstract. 2020
Renal response to rescue treatments in Relapsed Refractory Multiple Myeloma (RRMM) patients with renal impairment: final data of a large, observational, prospective study (MIR50)
Garcia-Guinon, Antonio; (...); de la Rubia, Javier
Meeting Abstract. 2021
Reply.
Lozano Almela, Maria Luisa, Sanz Alonso, Miguel Angel, Vicente Garcia, Vicente
Letter. 10.1016/j.medcli.2021.09.029. 2022
RESCUE TREATMENT WITH DECITABINE AFTER PROGRESSION TO AZACITIDINE IN AML
De la Fuente, A; (...); Montesinos, P
Meeting Abstract. 2018
RESPONSE TO AZACITIDINE IN A SERIES OF 94 PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA FROM THE SPANISH GROUP OF MYELODYSPLASTIC SYNDROMES
Triguero, A; (...); Sanz, G
Meeting Abstract. 10.1016/S0145-2126(17)30232-1. 2017
Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria*
Triguero, A.; (...); Sanz, G.
Article. 10.1016/j.leukres.2022.106836. 2022
Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia
Xicoy B; (...); Sanz G
Article. 10.1111/ejh.12679. 2016
Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.
Mallo M; (...); Solé F
Article. 10.1111/bjh.12354. 2013
Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 302 Patients with Relapsed or Refractory (r/r) Acute Myeloid Leukemia after Intensive Chemotherapy (ASTRAL-2 Study)
Roboz, Gail J.; (...); Dohner, Hartmut
Meeting Abstract. 10.1182/blood-2021-147769. 2021
Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)
Kantarjian, Hagop M.; (...); Chiao, Judy H.
Article. 10.1002/cncr.33828. 2021
Results of allogeneic stem cell transplantation in the Spanish MDS registry: Prognostic factors for low risk patients
Díez Campelo M; (...); Spanish Registry of MDS
Article. 10.1016/j.leukres.2014.07.009. 2014
RESULTS OF HLA IDENTICAL ALLOGENIC TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE VERSUS HAPLOIDENTIAL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: EXPERIENCE OF THE SPANISH HAEMATOPOIETIC TRANSPLANT GROUP (GETH)
Almorox Rebeca, Bailen; (...); Mi, Kwon
Meeting Abstract. 2021
Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain.
Torrent, Anna; (...); Ribera, Josep-Maria
Article. 10.1111/ejh.14031. 2023
Results of the Ebmt Saawp Phase III Prospective Randomized Multicenter Race Study of Horse Atg and Ciclosporin with or Without Eltrombopag in Naive Saa Patients
de Latour, RP; (...); Risitano, A
Meeting Abstract. 2020
RESULTS OF THE PEGASUS PHASE III TRIAL FOR THE COMPARISON OF PEGCETACOPLAN WITH ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Jarque, Isidro; (...); Peffault, de latour Regis
Meeting Abstract. 2020
RESULTS OF THE TREATMENT OF LYMPHOBLASTIC LYMPHOMA WITH PROTOCOLS OF LYMPHOBLASTIC ACUTE LEUKEMIA OF PETHEMA GROUP
Sagues, M.; (...); Ribera, J. M.
Meeting Abstract. 2019
Results of treatment with azacitidine in patients aged >= 75 years included in the Spanish Registry of Myelodysplastic Syndromes
Xicoy B; (...); Sanz G
Article. 10.3109/10428194.2013.834532. 2014
Results of two protocols for platelet transfusion in patients undergoing abo incompatible hematopoietic stem cell transplantation
Letter. 10.1016/j.transci.2019.02.002. 2019
RETROSPECTIVE CONTROL CASE STUDY ON THE EFFICACY OF AUTOLOGOUS TRANSPLANTATION OF HAEMATOPOIETIC PROGENITORS IN THE FIRST LINE TREATMENT OF PATIENTS WITH PERIPHERAL T CELL LYMPHOMA
Parra, ML; (...); Martin, A. A.
Meeting Abstract. 2017
RETROSPECTIVE STUDY OF AZACITIDINE IN PATIENTS OF ADVANCED AGE WITH ACUTE MYELOID LEUKEMIA (LMA). RESULTS OF THE ALMA/ PETHEMA COHORT IN COMPARISON WITH THE MRC RISK INDEX SCORE
Falantes, J.; (...); Ramos, F.
Meeting Abstract. 2015
Revealing the mutational landscape of acute promyelocytic leukemia
Editorial Material. 10.21037/tcr.2017.02.47. 2017
Review of Cutaneous Graft-vs-Host Disease.
Ballester-Sánchez R; (...); Botella-Estrada R
Article. 10.1016/j.ad.2015.10.003. 2016
Revisiting Co-existing Chromosomal Abnormalities in NPM1-mutated AML in Light of the Revised ELN 2022 classification.
Angenendt, Linus; (...); Schliemann, Christoph
Article. 10.1182/blood.2022018582. 2022
RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT
Baron, F; (...); Nagler, A
Article. 10.18632/oncotarget.9599. 2016
Risk factors and outcomes of follicular lymphoma after allogeneic hematopoietic stem cell transplantation using HLA-matched sibling, unrelated, and haploidentical-related donors.
Montoro, Juan; (...); Pinana, Jose Luis
Letter. 10.1038/s41409-020-01161-1. 2020
Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Tucunduva L; (...); Rocha V
Article. 10.1038/bmt.2014.72. 2014
Risk of Rh (D) alloimmunisation after Rh (D) positive platelet transfusions in patients undergoing haematopoietic stem cell transplantation
Letter. 10.1111/tme.12179. 2015
Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients
Ribera, Josep-Maria; (...); Sancho, Juan-Manuel
Meeting Abstract. 10.1182/blood-2019-125683. 2019
Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia.
Abrisqueta P; (...); Bosch F
Article. 10.1182/blood-2013-05-502773. 2013
RNA Sequencing Analysis for the Identification of a PCM1/PDGFRB Fusion Gene Responsive to Imatinib
Such, E; (...); Cervera, J
Article. 10.1159/000497348. 2019
Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era.
Mussetti, Alberto; (...); Sureda, Anna
Article. 10.1038/s41409-023-01949-x. 2023
Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Large B-Cell Lymphomas in the CART Era
Mussetti, Alberto; (...); Sureda, Anna
Meeting Abstract. 10.1182/blood-2022-160000. 2022
Role of Allogeneic Stem Cell Transplantation in Preventing Relapse in Adult BCR::ABL1-like Acute Lymphoblastic Leukemia
Ribera, Jordi; (...); Ribera, Josep-Maria
Meeting Abstract. 10.1182/blood-2023-186265. 2023
Role of Hematopoietic Stem Cell Transplantation in Acute Promyelocytic Leukemia.
Sanz, Jaime, Montesinos, Pau, Sanz, Miguel A
Review. 10.3389/fonc.2021.614215. 2021
Role of Measurable Residual Disease (MRD) in Redefining Complete Response (CR) in Elderly Patients with Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial
Paiva, B; (...); Montesinos, P
Meeting Abstract. 10.1182/blood-2018-99-113299. 2018
Role of microRNAs in the pathogenesis of melanoma
Murria, Rosa; (...); Botella, Rafael
Meeting Abstract. 2017
Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives.
Pinto-Merino, Alvaro; (...); Saiz-Rodriguez, Miriam
Article. 10.3390/pharmaceutics14030559. 2022
Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia
Robak, Tadeusz; (...); Jolles, Stephen
Meeting Abstract. 10.1182/blood-2019-129839. 2019
Ruxolitinib for foreign body reaction to silicone in a patient with chronic graft-versus-host disease.
Palacios-Diaz, Rodolfo David; (...); Botella-Estrada, Rafael
Letter. 10.1111/ijd.17365. 2024
RUXOLITINIB IN ACUTE AND CHRONIC GRAFT-VERSUS RECEPTOR DISEASE: LONG-TERM REAL-LIFE EXPERIENCE IN A MULTI-CENTRE STUDY IN PEDIATRIC POPULATION
Escamilla Gomez, Virginia; (...); Garcia Gutierrez, Valentin
Meeting Abstract. 2024
Ruxolitinib in Acute and Chronic Graft-Versus-Host Disease: Real Life Experience in a Multi-Centre Study
Escamilla Gomez, Virginia; (...); Perez-Simon, Jose A.
Meeting Abstract. 10.1182/blood-2022-164561. 2022
RUXOLITINIB IN ACUTE AND CHRONIC GRAFT-VERSUS-RECEPTOR DISEASE: LONG-TERM REAL-LIFE EXPERIENCE IN A MULTI-CENTRE STUDY
Escamilla Gomez, Virginia; (...); Perez-Simon, Jose Antonio
Meeting Abstract. 2024
Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study.
Escamilla Gómez V; (...); Pérez-Simón JA
Article. 10.1038/s41409-019-0731-x. 2020
Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program
Zeidan, Amer M.; (...); Garcia-Manero, Guillermo
Meeting Abstract. 10.1182/blood-2021-145626. 2021
Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia
Daver, Naval; (...); Sweet, Kendra
Meeting Abstract. 10.1182/blood-2021-146503. 2021
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study.
Montesinos P; (...); Wei AH
Article. 10.1038/s41375-020-0773-5. 2020
Safety and efficacy of the BCR inhibitors after allogeneic stem cell transplantation for CLL
Yanez, L; (...); Bosch, F
Meeting Abstract. 2019
Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review
Megias-Vericat, JE; (...); Montesinos, P
Review. 10.1007/s00277-018-3304-y. 2018
Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups
Vives, Susana; (...); PETHEMA Grp
Article. 10.3390/cancers16234028. 2024
Salvage Treatment with Novel Agents Is Preferable to Standard Chemotherapy in Patients with Large B-Cell Lymphoma Progressing after Chimeric Antigen Receptor T-Cell Therapy
Iacoboni, Gloria; (...); Abrisqueta, Pau
Meeting Abstract. 10.1182/blood-2022-169219. 2022
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders
Luis Pinana, Jose; (...); Navarro, David
Article. 10.1186/s13045-022-01275-7. 2022
SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC).
Piñana JL; (...); Sureda A
Article. 10.1002/ajh.26385. 2021
Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective.
Moles-Poveda, P; (...); Botella-Estrada, R
Article. 10.1016/j.ad.2017.11.003. 2018
Score to Guide Donor Choice in Haploidentical Stem Cell Transplant Using PostTransplant Cyclophosphamide for Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT
Sanz, Jaime; (...); Ciceri, Fabio
Meeting Abstract. 10.1182/blood-2023-180075. 2023
SCREENING FOR POTENTIAL THERAPEUTIC OPPORTUNITIES FOR B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WITH IKZF1 DELETIONS
Ribera, Jordi; (...); Ribera, Josep Maria
Meeting Abstract. 2020
Seasonal human coronaviruses respiratory tract infection in recipients of allogeneic hematopoietic stem cell transplantation.
Piñana JL; (...); Infectious Diseases Working Party of the European Society for Blood and Marrow T
Article. 10.1093/infdis/jiaa553. 2020
Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia
Kharfan-Dabaja, MA; (...); Mohty, M
Article. 10.1111/bjh.17426. 2021
SECOND ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT2) FOR PRIMARY GRAFT FAILURE IN PATIENTS WITH ACUTE LEUKEMIA IN REMISSION: ON BEHALF OF THE ALWP OF THE EBMT
Nagler, Arnon; (...); Mohty, Mohamad
Meeting Abstract. 2023
Secondary Acute Myeloid Leukemia from a Previous Chronic Myeloproliferative Neoplasm: A Study of Grelam-Chile Concerning Chilean Patients on Behalf of AML Pethema Registry
Espinoza, Marcela; (...); Martinez-Cuadron, David
Meeting Abstract. 10.1182/blood-2023-185288. 2023
Secondary and Therapy-Related Acute Promyelocytic Leukemia. Experience of the PETHEMA Registry
Montesinos, P; (...); GATLA Cooperative Grp
Meeting Abstract. 2017
Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: a long-term follow-up analysis from the Spanish GELTAMO registry
Jimenez-Ubieto, A; (...); Lahuerta, JJ
Letter. 10.1038/s41409-018-0096-6. 2018
Secondary neoplasms after umbilical cord blood transplantation. On behalf of eurocord and the european group for blood and marrow transplantation
El Ayoubi, H. Rafii; (...); Gluckman, E.
Meeting Abstract. 2022
Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option
Roman, E; (...); Gorriz, JL
Review. 10.1016/j.nefro.2017.01.006. 2017
SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial
Paoli, Alessandro; (...); Pellacani, Andrea
Meeting Abstract. 10.1182/blood-2021-150277. 2021
Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review.
Cortes JE; (...); Heuser M
Review. 10.1080/10428194.2020.1817445. 2020
Selective IgA Deficiency and Blood Component Transfusion: In Search of the Lost Evidence
Solves, Pilar; (...); de la Rubia, Javier
Article. 10.3390/hemato5020009. 2024
SEQUENCING OF THE EXOME IN THE RECALLING OR REFRACTORY AML
Simarro Claudia, Sargas; (...); Eva, Barragan
Meeting Abstract. 2021
Sequential systematic anti-mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation
Rosillo, C; (...); Perales, MA
Article. 10.1111/tid.12897. 2018
Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study
Stefania Infante, Maria; (...); Grande, Carlos
Article. 10.1002/cam4.4293. 2021
Severity of Covid-19 Clinical Outcomes and Mortality in Multiple Myeloma Patients over Year 1 of the Pandemic
Martinez-Lopez, Joaquin; (...); San-Miguel, Jesus F.
Meeting Abstract. 10.1182/blood-2021-149192. 2021
Sex differences in aortic prognosis in Marfan patients, a retrospective longitudinal study from the REPAG registry
Tura, G. Teixido; (...); Cabrera, F.
Meeting Abstract. 10.1093/eurheartj/ehae666.2264. 2024
Sex Differences in Opioid Response Linked to OPRM1 and COMT genes DNA Methylation/Genotypes Changes in Patients with Chronic Pain.
Agullo, Laura; (...); Peiro, Ana M.
Article. 10.3390/jcm12103449. 2023
Should we consider caplacizumab as routine treatment for acute thrombotic thrombocytopenic purpura? An expert perspective on the pros and cons.
Seguí IG; (...); de la Rubia J
Article. 10.1080/17474086.2024.2318347. 2024
Significance of Degree of HLA Disparity Using T-cell Replete Peripheral Blood Stem Cells From Haploidentical Donors With Posttransplantation Cyclophosphamide in AML in First Complete Hematologic Remission: A Study of the Acute Leukemia Working Party of the EBMT.
Kharfan-Dabaja, Mohamed A.; (...); Mohty, Mohamad
Article. 10.1097/HS9.0000000000000920. 2023
Similar Outcome of Adolescents and Young Adults (AYA) and Older Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) without Philadelphia Chromosome (Ph-) Included in the Pethema LAL-2019 Trial
Torrent, Anna; (...); Ribera, Josep-Maria
Meeting Abstract. 10.1182/blood-2024-207954. 2024
Simplified in-House Deep Sequencing Method of Inmunoglobulin Genes for Minimal Residual Dissease Quantification and Risk Stratification in Multiple Myeloma
Sanchez-Vega, Beatriz; (...); Martinez Lopez, Joaquin
Article. 2015
SINGLE CELL-LEVEL CHARACTERIZATION OF THE IMMUNE MICROENVIRONMENT OF MULTIPLE MYELOMA IDENTIFIES CD27 NEGATIVE T LYMPHOCYTES AS TUMOR SPECIFIC
Perez, Cristina; (...); Paiva, Bruno
Meeting Abstract. 2020
Single nucleotide polymorphism array karyotyping: a diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing.
Arenillas L; (...); Solé F
Article. 10.1002/gcc.22112. 2013
Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT
Baron, F; (...); Nagler, A
Article. 10.1186/s13045-017-0497-9. 2017
Single umbilical cord blood with or without CD34(+) cells from a third-party donor in adults with leukemia.
Sanz, J; (...); Grp Espanol Trasplante
Article. 10.1182/bloodadvances.2017006999. 2017
Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics: a retrospective study of the PETHEMA/Spanish Myeloma Group (GEM)
Villalba, Ana; (...); De la Rubia, Javier
Meeting Abstract. 2022
Single-Cell Characterization of Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-negative T cells as Potential Tumor-Reactive Lymphocytes
Botta, C; (...); Paiva, B
Meeting Abstract. 10.1016/j.clml.2019.09.581. 2019
Single-Nucleotide Polymorphism Array-Based Karyotyping of Acute Promyelocytic Leukemia
Gómez-Seguí I; (...); Sanz MA
Article. 10.1371/journal.pone.0100245. 2014
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high risk smoldering multiple myeloma included in the GEM-CESAR trial.
Puig N; (...); Mateos MV
Article. 10.3324/haematol.2024.285742. 2024
SINTRA-REV CLINICAL TRIAL: PRELIMINARY ANALYSIS OF EFFICACY AND SAFETY AT WEEK 12 OF TREATMENT IN MDS DEL(5Q) AND TRANSFUSION INDEPENDENCE
Cadenas, FL; (...); Diez-Campelo, M
Meeting Abstract. 2017
Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis.
Hernani, Rafael; (...); Solano, Carlos
Article. 10.1002/jha2.183. 2021
Sister chromatid exchange, (SCE), High-Frequency Cells (HFCs) and SCE distribution patterns in peripheral blood lymphocytes of Spanish adult smokers compared to non-smokers
Sebastià N; (...); Montoro A
Article. 10.1016/j.fct.2014.01.011. 2014
SJOGREN-LARSSON SYNDROME IN TWO SISTERS WITH AN INTRONIC VARIANT OF ALDH3A2 GENE: CLINICAL FINDINGS
Fernandez, F.; (...); Cervera, J.
Meeting Abstract. 2019
Slit-Robo Pathway Is Clinically Relevant and May Represent a Potential Target in Acute Promyelocytic Leukemia
Weinhauser, I; (...); Rego, EM
Meeting Abstract. 10.1182/blood-2018-99-115370. 2018
Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML.
Risueno, Alberto; (...); Hasan, Maroof
Article. 10.1016/j.leukres.2024.107497. 2024
Somatic Genetic and Epigenetic Architecture of Myelodysplastic Syndromes Arising from GATA2 Deficiency
Loyola, Victor Bengt Pastor; (...); Wlodarski, Marcin W.
Article. 2015
Spanish consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria
Villegas A; (...); Urbano-Ispizua Á
Editorial Material. 10.1016/j.medcli.2015.12.012. 2016
Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia.
Palomo L; (...); Such E
Article. 10.1111/bjh.16175. 2020
Spanish registry of hemoglobinopathies and rare anemias (REHem-AR): demographics, complications, and management of patients with ß-thalassemia.
Bardón-Cancho EJ; (...); Cela E
Article. 10.1007/s00277-024-05694-z. 2024
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts
Zeidan, AM; (...); Mascarenhas, J
Review. 10.1016/S2352-3026(20)30205-2. 2020
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.
Shallis RM; (...); Zeidan AM
Article. 10.1016/S2352-3026(23)00159-X. 2023
Starkeya nomas sp. nov., a prosthecate and budding bacterium isolated from an immunocompromized patient.
Sahuquillo-Arce JM; (...); López-Hontangas JL
Article. 10.1099/ijsem.0.005805. 2023
STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453)+azacitidine in higher risk MDS and CMML-2.
Zeidan AM; (...); Santini V
Article. 10.2217/fon-2022-1237. 2023
STUDY OF MUTATIONAL PROFILE AND CORRELATION OF RESPONSE TO EX VIVO PHARMACOLOGICAL TEST, IN THE DIAGNOSTIC OF THE AML
de la Fuente, EO; (...); Diaz, RA
Meeting Abstract. 2018
STUDY OF PRE-EXISTING MUTATIONS IN HEMATOPOYETIC CELLS OF THE BONE MEDULA IN PATIENTS WITH MYELOID NEOPLASIAS RELATED TO THERAPY
Ibanez, M; (...); Sanz, G
Meeting Abstract. 2017
STUDY OF THE CELL POPULATIONS INFUSED IN THE TRANSPLANT ALOGENICO OF BROTHER HLA-IDENTICAL
Villalba, A.; (...); Sanz, M. A.
Meeting Abstract. 2017
STUDY OF THE CLINICAL RELEVANCE AND GENOMIC PROFILE OF MINIMAL RESIDUAL MULTIPLE MYELOMA DISEASE IN PATIENTS WITH STANDARD RISK AND HIGH CYTOGENETIC RISK
Goicoechea, I; (...); Paiva, B.
Meeting Abstract. 2019
STUDY OF THE EFFECTIVENESS OF IMATINIB IN CHRONIC GRAFT-VERSUS-HOST DISEASE IN A SERIES OF 19 CASES
Poveda, PM; (...); Caballer, JS
Meeting Abstract. 2017
Study of the S427G polymorphism and of MYBL2 variants in patients with acute myeloid leukemia
Dolz S; (...); Barragán E
Article. 10.3109/10428194.2015.1049167. 2016
STUDY OF TRANSCRIPTIONAL DIFFERENCES BETWEEN THE IDH2 R140 AND R172 MUTATIONS BY MEANS OF MODELING IN THE ORGANISM CAENORHABDITIS ELEGANS
Gonzalez, Romero Elisa; (...); Cervera, Jose Vicente
Meeting Abstract. 2020
Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia
González-López TJ; (...); González-Porras JR
Article. 10.1002/ajh.23900. 2015
Summer Pruning, an Eco-Friendly Approach to Controlling Bitter Pit and Preserving Sensory Quality in Highly Vigorous Apple cv. 'Reinette du Canada'
Guerra, Marcos; (...); Antonio Casquero, Pedro
Article. 10.3390/agriculture11111081. 2021
SUPERIORITY OF THE BIOPSY OF BONE MARROW ON PET/TC IN THE PREDICTION OF THE FREE SURVIVAL OF PROGRESSION IN DIFFUSE LINFOMA B OF BIG CELL
Liang, THC; (...); Ortuno, F.
Meeting Abstract. 2017
Survival of hematological patients after discharge from the intensive care unit: a prospective observational study.
Bernal T; (...); Albaiceta GM
Article. 10.1186/cc13172. 2013
Survival of Patients with Acute Myeloid Leukemia According to Age in a University Hospital in Colombia
Melo, CLS; (...); Montesinos, P
Meeting Abstract. 2021
Survival of Patients with Acute Myeloid Leukemia, Taken to Hematopoietic Stem Cell Transplantation: Experience of A Center in Colombia
Melo, CLS; (...); Ortiz, MF
Meeting Abstract. 2021
Survival of Patients with Secondary Acute Myeloid Leukemia in a University Hospital in Colombia
Ortiz, MF; (...); Sossa, C
Meeting Abstract. 2021
Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy
Cortes, JE; (...); Heuser, M
Article. 10.1186/s13045-020-00929-8. 2020
Survival Outcomes for Patients (pts) in the QUAZAR AML-001 Trial Who Received Subsequent Therapy for Acute Myeloid Leukemia (AML) after Discontinuing Oral Azacitidine (Oral-AZA) or Placebo (PBO)
Pfeilstoecker, M.; (...); Doehner, H.
Meeting Abstract. 2023
Survival Outcomes for Patients in the QUAZAR AML-001 Trial Who Received Subsequent Therapy for Acute Myeloid Leukemia (AML) after Discontinuing Oral Azacitidine or Placebo
Ravandi, Farhad; (...); Doehner, Hartmut
Meeting Abstract. 10.1182/blood-2022-159045. 2022
Survival outcomes from the QUAZAR AML-001 trial with oral azacitidine (Oral-AZA) for patients with acute myeloid leukemia (AML) in remission by disease subtype, cytogenetic risk, and NPM1 mutation status at diagnosis (Dx)
Pfeilstoecker, Michael; (...); Menezes, Daniel
Meeting Abstract. 2022
Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001.
Ravandi, Farhad; (...); Roboz, Gail J
Article. 10.1111/bjh.19202. 2023
Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase 3 QUAZAR AML-001 trial.
Wei AH; (...); Ravandi F
Article. 10.3324/haematol.2022.282296. 2023
Sustained Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Discriminates Patients with Sustained Negative Minimal Residual Disease
Lakhwani, Sunil; (...); Teodoro Hernandez Garcia, Miguel
Meeting Abstract. 10.1182/blood-2023-179452. 2023
Syncope as a manifestation of mast cell activation disorder
Perales Chordá C; (...); Hernández Fernandez de Rojas D
Letter. 10.1016/j.anai.2014.11.019. 2015
Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia
Megías-Vericat JE; (...); Montesinos P
Review. 10.3390/pharmaceutics14040878. 2022
T Cell-Depleted Related HLA-Mismatched Peripheral Blood Stem Cell Transplantation as Salvage Therapy for Graft Failure after Single Unit Unrelated Donor Umbilical Cord Blood Transplantation
Moscardó F; (...); Sanz GF
Article. 10.1016/j.bbmt.2014.03.024. 2014
T lymphocytes as therapeutic arsenal for patients with hematological malignancies
Montoro, J; (...); Guerreiro, M
Review. 10.1097/CCO.0000000000000481. 2018
T REPLETE HAPLOIDENTICAL TRANSPLANTATION WITH POSTTRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH SECONDARY VERSUS DE NOVO AML: A STUDY FROM THE ALWP /EBMT
Nagler, Arnon; (...); Mohty, Mohamad
Meeting Abstract. 2023
t(1;19)(q23;p13) TCF3-PBX1 May Not Be an Intermediate-Risk Subtype in Adult B-Cell Precursor Acute Lymphoblastic Leukemia Patients Treated With MRD-Oriented Protocols from the PETHEMA Group
Ribera, J; (...); Ribera, JM
Meeting Abstract. 2021
Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide
Sanford D; (...); Cortes JE
Article. 10.1111/bjh.13607. 2015
Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia.
Martín-Sánchez E; (...); Zabaleta A
Article. 10.1182/bloodadvances.2024013212. 2024
TBI/fludarabine versus busulfan/fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allo-HCT. A study from the ALWP of the EBMT
Swoboda, R.; (...); Mohty, M.
Meeting Abstract. 2022
T-cell Depleted Peripheral Blood versus Unmanipulated Bone Marrow in Matched Sibling Transplantation for Aplastic Anemia.
Chorao, Pedro; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2023.01.016. 2023
T-cell-replete haploidentical transplantation versus autologous stem cell transplantation in adult acute leukemia: a matched pair analysis
Gorin NC; (...); Acute Leukemia Working Party of the European Society for Blood and Marrow Transp
Article. 10.3324/haematol.2014.111450. 2015
Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey
Pigneux, A; (...); Bruggemann, M
Article. 10.1186/s12885-018-5002-5. 2018
The addition of ofatumumab to the conditioning regimen does not improve the outcome of patients with high-risk CLL undergoing reduced intensity allogeneic haematopoietic cell transplantation: a pilot trial from the GETH and GELLC (CLL4 trial)
Montesinos, P; (...); Delgado, J
Letter. 10.1038/bmt.2016.145. 2016
The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation.
Piñana J; (...); Sanz J
Article. 10.1016/j.jinf.2019.12.022. 2020
The Clinical Spectrum, Diagnosis, and Management of GATA2 Deficiency.
Santiago, Marta; (...); Cervera, Jose
Article. 10.3390/cancers15051590. 2023
THE COMBINATION OF GENOMIC ANALYSIS AND MINIMAL RESIDUAL DISEASE IMPROVES THE STRATIFICATION OF ADULT PATIENTS WITH TYPE T-LYMPHOBLASTIC LEUKEMIA (LAL-T) TREATED ACCORDING TO THE PETHEMA PROTOCOLS
Gonzalez Gil, C.; (...); Genesca Ferrer, E.
Meeting Abstract. 2021
The Disease-Risk Stratification Scheme (DRSS), a Contemporary Risk-Stratification System for Allogeneic Stem Cell Transplantation.
Shouval R; (...); Nagler A
Meeting Abstract. 10.1182/blood-2019-123310. 2019
The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS
Xicoy, Blanca; (...); Sanz, Guillermo
Letter. 10.1016/j.leukres.2018.05.003. 2018
The effect of timing on community acquired respiratory virus infection mortality during the first year after allogeneic hematopoietic stem cell transplantation: a prospective epidemiological survey.
Piñana JL; (...); Navarro D
Article. 10.1038/s41409-019-0698-7. 2020
The experience of the International Consortium on Acute Promyelocytic Leukemia in monitoring minimal residual disease in acute promyelocytic leukaemia
Lange, AP; (...); Rego, EM
Letter. 10.1111/bjh.14490. 2018
The First Real-World Evidence Prospective Registry of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Tagraxofusp, a CD123-Targeted Therapy, in Europe
Platzbecker, Uwe; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2021-145099. 2021
The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi Trial
Mosquera Orgueira, Adrian; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2023-180482. 2023
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.
Medina-Herrera A; (...); Garcia-Sanz R
Article. 10.1038/s41408-024-01053-3. 2024
The Impact of Cytogenetic Risk on Outcome of Non-T Cell Depleted Haploidentical Stem Cell Transplantation in Relapsed/Refractory AML: A Study From The ALWP/EBMT
Nagler, A; (...); Mohty, M
Meeting Abstract. 2021
The Impact of DNMT3A Mutation on Survival of AML Patients Receiving Allogeneic Hematopoietic Cell Transplantation in First Remission Depends on the Karyotype and CoOccurring Mutations: On Behalf of the EBMT Acute Leukemia Working Party
Dalle, Abou; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2023-179531. 2023
The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Rubio MT; (...); Mohty M
Article. 10.3324/haematol.2014.119339. 2015
The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations.
Kanda, Junya; (...); Gluckman, Eliane
Article. 10.1038/s41409-021-01479-4. 2022
The Impact of GVHD on Outcomes After Adult Single Cord Blood Transplantation In European And Japanese Populations: The EUROCORD/ALWP EBMT And JSHCT/JDCHCT Collaborative Study
Kanda, J; (...); Gluckman, E
Meeting Abstract. 2021
The Interaction Between Collagen-Activated Platelets and Erythrocytes Selectively Increases the Release of Subsets of Platelet alpha-Granules Containing Pro-Angiogenic Substances
Teresa Santos, Maria; (...); Valles, Juana
Meeting Abstract. 2014
The International Network for Evaluating Outcomes (iNeo) of neonates: evolution, progress and opportunities
Shah, Prakesh S.; (...); Int Network Evaluating Outcomes iN
Review. 10.21037/tp.2019.07.06. 2019
THE LASTING RESPONSE OF ELTROMBOPAG IN PRIMARY PTI IS A PREDICTOR FOR THE PROBABILITY OF DISCONTINUING THE SUCCESS OF ELTROMBOPAG
Porras, JRG; (...); Bastida, J. M.
Meeting Abstract. 2017
The modular network structure of the mutational landscape of Acute Myeloid Leukemia
Ibanez, M; (...); Cervera, J
Article. 10.1371/journal.pone.0202926. 2018
THE MODULAR NETWORK STRUCTURE OF THE MUTATIONAL LANDSCAPE OF ACUTE MYELOID LEUKEMIA
Ibanez, M.; (...); Cervera, J.
Article. 2015
The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial
Ayala, R; (...); Montesinos, P
Article. 10.3390/cancers13102458. 2021
The Mutational Landscape of Acute Promyelocytic Leukemia Reveals an Interacting Network of Co-Occurrences and Recurrent Mutations
Ibáñez, M; (...); Cervera, J.
Article. 10.1371/journal.pone.0148346. 2016
The Oxygen Load Supplied during Delivery Room Stabilization of Preterm Infants Modifies the DNA Methylation Profile
Lorente-Pozo, Sheila; (...); Vento, Maximo
Article. 10.1016/j.jpeds.2018.07.009. 2018
The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients
Ribera, J; (...); Ribera, JM
Article. 10.1111/bjh.15887. 2019
The Post-CAR Prognostic Index (PC-PI): A New Prognostic Score to Predict Overall Survival in Large B-Cell Lymphoma Patients Progressing after Chimeric Antigen Receptor T-Cell Therapy
Lacoboni, Gloria; (...); Abrisqueta Costa, Pau
Meeting Abstract. 10.1182/blood-2023-184942. 2023
The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis
Hernandez-Sanchez, Alberto; (...); Hernandez-Boluda, Juan Carlos
Letter. 10.1002/ajh.27203. 2024
The QUAZAR AML-001 maintenance trial: Results of a phase III international, randomized, double-blind, placebo-controlled study of oral CC-486 in patients with Acute Myeloid Leukemia (AML) in first remission
Dohner, H; (...); Roboz, GJ
Meeting Abstract. 2020
The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
McGraw KL; (...); List AF
Article. 10.1038/bcj.2015.11. 2015
The Relevance of Minimal Residual Disease (MRD) Monitoring in Elderly Multiple Myeloma (MM) Patients
Paiva, Bruno; (...); San Miguel, Jesus
Meeting Abstract. 2015
The reliability of bone marrow cytology as response criterion in metastatic neuroblastoma.
Schumacher-Kuckelkorn R; (...); Berthold F
Article. 10.1002/pbc.28819. 2021
The Role of ADAMTS13 Activity Levels on Disease Exacerbation or Relapse in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of the Phase 3 HERCULES and Post-HERCULES Studies
Strebel, Johanna A. Kremer Hovinga; (...); Scully, Marie
Meeting Abstract. 10.1182/blood-2022-156306. 2022
The role of bone marrow biopsy and FDG-PET/CT in identifying bone marrow infiltration in the initial diagnosis of high grade non-Hodgkin B-cell lymphoma and Hodgkin lymphoma. accuracy in a multicenter series of 372 patients
Chen-Liang TH; (...); Ortuño FJ
Article. 10.1002/ajh.24044. 2015
The role of phototherapy in cutaneous chronic graft-vs-host disease: a retrospective study and review of the literature.
Ballester-Sánchez R; (...); Botella-Estrada R
Article. 10.1016/j.ad.2015.04.009. 2015
The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients.
Villar, Sara; (...); Montesinos, Pau
Article. 10.3389/fonc.2022.1054458. 2022
The Value of Bone Marrow Assessment by FDG PET/CT, Biopsy and Aspirate in the Upfront Evaluation of Mantle Cell Lymphoma: A Nationwide Cohort Study
Quinonero, Isabel Rodenas; (...); Ortuno, Francisco Jose
Article. 10.3390/cancers16244189. 2024
Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS
Kuendgen, A; (...); Sanz, G
Meeting Abstract. 10.1182/blood-2018-99-118215. 2018
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.
Kuendgen A; (...); Sanz G
Article. 10.1038/s41375-020-0917-7. 2020
Thiotepa-based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemia-A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Eder, S; (...); Nagler, A
Article. 10.1002/ajh.24567. 2017
Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Eder S; (...); Nagler A
Article. 10.1002/ajh.24823. 2017
Thiotepa-based reduced-intensity conditioning are a valid alternative to total-body irradiation-based regimens in patients with acute lymphoblastic leukemia: A study of the alwp of the ebmt
Battipaglia, G.; (...); Mohty, M.
Meeting Abstract. 2022
Thiotepa-Based Regimens Are Valid Alternatives to Total Body Irradiation-Based Reduced-Intensity Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Battipaglia, Giorgia; (...); Mohty, Mohamad
Article. 10.1016/j.jtct.2023.09.028. 2024
THROMBOTIC EVENTS IN PATIENTS WITH PTI TREATED WITH THROMBOPOIETIN RECEPTOR AGONISTS. IDENTIFICATION OF PREDISPOSING FACTORS
Lozano Almela, M. L.; (...); Vicente, V.
Meeting Abstract. 2019
Thyroid hormone biosynthesis machinery is altered in the ischemic myocardium: An epigenomic study
Gil-Cayuela, C; (...); Portoles, M
Article. 10.1016/j.ijcard.2017.05.042. 2017
Time and Cost of Hospitalisation for Salvage Therapy in Adults with Philadelphia Chromosome-Negative B Cell Precursor Relapsed or Refractory Acute Lymphoblastic Leukaemia in Spain
Boluda, B; (...); Montesinos, P
Article. 10.1007/s41669-018-0098-8. 2019
Time-dependent changes in mortality and transformation risk in MDS
Pfeilstocker, M; (...); Greenberg, PL
Article. 10.1182/blood-2016-02-700054. 2016
Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia.
Jonas, Brian A.; (...); Ofran, Yishai
Article. 10.1002/ajh.26600. 2022
TMPRSS4 protein overexpression and its promoter hypomethylation predict poor prognosis in squamous lung cancer patients
Villalba, M.; (...); Calvo, A.
Meeting Abstract. 10.1016/S0959-8049(16)61038-9. 2016
Torque Teno Virus plasma DNA load: a novel prognostic biomarker in CAR-T therapy
Benzaquen, Ana; (...); Solano, Carlos
Article. 10.1038/s41409-023-02114-0. 2024
TORQUE TENO VIRUS PLASMA DNA LOAD: A NOVEL PROGNOSTIC BIOMARKER IN CAR-T THERAPY
Hernani, Rafael; (...); Solano, Carlos
Meeting Abstract. 2023
Total body irradiation versus thiotepa/busulfan-based conditioning regimens for myeloablative allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia.
Article. 10.1038/s41409-024-02298-z. 2024
Towarda more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS).
Efficace, Fabio; (...); Zeidan, Amer M
Article. 10.1002/hem3.69. 2024
Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS
De La Serna, J; (...); Spanish Hematopoietic Transplant
Article. 10.1038/bmt.2016.42. 2016
TP53 ALLELIC STATE DID NOT INFLUENCE THE PROGNOSIS IN MYELODYSPLASTIC SYNDROMES (MDS) WITH 5Q DELETION
Montoro, M. J.; (...); Valcarcel, D.
Meeting Abstract. 10.1016/j.leukres.2023.107187. 2023
TP53 Allelic State in Myelodysplastic Syndromes with 5q Deletion
Montoro Gomez, Maria Julia; (...); Valcarcel, David
Meeting Abstract. 10.1182/blood-2022-165257. 2022
TP53 Gene allelic State in Myelodysplastic Syndromes (MDS) with Isolated 5q Deletion
Montoro, Julia; (...); Valcarcel, David
Meeting Abstract. 10.1182/blood-2023-179171. 2023
TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes
Bernard, Elsa; (...); Papaemmanuil, Elli
Meeting Abstract. 10.1182/blood-2019-129392. 2019
Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)
Patricia Simoes, Catia; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2022-163159. 2022
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia.
Simoes, Catia; (...); Montesinos, Pau
Letter. 10.1111/bjh.18815. 2023
TRANSCRIPTIONAL CHARACTERIZATION OF ACUTE MYELOID LEUKEMIA AT DIAGNOSIS IN THE ELDERLY PATIENT WITH IDENTIFICATION OF NEW PROGNOSTIC GROUPS
Sara, Villar; (...); Pau, Montesinos
Meeting Abstract. 2021
TRANSCRIPTOMICAL ANALYSIS AND MODELING IN C.ELEGANS OF THE IDH2 R140 R172 MUTATION
Gonzalez-Romero, E.; (...); Cervera-Zamora, J., V
Meeting Abstract. 2019
Transfusion Burden in Allogeneic Hematopoietic Stem Cell Transplantation over Time: Experience from a Single Institution.
Solves, Pilar; (...); Sanz, Jaime
Article. 10.3390/jcm12103467. 2023
Transfusion Management and Immunohematologic Complications in Liver Transplantation: Experience of a Single Institution
Article. 10.1159/000370260. 2015
Transfusion management in multiple myeloma patients receiving daratumumab: Experience of a single tertiary care centre.
Solves P; (...); Carpio N
Article. 10.1016/j.transci.2019.09.011. 2020
Transfusion of ABO non-identical platelets does not influence the clinical outcome of patients undergoing autologous haematopoietic stem cell transplantation
Article. 10.2450/2015.0195-14. 2015
TRANSFUSIONAL REQUIREMENTS OF PATIENTS UNDERGOING TRANSPLANTATION OF HAEMATOPOIETIC PROGENITORS OF DIFFERENT SOURCES
Blanco, JA; (...); Alonso, MAS
Meeting Abstract. 2018
Translating cancer epigenomics into the clinic: focus on lung cancer
Mari-Alexandre, J; (...); Sandoval, J
Review. 10.1016/j.trsl.2017.05.008. 2017
Translation of a tissue epigenetic signature to circulating free DNA suggests BCAT1 as a potential noninvasive diagnostic biomarker for lung cancer
Palanca-Ballester, Cora; (...); Sandoval, Juan
Article. 10.1186/s13148-022-01334-3. 2022
TRANSLOCATIONS IN THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: REVIEW OF 69 PATIENTS FROM THE SPANISH SMD GROUP DATABASE WITH AN EVALUABLE KARYOTYPE
Grau, Javier; (...); Granada, Isabel
Meeting Abstract. 2020
Treatment of acute promyelocytic leukemia in older patients: recommendations of an International Society of Geriatric Oncology (SIOG) task force.
Klepin HD; (...); Cordoba R
Review. 10.1016/j.jgo.2020.03.019. 2020
Treatment of Frail Older Adults and Elderly Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia: Results of a Prospective Trial With Minimal Chemotherapy
Ribera, JM; (...); Spanish Soc Hematology
Article. 10.1016/j.clml.2020.03.011. 2020
Treatment of High-Risk Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial
Ribera JM; (...); Feliu E
Article. 10.1200/JCO.2013.52.2425. 2014
Treatment of invasive fungal disease using anidulafungin alone or in combination for hematologic patients with concomitant hepatic or renal impairment
Montesinos P; (...); Sanz MÁ
Article. 10.1016/j.riam.2014.10.003. 2015
Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy.
Iacoboni, Gloria; (...); Kuhnl, Andrea
Article. 10.1002/hem3.62. 2024
Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic Registry
Martinez-Cuadron, David; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2023-189800. 2023
Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma
Cejalvo, MJ; (...); de la Rubia, J
Article. 10.1007/s00277-021-04529-5. 2021
Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study.
Lloret-Madrid, Pilar; (...); Montesinos, Pau
Article. 10.1002/cncr.35696. 2025
Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study.
Martínez-Cuadrón D; (...); Montesinos P
Article. 10.1182/bloodadvances.2021005335. 2022
Treatment Patterns and Overall Survival in Patients with Intermediate-Risk MDS: A Retrospective Analysis in the Spanish MDS Registry
Diez-Campelo, Maria; (...); Valcarcel, David
Meeting Abstract. 10.1182/blood-2021-146019. 2021
Trends and Predictive Factors for Outcome of Relapsed Acute Myeloid Leukemia After Allogeneic Hematopoeitic Cell Transplant: Improved Survival for Young Patients in Recent Years
Bazarbachi, A; (...); Mohty, M
Meeting Abstract. 2020
TRENDS IN THE USE OF HEMATOPOIETIC CELL TRANSPLANTATION FOR ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: A REPORT FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT
Giebel, Sebastian; (...); Ciceri, Fabio
Meeting Abstract. 10.1007/s00277-019-03771-2. 2024
TYK2 Variants in B-Acute Lymphoblastic Leukaemia.
Turrubiartes-Martínez E; (...); Fernández-Ruiz E
Article. 10.3390/genes11121434. 2020
Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?
Megías-Vericat JE; (...); Montesinos P
Review. 10.1016/j.blre.2020.100675. 2020
UBA1 Mutations Identify a Rare but Distinct Subtype of Myelodysplastic Syndromes
Sirenko, Maria; (...); Papaemmanuil, Elli
Meeting Abstract. 10.1182/blood-2023-182949. 2023
Umbilical Cord Blood Transplantation for Fanconi Anemia With a Special Focus on Late Complications: a Study on Behalf of Eurocord and SAAWP-EBMT.
Rafii H; (...); Gluckman E
Article. 10.1016/j.jtct.2024.02.024. 2024
Umbilical Cord Blood Transplantation for Secondary AML: A Retrospective Study From the Acute Leukemia Working Party of the Ebmt and Eurocord
Baron, Frederic; (...); Nagler, Arnon
Meeting Abstract. 2018
Umbilical cord blood transplantation from unrelated donors in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Piñana JL; (...); GITMO groups
Article. 10.3324/haematol.2013.091009. 2014
Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease
Piñana JL; (...); GETH GITMO groups
Article. 10.1111/ejh.12557. 2016
Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT
Baron, F; (...); Nagler, A
Article. 10.1038/s41408-019-0204-x. 2019
Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors.
Article. 10.1038/s41409-020-0921-6. 2020
Unique clinico-biological, genetic and prognostic features of adult early T cell precursor acute lymphoblastic leukemia.
Genescà E; (...); Ribera JM
Letter. 10.3324/haematol.2019.225078. 2020
Unraveling IKZF1 Deletion Therapeutic Vulnerabilities in Adult B-Cell Precursor Acute Lymphoblastic Leukemia
Ribera, Jordi; (...); Maria Ribera, Josep
Meeting Abstract. 2020
Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood-a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation
Baron F; (...); Nagler A
Article. 10.1186/s13045-015-0207-4. 2015
Unrelated Cord Blood Transplantation for Patients with Primary or Secondary Myelofibrosis
Robin M; (...); Eurocord and Chronic Malignancies Working Party-European Group for Blood and Mar
Article. 10.1016/j.bbmt.2014.06.011. 2014
UNRELATED DONOR SELECTION FOR STEM CELL TRANSPLANT USING POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR ACUTE MYELOID LEUKEMIA: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT
Sanz, Jaime; (...); Ciceri, Fabio
Meeting Abstract. 2024
Unrelated or haploidentical allogeneic hematopoietic cell transplantation in second complete remission for acute myeloid leukemia-Improved outcomes over time: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party study.
Al Hamed, Rama; (...); Mohty, Mohamad
Article. 10.1002/cncr.34843. 2023
Update of the Grupo Espanol de Leucemia Linfocitica Cronica clinical guidelines of the management of chronic lymphocytic leukemia
Garcia-Marco, JA; (...); Bosch, F
Editorial Material. 10.1016/j.medcli.2016.12.030. 2017
Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Erba, Harry P.; (...); Wang, Eunice S.
Meeting Abstract. 10.1182/blood-2022-167412. 2022
Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus.
Montesinos P; (...); Sanz MÁ
Article. 10.1007/s00277-019-03820-w. 2019
Updated efficacy and safety data from the AGILE study in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib plus azacitidine compared to placebo plus azacitidine.
De Botton, Stephane; (...); Dohner, Hartmut
Meeting Abstract. 2023
Updated efficacy and safety data from the AGILE study in patients with newly-diagnosed acute myeloid leukemia treated with ivosidenib plus azacitidine compared to placebo plus azacitidine
Heuser, M.; (...); Doehner, H.
Meeting Abstract. 2023
Updated results from DIAMOND-01 (CLI24-001) trial: A phase I/II study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in acute myeloid leukemia.
Solomon, Scott R.; (...); Ravandi, Farhad
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.7023. 2021
Updated Results of a Phase 2 Study from GELTAMO Investigating the Combination of Ibrutinib with R-GEMOX in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bua, BR; (...); Garcia-Sancho, AM
Meeting Abstract. 2021
Upper and/or Lower Respiratory Tract Infection Caused by Human Coronavirus After Allogeneic Stem Cell Transplantation
Pinana, JL; (...); Styczynski, J
Meeting Abstract. 2020
Upper and/or Lower Respiratory Tract Infection Caused by Human Metapneumovirus After Allogeneic Hematopoietic Stem Cell Transplantation.
Piñana JL; (...); de la Camara, Rafael
Article. 10.1093/infdis/jiad268. 2024
Upregulation of sFRP3 circulating expression levels correlates survival outcomes in glioblastoma
Bruixola, G; (...); Reynes, G
Meeting Abstract. 2019
Use of Azacitidine or Decitabine for the Up-Front Setting in Acute Myeloid Leukaemia: A Systematic Review and Meta-Analysis.
Saiz-Rodriguez, M; (...); Montesinos, P
Article. 10.3390/cancers13225677. 2021
USE OF CAPLACIZUMAB IN THE ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA
Dominguez Hernandez, L.; (...); Gomez Segui, I
Meeting Abstract. 2019
USE OF CRISPR/CAS9 TECHNOLOGY TO MODIFY THE IDH2 GENE IN BOTH IN-VIVO AND IN-VITRO MODELS
Gonzalez Romero, E.; (...); Cervera, J., V
Meeting Abstract. 2018
Use of eltrombopag after romiplostim in primary immune thrombocytopenia
González-Porras JR; (...); González-López TJ
Article. 10.1111/bjh.13266. 2015
Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia.
González-López TJ; (...); García-Frade LJ
Article. 10.1111/ejh.13370. 2020
Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study
Valcarcel, D; (...); Grp Espanol Sindromes Mielodisplas
Article. 10.1016/S2352-3026(15)00067-8. 2015
Use of optical genome mapping in the cytogenetic diagnosis of multiple myeloma
de la Rubia, Javier; (...); Such, Esperanza
Meeting Abstract. 2023
Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience
Labrador J; (...); Montesinos P
Article. 10.3390/cancers14071734. 2022
Utility of Optical Genome Mapping for Accurate Detection and Fine-Mapping of Structural Variants in Elusive Rare Diseases
Orellana, Carmen; (...); Martinez, Francisco
Article. 10.3390/ijms26031244. 2025
Validation of a multivariable prediction model for post-engraftment invasive fungal disease in 465 adult allogeneic hematopoietic stem cell transplant recipients
Rodriguez-Veiga, Rebeca; (...); Sanz, Miguel A.
Article. 10.1111/myc.12891. 2019
VALIDATION OF A NEW MASSIVE SEQUENCING TECHNIQUE FOR MOLECULAR DIAGNOSIS OF ACUTE MYELOBLASTIC LEUKEMIA
Llop Garcia, M.; (...); Barragan Gonzalez, E.
Meeting Abstract. 2015
Validation of a Next-Generation Sequencing Panel for AML Routine Diagnosis
Alonso, Carmen M.; (...); Barragan, Eva
Article. 2015
VALIDATION OF A PANEL OF GENES BY MASSIVE SEQUENCING FOR THE SCREENING OF GERMINAL MUTATIONS IN GENES ASSOCIATED WITH HEREDITARY MYELOID NEOPLASMS
Ibanez, M.; (...); Cervera, J., V
Meeting Abstract. 2019
Validation of a risk score for post-engraftment invasive fungal disease in 414 adult allogeneic hematopoietic stem cell transplant recipients
Montesinos, P.; (...); Sanz, M. A.
Meeting Abstract. 2016
VALIDATION OF DIFFERENT SYSTEMS OF STRATIFICATION OF PROGNOSIS OF SMD IN AN INDEPENDENT SERIES
Collado Jose, Esteban; (...); Sanz, Guillermo
Meeting Abstract. 2016
VALIDATION OF FREQUENT SPLICING EVENTS IN ACUTE MYELOID LEUKEMIA WITH POTENTIAL TO GENERATE NEOANTIGENS
Beatriz, Fernandez-Blanco; (...); Jose Vicente, Cervera Zamora
Meeting Abstract. 2021
Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry.
De la Torre EP; (...); Montesinos P
Letter. 10.3324/haematol.2023.284601. 2024
VALIDATION OF PRECISION MEDICINE TEST FOR ACUTE MYELOID LEUKEMIA IN AN OBSERVATIONAL CLINICAL TRIAL
Montesinos, P; (...); Sanz, MA
Meeting Abstract. 2017
Validation of the IMWG standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?
Jimenez Ubieto, Ana; (...); Lahuerta, Juan-Jose
Article. 10.1182/blood.2021012319. 2021
Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
Sekeres MA; (...); Sugrue MM
Letter. 10.1038/bcj.2014.62. 2014
Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry
de Swart L; (...); de Witte T
Article. 10.1111/bjh.13450. 2015
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)
Della Porta MG; (...); Cazzola M
Article. 10.1038/leu.2015.55. 2015
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
Pratz, Keith W.; (...); Fiedler, Walter
Article. 10.1038/s41408-022-00668-8. 2022
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
Wei, AH; (...); Panayiotidis, P
Article. 10.1182/blood.2020004856. 2020
Visceral leishmaniasis infection during adalimumab therapy: a case report and literature review
Tung Chen Y; (...); Salavert M
Letter. 10.1111/1756-185X.12427. 2014
VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Definitive Results of a Randomized Phase 3 Pethema/GEM Study
Dachs, LR; (...); Blade, J
Meeting Abstract. 10.1182/blood-2018-99-111924. 2018
Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy
Mugoni, V; (...); Pandolfi, PP
Article. 10.1038/s41422-019-0162-7. 2019
What Is the Frequency of Transplant-Eligible Multiple Myeloma Patients Being Cured? the Impact of an MGUS-like Signature at Diagnosis and MRD-Negativity
Paiva, Bruno; (...); Jose Lahuerta, Juan
Meeting Abstract. 2015
WHAT IS THE OUTCOME OF PATIENTS IN THE INTERMEDIATE IPSS-R SCORE GROUP? SPANISH APPROACH FOR BETTER STRATIFICATION WITH CLASSICAL TOOLS
Guijo, AMR; (...); Diez-Campelo, M
Meeting Abstract. 10.1016/S0145-2126(17)30374-0. 2017
WHO and ICC 2022 Cytogenetic Abnormalities Defining Acute Myelogenous Leukemia (AML) Myelodysplasia-Related in First-Line Decitabine in Unfit AML Patients
Ortiz Lopez, Alicia; (...); de la Fuente Burguera, Adolfo
Meeting Abstract. 2023
WHOLE GENE SEQUENCING FOR THE IDENTIFICATION OF SPLICING MUTATIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
Mireya, Morote-Faubel; (...); Jose, Cervera
Meeting Abstract. 2021
Whole genome grey and white matter DNA methylation profiles in dorsolateral prefrontal cortex
Sanchez-Mut, JV; (...); Gräff J
Article. 10.1002/syn.21959. 2017
Wilms Tumor 1 gene expression levels improve risk stratification in AML patients. Results of a multicentre study within the Spanish Group for Molecular Biology in Haematology
Martinez-Laperche, C; (...); Buno, I
Letter. 10.1111/bjh.14635. 2018
WORKING SYSTEM DOCUMENTATION OF PROCEDURES AND INSTRUCTIONS FOR USE IN THE HEMATOLOGY DIAGNOSIS UNIT
Montalt, M.; (...); Sanz, M. A.
Meeting Abstract. 2015
WT1 isoform expression pattern in acute myeloid leukemia.
Article. 10.1016/j.leukres.2013.10.009. 2013
Younger unrelated donors may be preferable over HLA match in the PTCy era: A study from the ALWP of the EBMT.
Sanz, Jaime; (...); Ciceri, Fabio
Article. 10.1182/blood.2023023697. 2024
Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML)
Zeidner, JF; (...); Smith, BD
Meeting Abstract. 10.1182/blood-2018-99-115018. 2018
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial.
Wang ES; (...); Fathi AT
Article. 10.1016/S1470-2045(24)00386-3. 2024
ZNF577 Methylation Levels in Leukocytes From Women With Breast Cancer Is Modulated by Adiposity, Menopausal State, and the Mediterranean Diet
Lorenzo, PM; (...); Crujeiras, AB
Article. 10.3389/fendo.2020.00245. 2020
Zoledronic acid as compared with observation in multiple myeioma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial
Garcia-Sanz, R; (...); Mateos, MV
Article. 10.3324/haematol.2015.128439. 2015
Biomarcadores Epigenéticos De Respuesta A Fármaco En Cáncer De Pulmon
Autor/es: Carla Muñoz Moyano
Tesis Doctoral
Director/s: JUAN SANDOVAL DEL AMOR
Características Y Resultado A Largo Plazo De Pacientes Mayores Con Leucemia Promielocítica Aguda Tratados Con Esquemas Terapéuticos Basados En Atra Más Antraciclinas
Autor/es: David Martínez Cuadrón
Tesis Doctoral
Director/s: MIGUEL ÁNGEL SANZ ALONSO
Estudio De La Reconstitución Inmunológica En Pacientes Con Neoplasias Hematológicas Sometidos A Trasplante De Sangre De Cordón Umbilical
Autor/es: Lourdes Cordon
Tesis Doctoral
Director/s: MIGUEL ÁNGEL SANZ ALONSO
Estudio Del Gen Ikzf1 Y De Microdeleciones Intragénicas En La Leucemia Linfoblástica Aguda
Autor/es: Inés Gómez Seguí
Tesis Doctoral
Director/s: MIGUEL ÁNGEL SANZ ALONSO
Flt3 Y Npm1 Como Marcadores Moleculares En La Leucemia Mieloblástica Aguda. Utilidad Pronóstica Y Diagnóstica
Autor/es: Juan Carlos Pajuelo Gámez
Tesis Doctoral
Director/s: MIGUEL ÁNGEL SANZ ALONSO
Tratamiento Adaptado Al Riesgo De La Leucemia Promielocítica Aguda Con Atra Y Quimioterapia
Autor/es: Pau Montesinos
Tesis Doctoral
Director/s: MIGUEL ÁNGEL SANZ ALONSO
Valor De La Citogenética En La Leucemia Mieloblástica Aguda
Autor/es: José Vicente Cervera Zamora
Tesis Doctoral
Director/s: MIGUEL ÁNGEL SANZ ALONSO